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1. Introduction 
 
1.1. Clinical course and standard treatment of prostate cancer 
 
Prostate cancer is one of the most prevalent cancers among men in the USA.
1 
For the screening 
and diagnosis of prostate cancer, prostate-specific antigen (PSA), a glycoprotein that is secreted by 
the prostate gland, has been widely used, and the PSA level in plasma is also utilized as a clinical 
marker to monitor the disease progression in patients who received medical treatment for prostate 
cancer. 
 In most cases of early stage disease, growth, maintenance and progression of prostate cancer is 
androgen-dependent.
2, 3
 Therefore, the current first-line treatment for prostate cancer is hormonal 
therapy, which is mainly targeted to reduce the production of testosterone secreted by the testes or 
block the signal transduction via androgen receptors. However, most of these patients eventually 
relapse and develop castration-resistant prostate cancer (CRPC). To date, limited therapeutic options 
for the treatment of CRPC are available, and management of the later stages of this disease is not 
always successful.  
The molecular mechanisms leading to the progression of CRPC are not yet fully defined, but 
recent studies
4-6
 have suggested that residual adrenal androgens that remain after castration could be 
responsible for CRPC evolution. Therefore, pharmacological methods to reduce adrenal androgen 
production can be considered as a new therapeutic option to delay CRPC progression. 
 
 
Figure 1. Standard treatment for prostate cancer. 
 
1.2. 17, 20-Lyase as a therapeutic target 
 
As around 80% of patients with prostate cancer respond to hormonal ablation,
7
 the current 
standard treatment for prostate cancer is surgical castration or medical castration, which involves the 
administration of luteinizing hormone–releasing hormone (LH–RH) agonists
8
 such as leuprorelin or 
 2 
 
goserelin, as shown in Figure 2. However, resistance to this therapy eventually occurs during 
medical treatment by hormonal therapy.
 
In the past decade, combination therapy of an LH–RH 
agonist with an anti-androgen, referred to as maximum androgen blockade (MAB), has also been 
used in the medical treatment of advanced prostate cancer.
9
 Unfortunately, unfavorable effects of 
anti-androgens, such as anti-androgen withdrawal syndrome, have been observed in some clinical 
cases.
10 
 
 
Figure 2. Current hormonal therapy options for prostate cancer. 
 
To address these issues in the clinical treatment of advanced prostate cancer, one possible 
approach to decrease androgen levels in tumor and plasma is to inhibit the 17,20-lyase activity of 
CYP17A1, which is an enzyme known to be responsible for androgen biosynthesis in both testes and 
adrenal glands, as shown in Figure 3.  
 
 
Figure 3. 17,20-Lyase as a therapeutic target. 
 
Indeed, over the past decade, steroidal and nonsteroidal inhibitors of 17,20-lyase,
11-45
 such as 
YM-116
28
 and abiraterone acetate
12
 (Figure 4), have been evaluated in clinical studies and have been 
found to effectively reduce circulating androgen levels. Ketoconazole (Figure 4), known as a class of 
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drugs to treat fungal infections, was also used clinically as an off-label drug for the treatment of 
prostate cancer because of its ability to inhibit androgen biosynthesis.
46
 Among them, the use of 
abiraterone acetate (Zytiga, Janssen Biotech, Inc.) with prednisone was approved by the U.S. Food 
and Drug Administration for the treatment of metastatic castration-resistant prostate cancer 
(mCRPC) after chemotherapy in 2011. 
 
 
Figure 4. Structures of previously developed 17,20-lyase inhibitors. 
 
The structural features of these inhibitors include a lipophilic moiety, such as a steroidal skeleton 
or a steroid mimetic fused ring with a heteroaromatic ring, which may bind heme iron in the targeted 
enzyme, as shown in Figure 4. 
 
1.3. Background of this study 
 
At the beginning of our study on novel nonsteroidal 17,20-lyase inhibitors, our group developed 
de novo designs based on the enzyme’s substrate, 17α-hydroxypregnenolone.
47
 Amongst several 
designed compounds, the naphthylmethyimidazole derivative 1 and its related compound 2 (Figure 
5) were identified as promising lead compounds for further development. However, compound 2 
was found to have hepatotoxicity risk after 5-days consecutive administration in rats. Therefore, 
optimization of this series of compounds was investigated to reduce the hepatotoxicity risk, mainly 
focused on the linker moiety between the naphthalene ring and imidazole ring, suggested by a 
docking study of compound 2 in the homology model of 17,20-lyase. As a result, compound S-3, 
with a hydroxyl group and isopropyl group in the linker moiety, showed potent 17,20-lyase 
inhibitory activity without hepatotoxicity risk in a 5-days consecutive administration test in rats. 
Therefore, further modifications based on the compound S-3, were continued to prepare a novel 
series of 17,20-lyase inhibitors. 
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Figure 5. De novo design of novel 17,20-lyase inhibitors and identification of a new lead compound 
S-3. 
 
2. Synthetic study on biphenylylmethylimidazole derivatives 
 
2.1. Molecular design 
 
Our group has previously reported that the naphthylmethylimidazole derivative S-3 (Table 1) 
and its related compounds, which together form a new class of 17,20-lyase inhibitor with a 
hydroxymethylimidazole ring that acts as a ligand for heme iron in the active site of 17,20-lyase, 
showed promising in vitro activity for further development.
48
 Unfortunately, compound S-3 was also 
found to be a potent inhibitor of CYP3A4, with an IC50 value of less than 1000 nM, as shown in 
Table 1. 
CYP3A4 is one of the key metabolizing enzymes of the cytochrome P450 (CYP) superfamily of 
heme-containing monooxygenases. As the CYP family of enzymes plays important roles not only in 
the xenobiotic metabolism and detoxification of a large number of drugs, but also in the biosynthesis 
of endogenous steroids, CYP inhibitors have potential risk to induce drug–drug interactions or 
significant systemic side effects. Therefore, high specificity and selectivity for 17,20-lyase over the 
other CYPs is an important requirement for clinical use. 
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Table 1. Inhibitory effects of S-3 on human 17,20-lyase and human CYP3A4 enzymes. 
 
 
Compound No. 
Enzyme inhibition IC50 (nM) 
human 17,20-lyase CYP3A4 
S-3 28 <1000 
 
Also, in our earlier studies, some steroid mimetic structures, such as stilbene, biphenyl and 
benzothiophene rings, were found to be suitable as lipophilic moieties of 17,20-lyase inhibitors, 
which were designed based on the structure of the substrate of 17,20-lyase, 
17-hydroxypregnenolone.
47
 Therefore, aiming to improve the selectivity for 17, 20-lyase over 
CYP3A4 of S-3, scaffold hopping was achieved by using a steroid A, C-ring mimetic approach to 
develop biphenylylmethylimidazole derivatives and related compounds (I) with distinct structural 
features in the hydroxymethylimidazole ring, as shown in Figure 6. 
 
 
Figure 6. Molecular design of novel 17, 20-lyase inhibitors. 
 
2.2. Chemistry 
 
General strategies for the synthesis of biphenylylmethylimidazole derivatives and related 
compounds (I) are summarized in Figure 7. Lithiation of biphenyl derivatives 4a–5b followed by 
addition to ketone 4
49
 gave biphenylylmethylimidazole derivatives and related compounds (I) 
(method A). Otherwise, coupling of lithium species generated from 1,3- or 1,4-dibromobenzene and 
n-butyllithium (n-BuLi) with N-protected ketone 11 provided the key intermediates 12a and 12b. 
The biphenylylmethylimidazole derivatives and related compounds (I) can be synthesized via a 
palladium-catalyzed Suzuki coupling reaction of bromide 12a or 12b with boronic acid derivatives 
(13a–d), followed by deprotection (method B). It was difficult to convert all the arylbromides 22a–e 
 6 
 
50
 to the corresponding aryl boronic acids; hence, the conversion of 12b to the suitable boronic acid 
21 was investigated as an alternative approach to give biphenylylmethylimidazole derivatives and 
related compounds (I) (method C). 
 
Figure 7. Retrosynthesis of novel biphenyl derivatives and related compounds as 17,20-lyase 
inhibitors. 
 
The synthesis of compounds 7–10 is shown in Scheme 1. Addition of lithium species generated 
from n-BuLi with commercially available 4a–5b to ketone 6 gave good-to-moderate yields of 7–10. 
Scheme 2 depicts the preparation of compounds 15–20. Treating 1,3- or 1,4-dibromobenzene with a 
sub stoichiometric amount of n-BuLi in tetrahydrofuran (THF), followed by addition to ketone 11 
gave bromide 12a or 12b in high yield. Compounds 15–20 were synthesized via a 
palladium-catalyzed Suzuki coupling reaction of 12a or 12b with the corresponding arylboronic 
acids 13a–d, followed by detritylation using pyridine hydrochloride in methanol (MeOH). As shown 
in Scheme 3, in all cases in which suitable arylboronic acids were unavailable, 12b was successfully 
converted to the boronic acid 21, which was then subjected to Suzuki coupling reaction without 
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purification to give 23a–e. Deprotection of 23a–e was performed by the same procedure used for 15 
to give low-to-moderate yields of compounds 24–28. 
 
 
Scheme 1. Reagents and conditions: (a) (1) 4a–5b, n-BuLi, THF, −78°C, then (2) 6, −78°C to rt, 39–
82%. 
 
 
 
Scheme 2. Reagents and conditions: (a) (1) n-BuLi, Et2O, −78°C, then (2) 11, −78 to −50°C, 82–
90%; (b) substituted phenylboronic acid 13a–d, Pd(PPh3)4, 2 M Na2CO3, DME, reflux, 32–96%; (c) 
pyridine hydrochloride, MeOH, 60°C, 21–79%. 
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Scheme 3. Reagents and conditions: (a) (1) n-BuLi; (2) trimethoxyborane (B(OMe)3), −78°C to rt; 
(3) 1 N HCl, compound 21 was not isolated; (b) substituted arylbromide 22a–e, Pd(PPh3)4, 2 M 
Na2CO3, DME, reflux, 23–72%; (c) pyridine hydrochloride, MeOH, 60°C, 26–61%. 
 
The synthesis of analogs of 19, in which the isopropyl group was replaced by hydrogen or other 
alkyl groups, is shown in Scheme 4. Coupling of lithium species, generated from 1, 
4-dibromobenzene and n-BuLi, with N-tritylated aldehyde 29
51
 was performed in the same manner 
as for 12a, followed by oxidation of 30 with manganese dioxide (MnO2) to give ketone 31. The 
ketone 31 was then subjected to Suzuki coupling reaction to give the acetamide derivative 32, which 
was treated with Grignard reagent to give good-to-moderate yields of 33a–c. As deprotection of 33a 
or 33c using pyridine hydrochloride in MeOH gave an unsatisfactory yield (39–59%), an alternative 
method using Pd/C (10%) under a hydrogen atmosphere was investigated for the deprotection of 33b 
and found to give a good yield of the desired compound 35. Otherwise, deprotection of the 
acetamide derivative 32 with pyridinium hydrochloride provided 37, which was then subjected to 
reduction with sodium borohydride to give a good yield of the alcohol 38. 
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Scheme 4. Reagents and conditions: (a) (1) n-BuLi, THF, −78 to −50°C, then (2) 29, 56%; (b) MnO2, 
CH2Cl2, rt, 78%; (c) 13c, Pd(PPh3)4, 2 M Na2CO3, toluene, EtOH, reflux, 76%; (d) RMgBr, THF, 
0°C, 61% to quant.; (e) For 33a, 33c, pyridine hydrochloride, MeOH, 60°C, 39–59%, for 33b, H2, 
10%Pd/C, 1 N HCl, EtOH, rt, 84%; (f) pyridine hydrochloride, MeOH, 60°C, 88%; (g) NaBH4, 
MeOH, 0°C to rt, 76%. 
 
2.3. Asymmetric synthesis of compound (−)-19 
 
The synthetic route toward chiral (−)-19 is shown in Scheme 5. The preparation of 
-hydroxyketone 43 began from chiral silylether 40, which was easily prepared from the known 
morpholine amide 39
52
 or achiral 42. Chiral silylether 40 was treated with lithium species generated 
from 1,4-dibromobenzene and n-BuLi to yield 41, followed by removal of the tert-butyldimethylsilyl 
(TBS) group with tetrabutylammonium fluoride (TBAF) to give -hydroxyketone 43 in moderate 
chemical yield with 96% enantiomeric excess (ee) (in two steps). The enantiomeric purity of the 
obtained chiral compounds was determined by high-performance liquid chromatography (HPLC) on 
a Chiralpak AD column. Alternatively, osmium-catalyzed asymmetric dihydroxylation of the 
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corresponding enol ethers derived from 42 gave the desired -hydroxyketone 43 in good chemical 
yield with excellent ee (98% ee). 
 
 
Scheme 5. Reagents and conditions: (a) TBSCl, imidazole, DMF, 0°C to rt, 98%; (b) (1) n-BuLi, 
THF, −78°C, then (2) 40, 92%; (c) TBAF, THF, 0°C, 82% (96%ee); (d) (1) NaHMDS, TBSCl, THF, 
−70°C to rt, then; (2) AD-mix-β, CH3SO2NH2, tert-BuOH, H2O, 5°C to rt, 87% (98%ee); (e) 
i-PrMgBr, THF, 0°C, 59%; (f) oxalylchloride (COCl)2, DMSO, triethylamine (Et3N), CH2Cl2, −70°C 
to rt, 84%; (g) pyridinium bromide perbromide, THF, rt, 65%; (h) (1) TMSOTf, 2,6-lutidine, THF, 
0°C to rt, then (2) formamidine acetate, satd NH3, MeOH, THF, rt, 74% (90% ee); (i) (1) trityl 
chloride, Et3N, DMF, 0°C to rt; (2) recrystallization from hexane–AcOEt, 63% (99% ee); (j) 
3-acetamidophenylboronic acid 13c, Pd(PPh3)4, 2 M Na2CO3, toluene, EtOH, reflux, 87% (99% ee); 
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(k) 90% formic acid, THF, reflux, 83% (92% ee); (l) H2 (4 atm), 10% Pd/C, EtOH, 70°C, 61% (99% 
ee). 
 
To construct the chiral center of compound (−)-19, a chelation-controlled Grignard reaction was 
used for the synthesis of (2R,3S)-diol 44; compound 43 with 96% ee was treated with 
isopropylmagnesium bromide (i-PrMgBr) to give (2R,3S)-diol 44 together with some by-products, 
including reduction product 44'. Isolation of 44 from the other by-products proved troublesome; 
therefore, optical purity of (2R,3S)-diol 44 was not determined. Swern oxidation of (2R,3S)-diol 44 
gave 45, which was then converted to bromide 46 at moderate yield. After protection of 46 with a 
trimethylsilyl group, imidazole ring closure was performed with formamidine acetate in saturated 
NH3 solution in MeOH and THF to give 47 at good chemical yield with 90% ee. Unfortunately, the 
conversion of -hydroxyketone 43 into 47 proceeded with decreased optical purity, whereas 
recrystallization of the N-tritylated imidazole 48 with 90% ee led to improved optical purity of 48, 
up to 99% ee. Compound 48 was then subjected to Suzuki coupling reaction to give a good yield of 
the acetamide derivative 49 with 99% ee. Deprotection of compound 49 using 90% formic acid 
resulted in decreased enantiomeric excess; however, an alternative approach using catalytic 
hydrogenation of 49 was performed to give (−)-19 without any loss of optical purity. Finally, the 
absolute configuration of compound (−)-19 was confirmed to be S by X-ray crystallographic analysis 
of the precursor 48 (Figure 8). 
 
 
 
 
 
 
 
 
 
Figure 8. ORTEP drawing of 48. 
 
2.4. Structure–activity relationships (SARs) for 17,20-lyase and CYP3A4 
 
Results of the initial SAR study of m- and p-biphenyl compounds 7–10 and 15–18 are shown in 
Table 2. The unsubstituted compounds 7 and 9 demonstrated promising potency against 17,20-lyase, 
with IC50 values of 15 and 33 nM, respectively, for rat enzymes, and 18 and 33 nM, respectively, for 
human enzymes. However, these compounds also showed potent inhibitory activity against CYP3A4. 
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Regarding the m-biphenyl derivatives, all 4'-substituted compounds (8, 15 and 16) showed potent 
inhibition of rat 17,20-lyase, but insufficient selectivity between 17,20-lyase and CYP3A4 inhibition. 
Furthermore, the introduction of a methoxy group on to the phenyl ring led to decreased activity of 
human 17,20-lyase. 
 
Table 2. Effects of meta or para substitution and R substituents on inhibition of rat and human 
17,20-lyase and human CYP3A4 enzymes 
 
 
Compound No. 
Meta or para 
substitution 
R 
Enzyme inhibition IC50 (nM) 
Ratio
a
 17,20-lyase CYP3A4 
Rat Human 
7 m- H 15 18 1200 67 
8 m- OMe 10 130 2000 15 
15 m- F 8.3 19 2100 111 
16 m- Cl 19 49 2400 49 
9 p- H 33 33 3700 112 
10 p- OMe 120 54 4900 91 
17 p- F 28 27 5300 196 
18 p- Cl 29 28 7600 271 
a Ratio is given by IC50 value of CYP3A4 inhibition/IC50 value of human 17,20-lyase inhibition. 
 
On the other hand, p-biphenyl derivatives, other than 10, exhibited potent inhibitory activities 
against both rat and human 17,20-lyase and the introduction of an appropriate substituent into the 
benzene ring was tolerated. Additionally, as a general trend, p-biphenyl derivatives showed 
improved selectivity of 17,20-lyase over CYP3A4 inhibition compared with the corresponding 
m-biphenyl derivatives. These results encouraged us to focus on further modification of the 
p-biphenyl derivatives. 
To increase the inhibitory activities of p-biphenyl derivatives, a homology model of human 
17,20-lyase was developed using the X-ray crystallographic structure of the mammalian CYP2C5 
enzyme. Among several inhibitors, we selected (S)-17 as one of the representative compound that 
was used in the docking study in the homology model of human 17,20-lyase. This was because the 
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racemate 17 showed potent inhibition against human 17,20-lyase with an IC50 value of 27 nM and 
both of the enantiomers of 17 are expected to have inhibitory activity against human 17,20-lyase, 
based on the previously reported results on compound 3 and its enantiomers.
48
 The docking 
experiment was designed on the assumption that (S)-17 should be coordinated to the heme iron via 
the nitrogen of the imidazole ring, and the proposed binding mode of (S)-17 is shown in Figure 9. 
Results of docking studies indicated that the biphenyl ring of (S)-17 occupied a hydrophobic region 
in the active site of the enzyme and there was still enough space between the I-helix and the F-helix 
to introduce an appropriate substituent at the C-3' or C-4' position of the benzene ring of the 
inhibitor. 
I-helix
F-helix
heme
C-3’
C-4’
 
Figure 9. Docking analysis of (S)-17 in the homology model of 17,20-lyase. 
 
Additionally, it was postulated that reducing the lipophilicity of inhibitors would improve the 
selectivity for 17,20-lyase over CYP3A4. That is because, in general, the CYP family of enzymes is 
known to favor lipophilic molecules as substrates or inhibitors. 
Based on the observations, the introduction of a polar substituent at the C-3' or C-4' position on 
the benzene ring or replacement of the benzene ring with pyridine ring in this series of inhibitors 
seems to be a promising strategy to improve the selectivity for 17,20-lyase over CYP3A4 while 
retaining the inhibitory activity against 17,20-lyase. Therefore, the effects of polar substituents on 
the benzene ring and replacement of the benzene ring with pyridine ring in p-biphenyl derivatives 
were investigated (Table 3). As a result, compound 19 with an acetamide group at C-3' position, 
showed potent activity against both rat and human 17,20-lyase and the selectivity for inhibition of 
17,20-lyase over CYP3A4 was similar to that observed with 18. On the other hand, 20 with an 
acetamide group at the C-4' position, exhibited less potent activity against human 17,20-lyase and 
decreased selectivity for 17,20-lyase versus CYP3A4. Among the various substituent groups at the 
C3'-position, the acetamide group provides optimal inhibitory activity against 17,20-lyase and 
selectivity for the inhibition of 17,20-lyase over CYP3A4. Furthermore, 27 exhibited less potent 
activity against human 17,20-lyase compared with 9. In contrast, 28 bearing an acetamide group on 
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the pyridine ring showed potent inhibition of human 17,20-lyase and reduced CYP3A4 inhibition. In 
summary, the introduction of an appropriate polar substituent such as an acetamide group on the 
benzene or pyridine rings of the inhibitor was tolerated, as predicted by results of the docking study 
of (S)-17. 
 
Table 3. Effects of R1 and R2 substituents and X on inhibition of rat and human 17,20-lyase and 
human CYP3A4 enzymes 
 
 
Compound  
No. 
X R
1
 R
2
 
Enzyme inhibition IC50 (nM) 
17,20-lyase CYP3A4 
Rat Human 
19 C NHAc H 17 24 7100 
20 C H NHAc 24 120 1000 
24 C CONHMe H 49 44 8100 
25 C SO2NHMe H 71 160 3300 
26 C NHCONHMe H 24 21 5500 
27 N H H 210 150 5200 
28 N NHAc H 53 36 >10000 
 
The effects of substituents at the linker position between the biphenyl and imidazole rings are 
summarized in Table 4. When the isopropyl (i-Pr) group of 19 was replaced with other alkyl groups 
or hydrogen at the linker position, small alkyl substituents such as methyl, ethyl, and cyclopropyl 
(cyclo-Pr) groups were shown to maintain inhibitory activity against human 17,20-lyase. On the 
other hand, replacement of the i-Pr group of 19 with hydrogen decreased the inhibitory activity 
against human 17,20-lyase. These results suggest that the introduction of a small alkyl group into the 
linker position was necessary to show inhibitory activity against human 17,20-lyase, and that the i-Pr 
group gives optimal potency. 
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Table 4. Effects of R substituents on inhibition of rat and human 17,20-lyase and human CYP3A4 
enzymes 
 
 
Compound No. R 
Enzyme inhibition IC50 (nM) 
17,20-lyase CYP3A4 
Rat Human 
19 i-Pr 17 24 7100 
34 Me 62 38 >10,000 
35 Et 25 40 >10,000 
36 cyclo-Pr 81 45 5500 
38 H 320 77 >10,000 
 
Finally, we selected compounds 19, 28, and 35 as candidates for chiral resolution by HPLC, to 
evaluate whether the interaction with enzymes such as 17,20-lyase and CYP3A4 by these inhibitors 
is stereospecific. Table 5 shows the biological activities of the obtained optical isomers. Interestingly, 
each enantiomer had different inhibitory activity against 17,20-lyase and all of the (−)-enantiomers 
had potent activity against both rat and human 17,20 lyase, with greater than 300-fold selectivity for 
the inhibition of 17,20-lyase over CYP3A4. These findings suggest that the chiral configuration at 
the linker position between the biphenyl and imidazole rings plays an important role in inhibition of 
17,20-lyase and the selectivity of 17,20-lyase over CYP3A4 inhibition. 
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Table 5. Inhibitory effects of (±)-19, (±)-28 and (±)-35 enantiomers on rat and human 17,20-lyase 
and human CYP3A4 enzymes 
 
 
Compound No. X R 
Enzyme inhibition IC50 (nM) 
17,20-lyase CYP3A4 
Rat Human 
(−)-19 C i-Pr 14 26 >10,000 
(+)-19 C i-Pr 770 340 6700 
(−)-28 N i-Pr 33 26 >10,000 
(+)-28 N i-Pr >1000 92 >10,000 
(−)-35 C Et 19 22 >10,000 
(+)-35 C Et 450 240 >10,000 
 
2.5. In vivo efficacy on (-)-19 
 
Among synthesized inhibitors, the active enantiomer (−)-19, which showed potent inhibitory 
activity against human 17,20-lyase in vitro, was selected as a representative for the evaluation of in 
vivo activity. In a monkey model, both testicular androgen testosterone and adrenal androgen 
dehydroepiandrosterone (DHEA) concentrations were investigated. As shown in Table 6, single oral 
doses of (−)-19 3 mg/kg significantly decreased both serum testosterone and DHEA concentrations 
in male cynomolgus monkeys. These biological results indicate that (−)-19 might be useful for the 
treatment of both hormone-dependent and castration-resistant prostate cancer. 
 
Table 6. In vivo effects of S-(−)-19 on serum testosterone and DHEA levels after single oral dosing 
(3 mg/kg) in monkeys 
Compound No. 
% of average 0 h values, mean ± SD 
Serum testosterone 
 
Serum DHEA 
2 h 5 h  2 h 5 h 
Vehicle 110 ± 29 98 ± 33  116 ± 95 148 ± 53 
S-(−)-19 (3 mg/kg) 52 ± 8
a
 23 ± 5  23 ± 9 13 ± 6
b
 
n = 3. aP <0.05 versus vehicle (t-test). bP <0.05 versus vehicle (Welch test). 
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2.6. Conclusions 
 
The scaffold hopping approach successfully led to the discovery of novel 
biphenylylmethylimidazole derivatives as a new class of 17,20-lyase inhibitors. On the basis of 
molecular modeling, compounds 19, 28 and 35, bearing an acetamide group on the benzene or 
pyridine rings, were synthesized and their biological activities were evaluated. Optical resolution of 
these inhibitors by HPLC gave the biologically active enantiomers (−)-19, (−)-28 and (−)-35, 
respectively, which showed potent activities against both rat and human 17,20-lyase, with excellent 
selectivity (>300-fold) for the inhibition of 17,20-lyase over CYP3A4. Among these enantiomers, 
(−)-19 significantly reduced both serum testosterone and DHEA concentrations in a monkey model. 
Additionally, asymmetric synthesis of the active enantiomer (−)-19 was also achieved via a chiral 
intermediate using a diastereoselective Grignard reaction.  
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3. Synthetic study on naphthylmethyimidazole derivatives part-I 
 
3.1. Molecular design 
 
As described in the section 2.1., compound S-3 was found to have an issue on CYP3A4 
inhibition for further development, and a scaffold hopping approach to improve the selectivity of S-3 
between 17,20-lyase and CYP3A4 by replacement of the naphthalene ring with a biphenyl ring was 
successfully investigated to discover biphenylylmethyl derivatives. In the following section, another 
approach to improve the selectivity between 17,20-lyase and CYP3A4 for S-3 will be described and 
discussed. 
Our previous efforts on this series of compounds revealed that the introduction of a small alkoxy 
group, such as methoxy or ethoxy group, at the 6-position of the naphthalene ring of 
naphthylmethyimidazole derivatives was well tolerated in terms of in vitro activity. Moreover, 
docking studies of S-3 using a homology model for human 17,20-lyase suggested that the methoxy 
group at the 6-position on the naphthalene ring might form a hydrogen bond with threonine 101 
(Thr101) in the active site of 17,20-lyase.  
Based on these observations, one possible approach to optimize the substituent at the 6-position 
on the naphthalene ring was proposed and with the aim of improving the selectivity for 17,20-lyase 
over CYP3A4, introduction of a hydrophilic substituent at the 6-position of the naphthalene ring was 
initially designed and examined. Additionally, further modifications, including SAR studies at the 
5-and 7-position on the naphthalene ring and ring cyclization, were also investigated, as shown in 
Figure 10. 
 
 
Figure 10. Molecular design of novel 17,20-lyase inhibitors. 
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3.2. Chemistry 
 
The synthesis of ketone 53 is outlined in Scheme 6. As reported previously,
53
 conversion of 
6-bromo-2-naphthol to dibromide 50 was achieved by the treatment with triphenylphosphine (PPh3) 
and bromine at 70–300°C. Treating dibromide 50 with a sub-stoichiometric amount of 
n-butyllithium (n-BuLi) in tetrahydrofuran (THF) followed by the addition of ketone 11, gave 
bromide 51 in high yield. Sequential treatment of bromide 51 with n-BuLi generated the lithium 
dianion, to which Weinreb’s amide was added at −78°C to give a moderate yield of ketone 52. 
Finally, removal of the trityl group with pyridine hydrochloride in methanol (MeOH) provided the 
targeted ketone 53. 
 
 
Scheme 6. Reagents and conditions: (a) (1) PPh3, Br2, CH3CN, 70°C, then 300°C, 29%; (b) (1) 
n-BuLi, THF, −50°C; (2) 11, THF, −50°C, 93%; (c) (1) n-BuLi, THF, −70°C; (2) 
N-methoxy-N-methylacetamide, THF, −70°C, 54%; (d) pyridine hydrochloride, MeOH, CHCl3, 
60°C, 81%. 
 
The syntheses of 57a and 57b are shown in Scheme 7. Conversion of bromide 51 into 54 was 
performed by Buchwald’s method using tris(dibenzylideneactone)dipalladium (Pd2(dba)2), 
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), sodium tert-butoxide (tert-BuONa) and 
benzophenonimine, to provide good yields of 54. The resulting imine 54 was deprotected to give 55, 
which was then treated with acetic anhydride or phenyl chloroformate, followed by methylamine 
hydrochloride to yield 56a and 56b, respectively. Subsequent deprotections of 56a and 56b were 
performed by treatment with pyridine hydrochloride to give 57a and 57b, respectively. 
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Scheme 7. Reagents and conditions: (a) benzophenoneimine, Pd2(dba)2, BINAP, tert-BuONa, 
toluene, 80°C, 87%; (b) NH2OH·HCl, AcONa, THF, MeOH, rt; (c) Ac2O, pyridine, rt; (d) (1) phenyl 
chloroformate, pyridine, THF, 0°C, then (2) MeNH2·HCl, 10 N NaOH, DMSO, rt; (e) pyridine 
hydrochloride, MeOH, CHCl3, 60°C, 31–80% in three steps. 
 
The syntheses of the trisubstituted naphthalene derivatives 58b–d are shown in Scheme 8. 
6-Bromo-2-naphthol was chlorinated at the 1-position with sulfuryl chloride to give a moderate yield 
of 58b. After Wolff–Kishner reduction of 1-formyl-2-naphthol, 59 was treated with bromine to give 
6-brominated 58c in high yield. Trimethoxyborane-catalyzed reduction of 60 with lithium 
borohydride gave alcohol 61. The alcohol 61 was successively oxidized with manganese dioxide 
(MnO2) to produce 62 in high yield (in two steps). After Wolff–Kishner reduction of the aldehyde 62, 
conversion of the methoxy group of 63 with BBr3 was carried out to give a high yield of phenol 58d. 
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Scheme 8. Reagents and conditions: (a) SO2Cl2, Et2O, 0°C to rt, 51%; (b) hydrazine monohydrate, 
KOH, triethyleneglycol, 170–190°C, 89%; (c) Br2, AcOH, 10–20°C, 99%; (d) LiBH4, cat.B(OMe)3, 
THF; refluxed; (e) MnO2, CH2Cl2, refluxed, 94% in two steps; (f) hydrazine monohydrate, KOH, 
triethyleneglycol, 160–180°C, 98%; (g) BBr3, CH2Cl2, −70°C to rt, 89%. 
 
The syntheses of 69 and 71a–71h are shown in Scheme 9. Phenols 58a–d were protected with 
tert-butyldimethylsilyl chloride (TBSCl), the resulting silyl ethers were treated with n-BuLi at 
−78°C, followed by addition of ketone 11 to produce excellent yields of 65a–d, respectively. 
Removal of the tert-butyldimethylsilyl (TBS) group with tetrabutylammonium fluoride (TBAF) 
provided phenols 66a–d, which were allowed to react with trifluoromethansulfonic anhydride (Tf2O) 
to give 67a–d, respectively. Methoxycarbonylation of 67a–d using palladium(II) acetate (Pd(OAc)2) 
and 1,1'-bis(diphenylphosphino)ferrocene (dppf) in MeOH and N,N-dimethylformamide (DMF) 
under CO atmosphere gave the corresponding esters, which underwent hydrolysis, followed by 
treatment with diphenylphosphoryl azide (DPPA) and ammonium bicarbonate or 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI·HCl) and alkylamine to 
provide carbamoyl derivatives 70a–h in good yield. Deprotections of 68a and 70a–h were 
performed according to a similar method as described for 53 to give the desired compounds 69 and 
71a–h, respectively. 
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Scheme 9. Reagents and conditions: (a) TBSCl, imidazole, DMF, 0°C to rt, 85–98%; (b) (1) n-BuLi, 
THF, −70°C; (2) 11, 84–93%; (c) TBAF, THF, 0°C to rt, 89–98%; (d) Tf2O, pyridine, 0°C, 61–94%; 
(e) CO, Pd(OAc)2, dppf, Et3N, DMF, MeOH, 70°C, 81–95%; (f) pyridine hydrochloride, MeOH, 
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CHCl3, 60°C, 94%; (g) (1) 4 N NaOH, THF, MeOH, 60°C, then (2) for 70a, NH4HCO3, DPPA, Et3N, 
DMF, rt, quant., for 70b–h, R3NH2, EDCI·HCl, HOBt·H2O, Et3N, DMF, rt, 75% to quant.; (h) 
pyridine hydrochloride, MeOH, CHCl3, 60v, 73–93%. 
 
The syntheses of 74a and 74b are shown in Scheme 10. Substituted naphthalene 68c was 
brominated using N-bromosuccinimide (NBS) and 2,2'-azobis(2-methylpropionitrile) (AIBN) to 
yield 72, which was subjected to lactam cyclization to form 73a and 73b, respectively. Deprotections 
of each compound yielded the desired 74a and 74b. The regioisomers 77a and 77b were also 
synthesized from 68d in a similar manner, as shown in Scheme 11. 
 
Scheme 10. Reagents and conditions: (a) NBS, AIBN, CCl4, refluxed, 59% as a mixture of 72 and 
68c (72:68c = ca. 7:1); (b) for 73a, saturated NH3 in MeOH, THF, 0°C to rt, 26%; (c) for 73b, 40% 
NH2Me in MeOH, rt, quant.; (d) pyridine hydrochloride, MeOH, CHCl3, 60°C, 75–90%. 
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Scheme 11. Reagents and conditions: (a) NBS, AIBN, CCl4, refluxed, quant.; (b) for 76a, saturated 
NH3 in MeOH, THF, 0°C to rt; (c) for 76b, 40% NH2Me in MeOH, rt; (d) pyridine hydrochloride, 
MeOH, CHCl3, 60°C, 22–64% in two steps. 
 
To examine the stereochemical requirement at the chiral centers of these inhibitors, optical 
resolutions of 74a and 74b into (−)-74a and (+)-74a, and (−)-74b and (+)-74b, respectively, were 
performed using preparative HPLC with a Chiralpak AD column. Additionally, as shown in Scheme 
12, (+)-74b was converted to the 4-bromobenzenesulfonyl derivative 78 and the absolute 
configuration of (+)-74b was confirmed to be R by X-ray crystallographic analysis of 78, as shown 
in Figure 11. 
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Scheme 12. Reagents and conditions: (a) optical resolution using preparative HPLC on a Chiralpak 
AD column; (b) 4-bromobenzenesulfonyl chloride, Et3N, DMF, rt, 88%. 
 
 
Figure 11. ORTEP drawing of 78. 
 
3.3. Asymmetric synthesis of compound (−)-74b 
 
The asymmetric synthesis of (−)-74b, which represents the promising in vitro and in vivo profiles 
in the following sections 3.3. through 3.8., is shown in Scheme 13. Diastereoselective Grignard 
reactions are versatile and effective methods for providing chiral tertiary alcohols.
54-56
 Our group has 
previously reported the application of this method to substrates with an α-hydroxy ketone and 
established effective methods to synthesize chiral hydroxymethylimidazole derivatives utilizing 
diastereoselective Grignard reactions.
57, 58
 To construct the chiral center of (−)-74b, we used our 
previously reported method using α-hydroxy ketone 80b. The key intermediate 80b was easily 
prepared from the known morpholine amide 40.
52
 The synthesized 40 was treated with lithium 
species generated from 79b and n-BuLi to give 80a, which was followed by deprotection of the TBS 
group with TBAF to afford moderate yield of the desired 80b. 
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Scheme 13. Reagents and conditions: (a) (1) SOCl2, DMF, THF, 60°C; (2) diisopropylamine, Et3N, 
THF, 0°C –rt; 88%; (b) (1) n-BuLi, toluene, THF, −70°C; (2) 40, THF, −78°C; (c) TBAF, THF, −10 
to 0°C, 58% from 40; (d) isopropylmagnesium bromide, THF, −10 to 0°C, 54%; (e) n-BuLi, 
TMEDA, DMF, THF, −70°C; (f) 2 M MeNH2 in THF, NaBH(OAc)3, AcOH, CH2Cl2, rt; (g) LDA, 
THF, −70 to −10°C, 42% as a mixture of 84a and 84b; (h) DMSO, (COCl)2, Et3N, CH2Cl2, −70 to 
−20°C, 33%; (i) pyridinium bromide perbromide, THF, 0°C to rt; (j) 
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N,O-bis(trimethylsilyl)acetamide, cat. TBAF, DMF, rt, 54% from 85; (k) formamidine acetate, 
saturated NH3 in MeOH, THF, −15°C to rt, 54%, >99% ee. 
 
Treatment of 80b with isopropylmagnesium bromide gave the crude (1S,2R)-diol 81 in a 
diastereoselective manner together with some by-products, followed by crystallization to give 81 
with 95% purity; this was used without further purification in the next step. Ortho-lithiation of 81 
followed by the addition of DMF gave a mixture of 82a and 82b (82a:82b = ca. 6:1), which was 
then treated with methylamine under reductive amination conditions to yield a mixture of 83a and 
83b. Subsequent internal cyclization of a mixture of 83a and 83b using lithium diisopropylamide 
(LDA), followed by recrystallization gave a mixture of the regioisomers such as 84a and 84b 
(84a:84b = 93:7) in moderate yield. Swern oxidation of a mixture of 84a and 84b, and subsequent 
recrystallization of the product gave 85 with >99% purity, which was then subjected to the 
α-bromination condition using pyridinium bromide perbromide to give α-bromoketone 86. 
Since the direct conversion from 86 to (−)-74b gave insufficient yield of (−)-74b with 2% (not 
shown in Scheme 8), imidazole ring closure was performed after protection of 86 with a 
trimethylsilyl group by N,O-bis(trimethylsilyl)acetamide. The obtained 87 was then subjected to the 
reaction conditions using formamidine acetate in saturated NH3 solution, shown in Scheme 8 to give 
(−)-74b in moderate chemical yield with excellent ee (>99%ee). In summary, an 11-step method was 
developed for asymmetric synthesis of the selected (−)-74b from 6-bromo-2-naphthoic acid 79a 
using the diastereoselective Grignard reaction as a key step to construct the chiral center of (−)-74b. 
 
3.4. Structure–activity relationships (SARs) for 17,20-lyase, CYP3A4 and 11-hydroxylase 
 
As previously described,
48
 we have shown that the substituents at the 6-position of the 
naphthalene ring are likely to have an important role in hydrogen bond formation with Thr101 in 
17,20-lyase. Therefore, a number of modifications to optimize the substituent at the 6-position of the 
naphthalene ring were investigated. 
The results of a SAR study on replacement of the substituent at the 6-position of the naphthalene 
ring are shown in Table 7. On the basis of a docking study of S-3, hydrogen bond acceptors were 
examined as replacements for the methoxy group of compound S-3. Although replacing the methoxy 
group (S-3) with an acetyl group (53) or a methoxycarbonyl group (69) had little effect on potency 
against human 17,20-lyase with slightly improved selectivity between human 17,20-lyase and 
CYP3A4, replacing the methoxy group (S-3) with an acetamide group (57a) or a methylureido group 
(57b) led to slightly decreased inhibitory activity against human 17,20-lyase without improved 
selectivity between human 17,20-lyase and CYP3A4. Replacement of the methoxy group (S-3) with 
a methylcarbamoyl group (71b), on the other hand, resulted in both increased inhibitory activity 
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against human 17,20-lyase and a promising improvement in selectivity between the two enzymes. 
These results indicate that the methylcarbamoyl group on the naphthalene ring is optimal in terms of 
both inhibition of 17,20-lyase and selectivity between 17,20-lyase and CYP3A4. 
 
Table 7. Effect of R substituent on inhibition of rat and human 17,20-lyase and human CYP3A4 
 
 
Compound No. R 
Enzyme inhibition IC50 (nM) 
Ratio
a
 17,20-lyase CYP3A4 
Rat Human 
S-3 OMe 21 28 <1000 <36 
53 Ac 14 28 1400 50 
57a NHAc 29 39 <1000 <26 
57b NHCONHMe 11 36 <1000 <28 
69 COOMe 43 24 1400 58 
71b CONHMe 6 16 3600 225 
a Ratio is given by IC50 value of CYP3A4 inhibition/IC50 value of human 17,20-lyase inhibition.
 
 
We then focused on modification of the methylcarbamoyl group and the introduction of a 
substituent at the 5- or 7-position of the naphthalene ring. The results are shown in Table 8. 
Replacement of the methylcarbamoyl group (71b) with a carbamoyl (71a) or other small alkyl 
carbamoyl group (71c, 71d and 71e) resulted in a 2–5-fold loss in potency against human 
17,20-lyase and a 2–3-fold decrease in selectivity for human 17,20-lyase over CYP3A4. The 
introduction of a substituent at the 5-position of the naphthalene ring also resulted in decreased 
potency. For example, incorporation of a chlorine substitution (71f) at the 5-position resulted in a 
decrease in potency of more than an order of magnitude when compared with the unsubstituted 71b. 
Even a relatively small methyl group (71g) led to marked reductions in potency against human 
17,20-lyase. On the other hand, introduction of a methyl group at the 7-position of the naphthalene 
ring (71h) resulted in only a slight decrease in inhibition of human 17,20-lyase and no change in 
inhibition of CYP3A4 compared with 71b. These results suggested that the methylcarbamoyl group 
(71b) was optimum in size and the bulkiness at the 5- or 7-position may have some effect on fixing 
the conformation of the carbamoyl group. 
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Table 8. Effect of R1, R2, R3 substituents on inhibition of rat and human 17,20-lyase and human 
CYP3A4 
  
 
Compound No. R
1
 R
2
 R
3
 
Enzyme inhibition IC50 (nM) 
17,20-lyase CYP3A4 
Rat Human 
71a H H H <10 30 3700 
71b H H Me 6 16 3600 
71c H H Et 11 46 5700 
71d H H Pr 13 38 3400 
71e H H iPr 12 75 9300 
71f Cl H Me 91 200 >10000 
71g Me H Me 200 160 >10000 
71h H Me Me 12 39 3600 
 
Therefore, fixing the angle of the carbamoyl group seemed to be a promising strategy for further 
development, and tricyclic compounds such as 74a, 74b, 77a and 77b were prepared to make the 
conformation of the carbonyl group more rigid. As a result, all of these tricyclic compounds had 
reduced inhibitory activity against CYP3A4 compared with 71b, but maintained activity against 
17,20-lyase, shown in Table 9. Among them, 74b had the best selectivity for 17,20-lyase over 
CYP3A4 by more than 400-fold. 
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Table 9. Effect of R
1
 substituent on inhibition of rat and human 17,20-lyase and human CYP3A4 
 
 
 
Compound No. R
1
 
Enzyme inhibition IC50 (nM) 
17,20-lyase CYP3A4 
Rat Human 
74a H <10 18 6700 
74b Me 15 22 >10000 
77a H 42 36 >10000 
77b Me 70 19 5400 
 
Further investigations regarding the stereochemical requirement at the chiral center of these 
inhibitors were performed using optical isomers such as (−)-74a, (+)-74a, (−)-74b, and (+)-74b, 
respectively, as shown in Table 10. As expected, each isomer exhibited markedly different potencies 
against 17,20-lyase, as well as selectivity between 17,20-lyase and CYP3A4. Each (−)-isomer had 
potent inhibitory activity against 17,20-lyase and selectivity by more than 500-fold for 17,20-lyase 
over CYP3A4. These data indicate that the orientation of the isopropyl group at the benzyl moiety 
may be critical for binding to targeted 17,20-lyase. 
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Table 10. Stereochemical requirement for inhibitory activities of (±)-74a and (±)-74b against rat and 
human 17,20-lyase, rat 11-hydroxylase and human CYP3A4 enzymes 
 
 
Compound No. R
1
 
Enzyme inhibition IC50 (nM) 
17,20-lyase 11-hydroxylase CYP3A4 
Rat Human 
(−)-74a H <10 15 13 >10000 
(+)-74a H 180 60 220 7400 
(−)-74b Me <10 19 >1000 >10000 
(+)-74b Me 110 270 >1000 >10000 
 
Compounds (−)-74a, (+)-74a, S-(−)-74b, and R-(+)-74b were also tested for their ability to 
inhibit rat 11-hydroxylase, which belongs to the CYP family of enzymes. Because this enzyme is 
known to play an important role in the biosynthesis of both glucocorticoid and mineralocorticoid, 
and high specificity for 17,20-lyase over 11-hydroxylase should be considered for further 
development. Compounds (−)-74a and (+)-74a showed highly potent inhibitory activity against 
11-hydroxylase, while (−)-74b and (+)-74b showed low levels of 11-hydroxylase inhibition at 
concentrations of up to 1000 nM. In summary, selected (−)-74b showed promising in vitro profiles 
such as potent inhibitory activity against 17,20-lyase and excellent selectivity for the inhibition of 
17,20-lyase over 11-hydroxylase and CYP3A4. 
 
3.5. Inhibitory effect of (-)-74b on CYP isoform-specific activity 
 
During a series of in vitro studies, (−)-74b was further investigated against other P450 enzymes 
such as CYP2D6, CYP2C8, and CYP2C9, which have been identified as important P450 enzymes 
involved in drug metabolism.
59-62
 As shown in Table 11, (−)-74b demonstrated specific inhibition of 
CYP2C9 versus CYP2C8, CYP2D6, and CYP3A4; however, it also showed good selectivity 
(>1000-fold) for inhibition of human 17,20-lyase over CYP2C8, CYP2D6 and CYP3A4. 
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Table 11. Inhibitory effect of S-(−)-74b on marker enzyme activities in microsomes expressing 
human CYP isoforms. 
Compound 
No. 
 
Enzyme inhibition IC50 (nM) 
17,20-lyase  Human CYP isoforms 
Rat Human  CYP2C8 CYP2C9 CYP2D6 CYP3A4 
S-(−)-74b  <10 19  28000 <3000 >30000 27000 
 
3.6. Docking experiments 
 
The docking of (−)-74b was studied using a homology model of 17,20-lyase. In the docking 
experiment it was postulated that (−)-74b should be connected to the catalytic heme iron via the 
nitrogen of the imidazole ring moiety, and the proposed binding mode of (−)-74b is shown in Figure 
12. Results of docking studies indicated that the tricyclic ring of (−)-74b occupied a hydrophobic 
region in the active site of the enzyme and the carbonyl moiety on the lactam ring formed a 
hydrogen bond with Thr101. These findings are consistent with our previous results on the docking 
study of S-3.
48
 Furthermore, an additional hydrogen bond between the hydroxyl group at the linker 
position between the tricyclic and imidazole rings of (−)-74b with Thr306 was also observed in this 
model. 
 
Figure 12. Docking of (−)-74b in the 17,20-lyase homology model. 
 
3.7. In vivo efficacy on (-)-74b 
 
Based on the in vitro profiles, (−)-74b was selected for further biological investigation. In a 
monkey model both testicular androgen testosterone and adrenal androgen DHEA levels were 
examined to evaluate in vivo potency of (−)-74b. As shown in Table 12, (−)-74b markedly reduced 
serum testosterone and DHEA levels at 4 and 8 h after administration of an oral dose (1 mg/kg) in 
 33 
 
monkeys. These results indicate that compound (−)-74b could be useful for the treatment of both 
hormone-dependent and castration-resistant prostate cancer. 
 
Table 12. In vivo effects of (−)-74b on serum testosterone and DHEA levels after single oral dosing 
(1 mg/kg) in monkeys 
 
Compound No. 
% of average 0 h values, mean ± SD 
Serum testosterone  Serum DHEA 
4 h 8 h  4 h 8 h 
Vehicle 89.1 ± 15.6 68.5 ± 27.3 105.7 ± 4.2 38.5 ± 18.4 
(−)-74b (1 mg/kg) 13.2 ± 7.5
b
 9.8 ± 4.9
a
 16.8 ± 7.0
c
 7.7 ± 4.3
a
 
n = 3. aP <0.05 versus vehicle (Dunnett test). bP <0.005 versus vehicle (Dunnett test). cP <0.001 versus vehicle (Dunnett test). 
 
3.8. Pharmacokinetics of (-)-74b 
 
Pharmacokinetic studies of (−)-74b were performed in rats (not evaluated in monkeys). As shown 
in Table 13, (−)-74b demonstrated good pharmacokinetic profiles with large oral AUC and excellent 
bioavailability values; these results are encouraging for the further development of (−)-74b as a 
therapeutic agent. 
 
Table 13. Selected pharmacokinetic data for compound (−)-74b after oral or intravenous (IV) 
administration in rats 
Dosage 
route 
Dose 
(mg/kg) 
Tmax (h) Cmax (μg/mL) 
AUC
a
 
 (μg h/mL) 
Bioavailability (%) 
Oral 10 0.42 ± 0.14 2.943 ± 0.611 7.315 ± 2.148 127.7 ± 38.1 
IV 1 
  
0.573 ± 0.030 
 
Mean ± SD (n = 3). a0–24 h. 
 
3.9. Conclusions 
 
A novel series of naphthylmethylimidazole derivatives and related compounds have been 
investigated as selective 17,20-lyase inhibitors. Optimization of the substituent at the 6-position on 
the naphthalene ring was performed to yield a methylcarbamoyl derivative, which exhibited potent 
inhibitory activity against human 17,20-lyase and promising selectivity (>200-fold) for 17,20-lyase 
over CYP3A4. Further modifications aimed at fixing the orientation of the carbonyl group of the 
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inhibitor yielded tricyclic compounds 74a and 74b that were potent and selective human 17,20-lyase 
inhibitors. Among them (−)-74b showed good selectivity (>1000-fold) for the inhibition of 
17,20-lyase over CYP3A4, while showing potent inhibitory activity against 17,20-lyase. Additional 
biological evaluation revealed that (−)-74b exhibited potent in vivo efficacy at an oral dose of 1 
mg/kg in monkeys and showed favorable pharmacokinetic profiles when administered to rats. 
Additionally, asymmetric synthesis of (−)-74b was also achieved using a chiral α-hydroxy ketone. In 
summary, selected (−)-74b represents a selective 17,20-lyase inhibitor for the inhibition of 
17,20-lyase over CYP3A4, with a potent in vivo efficacy in a monkey model. 
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4. Synthetic study on naphthylmethylimidazole derivatives part-II 
 
4.1. Molecular design 
 
As discussed in section 3.4., racemic 71b showed potent inhibitory activity against 17,20-lyase 
with modest selectivity for the inhibition of 17,20-lyase over CYP3A4, therefore, optical resolution 
of 71b was conducted using preparative HPLC on a Chiralpak AD column, as shown in Scheme 14. 
The absolute configuration of the obtained enantiomer (-)-71b was determined to be S by X-ray 
crystallographic analysis of the sulfonyl derivative 88, as shown in Figure 13. The biological 
evaluation revealed that (-)-71b showed potent human 17,20-lyase inhibition with an IC50 value of 
5.5 nM, along with relatively potent CYP3A4 inhibition (IC50 value of 7800 nM). Therefore, we 
continued to further modify this series of compounds, with the aim of improving selectivity to 
17,20-lyase over other CYP enzymes. 
 
 
Scheme 14. Reagents and conditions: (a) optical resolution using preparative HPLC on a Chiralpak 
AD column, (-)-71b (>99.9% ee) and (+)-71b (99.8% ee), respectively; (b) 4-bromobenzenesulfonyl 
chloride, Et3N, DMF, room temperature, 79%. 
 
Figure 13. ORTEP drawing of 88. 
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To understand the binding mode of (-)-71b, we conducted a docking study of the compound 
using a homology model of the catalytic domain of 17,20-lyase, which was constructed based on the 
mammalian CYP2C5 X-ray crystal structure.
63
 In the docking experiment it was postulated that 
(-)-71b should be coordinated to the heme iron via the nitrogen of the imidazole ring moiety; the 
results of the docking study of (-)-71b are illustrated in Figure 14. The docking study suggested that: 
(a) (-)-71b formed two hydrogen bonds with the enzyme (the carbamoyl moiety of (-)-71b with 
Thr101, and the hydroxyl group of (-)-71b with Thr306; (b) the naphthalene ring occupied a 
hydrophobic region surrounded by Ala113, Phe114, Ile205, Ala302 and Ile371; and (c) the isopropyl 
group was located in a small hydrophobic pocket created by Val483, Phe484 and Leu485. 
 
 
Figure 14. Docking study of (-)-71b in a homology model of 17,20-lyase. 
 
In the docking experiment, both the hydrogen bonds with Thr101 and Thr306 and the 
coordinated bond to the heme iron seem to contribute to the in vitro inhibitory activity of (-)-71b. 
Therefore, further modifications were mainly focused on the conversion of the isopropyl moiety of 
(-)-71b. Due to the limited space around the isopropyl group, we developed a new class of 
17,20-lyase inhibitors with a fused imidazole ring system, as shown in Figure 15. 
 
Figure 15. Molecular design of novel 17,20-lyase inhibitors. 
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4.2. Chemistry 
 
The preparations of key intermediates 92, 93 and 95a–e are shown in Scheme 15. The synthesis 
of cyclic ketone 92 from compound 90 was achieved by a modification of the procedure reported by 
Christine et al.
64
 Compound 90 was converted to 91, using hydrogen bromide (HBr) in acetic acid 
(AcOH), and isolated as HBr salt. Subsequent cyclization of 91 was performed effectively in the 
presence of Et3N, to produce 92 in moderate yield. Dimethylation of 92 using methyl iodide (MeI) 
afforded 93 with moderate yield. Coupling of commercially available carboxylic acid 94 with 
alkylamine was performed by using EDCI·HCl and 1-hydroxybenzotriazole (HOBt) or by 
conversion of carboxylic acid 94 into the corresponding acid chloride to give good to moderate 
yields of 95a–e, respectively. The designed fused imidazole derivatives and related compounds were 
prepared as shown in Scheme 16. The addition of lithium species, generated from 94 and 95a–e with 
n-butyllithium (n-BuLi), to ketone 92 or 93 gave moderate to low yields of the desired alcohols 89a, 
89c, 89e–h, respectively. Coupling of 89a with ammonium salt of HOBt was performed in the same 
manner as described for 95a–d to afford 89b in low yield. Removal of hydroxyl group of 89c by 
using Pd/C under a hydrogen atmosphere was carried out to give 89d in good yield. 
Diisopropylcarbamoyl derivative 89h was treated with lithium amides, generated from methylamine 
with n-BuLi, to give the desired 89i in low yield. Compound 95a was subjected to coupling reaction 
with 96 
65
 to form 89j in moderate yield. 
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Scheme 15. Reagents and conditions: (a) 25% HBr, AcOH, 0°C to room temperature, quant.; (b) 
Et3N, CH3CN, 70°C, 61%; (c) MeI, t-BuOK, THF, 43%; (d) for 95a–d, EDCI·HCl, HOBt, 
(i-Pr)2NEt, R
1
H, DMF, 0°C to room temperature, 60–82%; for 95e, (i) SOCl2, DMF, THF, 60°C, (ii) 
N,N-diisopropylamine, Et3N, THF, 0°C to room temperature, 88%. 
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Scheme 16. Reagents and conditions: (a) for 89a, (i) 94, n-BuLi, THF, −100 to −80°C, (ii) 92, THF, 
−70°C, 12%, for 89c, 89e–h, (i) 95a–e, n-BuLi, THF, −70°C, (ii) 92 or 93, THF, −70°C, 26–37%; 
(b) EDCI·HCl, ammonium salt of HOBt, (i-Pr)2NEt, DMF, 0°C to room temperature, 12%; (c) H2 
(3–4 atom), Pd/C, 1 N HCl, MeOH, room temperature, 72%; (d) n-BuLi, MeNH2, THF, −70°C to 
room temperature, 33%; (e) n-BuLi, THF, −65 to 60°C, 38%. 
 
We next focused on the preparation and asymmetric synthesis of (+)-89c as a candidate for 
further development. The synthetic strategy toward racemic 89c and (+)-89c is outlined in Scheme 
17 as a retrosynthetic analysis. Initially, we adopted two approaches, routes A and B, to prepare 
racemic 89c, which could be efficiently resolved by high-performance liquid chromatography 
(HPLC) or diastereomeric salt formation to obtain optically pure (+)-89c. Route A is a convergent 
synthetic method via cyclic ketone I,
64
 whereas route B represents a linear synthetic method via diol 
III and ketone IV. Otherwise, we developed an asymmetric synthesis of (+)-89c using a newly 
developed stereocontrolled Reformatsky reaction (route C).
66
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Scheme 17. Retrosynthesis of compounds (+)-89c and 89c. 
 
4.3. Improved method for the synthesis of racemic 89c and preparation of (+)-89c via 
optional resolution of racemic 89c 
 
The improved method for the synthesis of racemic 89c is illustrated in Scheme 18 (route A). As 
described above, the coupling reaction of lithium species, generated from 95a with n-BuLi to ketone 
92 resulted in 26% yield, therefore, the reaction condition using lithium species from 95a and cyclic 
ketone 92 was optimized. As a result, the use of 1 equivalent of o-trifluoromethylphenyl lithium 
gave improved yield of desired product 89c. That is, the addition of lithium species, generated from 
2-bromobenzotrifluoride with n-BuLi to 95a gave lithium salt, which was allowed to react with 
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n-BuLi to afford dilithium salt in the reaction vessel. The obtained dilithium salt was then subjected 
to a coupling reaction with cyclic ketone 92 to produce in 45% yield of racemic 89c. 
 
 
Scheme 18. Improved method for the synthesis of racemic 89c. Reagents and conditions: (a) (i) 
2-bromobenzotrifluoride, n-BuLi, THF, −65°C, (ii) 95a, THF, −55°C, then (iii) n-BuLi, THF, −65°C, 
(iv) 92, THF, −65°C, 45%. 
 
An alternative method to synthesize racemic 89c is shown in Scheme 19 (route B). Coupling of 
lithium species, generated from amide 95e and n-BuLi, to aldehyde 29 gave alcohol 97. Oxidation of 
the obtained alcohol 97 was conducted using manganese (IV) oxide (MnO2) to give ketone 98 with 
moderate yield in two steps. Addition of lithium enolates, formed by ethyl acetate (AcOEt) in the 
presence of lithium diisopropylamide (LDA), to 98 gave 99. The alcohol 99 was then reduced using 
sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) to provide the diol 100 with good yield in 
two steps. The diol 100 was allowed to react with methanesulfonyl chloride (MsCl) and the resulting 
mesylate underwent cyclization under basic conditions to produce the cyclized compound 101 in 
good yield. Subsequent coupling of 101 with lithium amides, generated from methylamine (MeNH2) 
with n-BuLi, gave the desired racemic 89c in good yield. 
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Scheme 19. Reagents and conditions: (a) (i) n-BuLi, toluene/THF, −70°C, (ii) 29, THF, −70°C; (b) 
MnO2, CH2Cl2, room temperature, 60% in 2 steps; (c) AcOEt, LDA, THF, −70°C to −30°C; (d) 
Red-Al, toluene, −15°C to 0°C, 98% in 2 steps; (e) (i) MsCl, (i-Pr)2NEt, THF, 0–10°C, (ii) CH3CN, 
70°C, (iii) (i-Pr)2NEt, MeOH, CH3CN, 70°C, 87%; (f) n-BuLi, MeNH2, THF, −78°C to room 
temperature, 79%. 
 
Successively, optical resolution of racemic 89c obtained above was performed by preparative 
HPLC using a Chiralpack AD column to yield (+)-89c and (−)-89c with 99.8% ee, respectively, as 
shown in Scheme 20. 
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Scheme 20. Optical resolution of racemic 89c. Reagents and conditions: (a) optical resolution using 
preparative HPLC on a Chiralpak AD column, (+)-89c (99.8% ee) and (−)-89c (99.8% ee), 
respectively. 
 
4.4. Optical resolution of racemic 89c by diastereomeric salt formation with 
(2S,3S)-(−)-tartranilic acid 
 
To prepare optically active (+)-89c by an alternative method using diastereomeric salt formation, 
we screened a number of optically active acid derivatives. As a result, it was found that 1 equivalent 
of (+)-89c efficiently formed poorly soluble crystals with 2 equivalent of (2S,3S)-(−)-tartranilic acid 
in ethanol (EtOH). In fact, recrystallization of the obtained diastereomeric salts gave optically 
purified (99% de) salts, which were subjected to neutralization with 1 N NaOH, followed by 
recrystallization to yield free (+)-89c with >99% ee. 
 
4.5. X-ray crystallographic analysis of (+)-89c with (2S,3S)-(−)-tartranilic acid 
 
To determine the absolute configuration of (+)-89c, the crystal structure of the diastereomeric salt 
of (+)-89c with (2S,3S)-(−)-tartranilic acid was analyzed. The crystal contained one molecule of 
(+)-89c and two molecules of (2S,3S)-(−)-tartranilic acid in the asymmetric unit. The absolute 
configuration of (+)-89c was determined to be S using the absolute stereochemistry of 
(2S,3S)-(−)-tartranilic acid as an internal reference (Figure 16). 
 
Figure 16. ORTEP drawing of (+)-89c with (2S,3S)-(−)-tartranilic acid. 
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4.6. Asymmetric synthesis of (+)-89c 
 
To establish an efficient and practical asymmetric synthesis of (+)-89c, we focused on 
development of the coupling reaction from ketone 98 to 99, as shown in Scheme 19, for the 
application of a chelation-assisted enantioselective Reformatsky reaction.
45
 Asymmetric 
Reformatsky reactions are versatile and effective methods for providing chiral β-hydroxy esters and, 
to date, several asymmetric Reformatsky reactions have been reported by several groups.
67-79
 In most 
of the reported cases, 1,2-aminoalcohols were used as chiral ligands to give high enantioselectivity 
in the asymmetric Reformatsky reactions. More recently, our group reported chelation-assisted 
enantioselective Reformatsky reactions of ketones, using cinchona alkaloids as chiral ligands.
66
 We 
have previously analyzed a selection of chiral ligands and the effect of additives such as pyridine, as 
well as the effect of reaction temperature on the enantioselectivity in the Reformatsky reaction. Table 
14 summarizes the selected results for the asymmetric Reformatsky reaction with ketone 98 using 
zinc reagents (102a and 102b) generated from ethyl or tert-butyl bromoacetate and activated zinc. 
The enantioselectivity of the obtained tertiary alcohol 103a was improved by reduction of the 
reaction temperature (entry 1 vs 3), the addition of an excess amount of pyridine (entry 1 vs 4) and 
the addition of a slight excess of cinchonine with an excess amount of pyridine (entry 4 vs 5), 
respectively in this reaction. Additionally, the use of Reformatsky reagent with tert-butyl ester (102b, 
entries 2 and 6) gave a slightly improved enantioselectivity, up to 95% ee, when compared with the 
corresponding reagent with ethyl ester (102a, entries 1 and 5) under the same reaction conditions. 
The chiral tertiary alcohol of 103b with 71% ee obtained in entry 2 was successfully converted to 
(+)-89c with 69% ee as a similar manner shown in Scheme 19, and the configuration of 103b 
obtained in this reaction using cinchonine as a chiral ligand was determined to be S. 
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Table 14. Reaction conditions of newly developed asymmetric Reformatsky reaction using ketone 
98 and zinc reagents 102a and 102b 
 
 
Entry zinc reagent 
Temp  
(°C) 
Additive  
(eq.) 
Cinchonine 
(eq.) 
ee (%) Yield
a
 (%) 
1 102a 0 None 1 67 Quant. 
2 102b 0 None 1 71
b
 Quant. 
3 102a −42 None 1 76 97 
4 102a −42 Pyridine (3) 1 85 98 
5
c
 102a −42 Pyridine (4) 1.25 90 99 
6
d
 102b −42 Pyridine (4) 1.25 95 (92)
e
 Quant. (97)
e
 
a
Determined by HPLC. 
b
The absolute configuration of 103b was determined to be S after the 
conversion to (+)-89c. 
c
4 eq. of Reformatsky reagent 102a was used.
 d
4 eq. of Reformatsky reagent 
102b was used.
 e
Isolated yield and enantiomeric excess. 
 
4.7. Structure–activity relationships (SARs) for 17,20-lyase, CYP3A4 and 11-hydroxylase 
 
The impact of fused imidazole derivatives and related compound 89j on inhibition of rat and 
human 17,20-lyase, 11-hydroxylase and CYP3A4 are shown in Table 15 and 16. The cyclized 
compound 89c demonstrated both promising inhibitory activity against human 17,20-lyase with IC50 
value of 38 nM and selectivity between human 17,20-lyase and the other CYPs (vs 11-hydroxylase 
and CYP3A4). On the contrary, gem-dimethyl derivatives 89i with fused imidazole ring exhibited 
decreased inhibitory activity against human 17,20-lyase with lower selectivity between human 
17,20-lyase and the other CYPs, compared with 89c. The results were consistent with our previous 
docking experiment of (-)-71b, and they suggested that the bulkyness near the coordinated site 
should give some negative impact on inhibitory activity against 17,20-lyase. Additionally, for better 
understanding of excellent selectivity between human 17,20-lyase and the other CYPs of 89c, a few 
analogues of 89c were also investigated. 
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Table 15. Inhibitory effect of compounds 71b, 89c–d, 89i–j on rat and human 17,20-lyase, 
11-hydroxylase and CYP3A4 
 
 
Compound No. R
2
 R
3
 
Enzyme inhibition IC50 (nM) 
17, 20-lyase 11-hydroxylase CYP3A4 
Rat Human 
71b — 6.1 16 >1000 3600 
89c H OH 54 38 >1000 >10,000 
89i Me OH 110 88 520 3200 
89d H H 15 13 290 <1000 
89j — >1000 410 >1000 6900 
 
Table 16. Inhibitory effect of compounds 89b–c, 89e–g on rat and human 17,20-lyase, 
11-hydroxylase and CYP3A4 
 
 
Compound 
No. 
R
1
 
Enzyme inhibition IC50 (nM) 
17, 20-lyase 11-hydroxylase CYP3A4 
Rat Human 
89c NHMe 54 38 >1000 >10,000 
89b NH2 24 29 100 >10,000 
89e NHEt 110 190 >1000 >10,000 
89f NHcyclopropyl 100 290 >1000 >10,000 
89g NHi-Pr 160 400 >1000 >10,000 
 
As a result, the removal of hydroxyl group (89d) of 89c led to considerably decreased selectivity 
between human 17,20-lyase and the other CYPs while keeping the potent inhibitory activity against 
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human 17,20-lyase. The cleaved derivatives (89j) of fused imidazole ring on 89c was also 
investigated to result in both decreased inhibitory activity against 17,20-lyase and selectivity 
between 17,20-lyase and CYP3A4. These results indicated that both hydroxyl group and fused ring 
structure of 89c may have the responsibility for its selectivity between 17,20-lyase and CYP3A4. 
The effect of substitution of carbamoyl group on inhibition of rat and human 17,20-lyase, 
11-hydroxylase and CYP3A4 was summarized in Table 16. Replacement of methylcarbamoyl group 
of 89c with carbamoyl group (89b) had little effect on inhibitory activity against human 17,20-lyase 
and selectivity between 17,20-lyase and CYP3A4, but led to decreased selectivity between 
17,20-lyase and 11-hydroxylase. Replacing the methyl group of 89c with small alkyl groups such as 
ethyl (89e), cyclopropyl (89f) and i-propyl (89g) groups resulted in 5–11-fold weaker inhibitory 
activity against human 17,20-lyase. These results suggested that the methylcarbamoyl group (89c) 
was optimal in terms of both inhibitory activity against human 17,20-lyase and selectivity between 
17,20-lyase and the other CYPs. 
The enantiomers, (+)-89c and (−)-89c, both exhibited potent inhibitory activity against human 
17,20-lyase and promising selectivity between human 17,20-lyase and CYP3A4, as shown in Table 
17. In particular, the inhibitory effect on CYP3A4 of (+)-89c was hardly detectable at 10,000 nM. 
Therefore, (+)-89c was identified as a highly selective inhibitor with a greater than 500-fold 
selectivity between 17,20-lyase and CYP3A4. The enantiomers were also assessed for the inhibition 
of 11-hydroxylase, and both (+)-89c and (−)-89c exhibited low probability of inhibition against 
11-hydroxylase below 1000 nM. 
 
Table 17. Inhibitory effect of (+)-89c and (−)-89c on rat and human 17,20-lyase, 11-hydroxylase and 
CYP3A4 
Compound No. 
Enzyme inhibition IC50 (nM) 
17, 20-lyase 11-hydroxylase CYP3A4 
Rat Human 
(+)-89c 48 19 >1000 >10,000 
(−)-89c 180 48 >1000 >10,000 
 
4.8. A preliminary study in cynomolgus monkeys 
 
In addition to the in vitro studies, the ability of (+)-89c and (−)-89c to reduce serum androgen 
concentrations were examined in a preliminary study using cynomolgus monkeys, and in these 
studies both testicular androgen testosterone and adrenal androgen dehydroepiandrosterone (DHEA) 
levels were measured. As a result, (+)-89c administered orally at a dose of 1 mg/kg reduced serum 
testosterone and DHEA levels 8 h after administration (Table 18). In contrast, (−)-89c had a smaller 
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effect on these parameters. This difference in in vivo efficacy between (+)-89c and (−)-89c may 
reflect differences in in vitro inhibitory activities and the pharmacokinetic profiles of the two 
compounds, but additional investigations would be required to examine these possibilities. In 
summary, these biological evaluations revealed that (+)-89c had a promising profile for further 
development in terms of both in vitro inhibitory activity and in vivo potency with exploitable 
selectivity between 17,20-lyase and CYP3A4. 
 
Table 18. In vivo effects of (+)-89c and (−)-89c on serum testosterone and DHEA levels after single 
oral dosing (1 mg/kg) in cynomolgus monkeys 
Compound No. 
% of average 0 h values, mean ± SD 
Serum testosterone Serum DHEA 
8 h 8 h 
Vehicle for (+)-89c 101 ± 54 54 ± 25 
(+)-89c (1 mg/kg) 30 ± 23 12 ± 8.0 
Vehicle for (−)-89c 296 ± 277 25 ± 6.2 
(−)-89c (1 mg/kg) 258 ± 302 91 ± 126 
 
4.9. In vivo efficacy on (+)-89c 
 
In a monkey model, both testosterone and DHEA levels were investigated at different time points 
(2, 5 and 10 h) after dosing to evaluate in vivo potency of (+)-89c, as shown in Table 19. When given 
orally to monkeys at a dose of 1 mg/kg, (+)-89c markedly reduced serum testosterone and DHEA at 
5 h after administration. This finding suggested that (+)-89c should be useful for the clinical 
treatment of both hormone-dependent prostate cancer and CRPC. 
 
Table 19. In vivo effects of (+)-89c on serum testosterone and DHEA levels after single oral dosing 
(1 mg/kg) in cynomolgus monkeys 
Compound No. 
% of pre-treatment average
 a
, mean ± SD 
Serum testosterone Serum DHEA 
2 h 5 h 10 h 2 h 5 h 10 h 
Vehicle 90.0 ± 16.6 63.0 ± 19.2 269.8 ± 94.5 97.9 ± 22.3 88.6 ± 4.4 7.2 ± 0.99 
(+)-89c (1 mg/kg) 75.9 ± 50.0 14.2 ± 3.2 55.6 ± 18.7 61.1 ± 15.1 32.8 ± 11.1 7.6 ± 1.8 
a 
Mean serum testosterone and DHEA levels on three consecutive days prior to treatment.
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4.10. Inhibitory effect of (+)-89c on CYP isoform-specific activity 
 
In a series of in vitro studies, the possible inhibitory effect of the selected compound (+)-89c on 
CYP-specific activities was investigated using microsomes expressing human CYP isoforms. As 
shown in Table 20, (+)-89c inhibited the specific activities of CYP2C19; however, the IC50 values 
for all the CYP-specific activities were greater than 10,000 nM. Inhibitory effects on CYP2A6, 
CYP2B6 and CYP3A4 were hardly detectable with IC50 values of up to 30,000 nM. Compound 
(+)-89c was shown to exhibit greater inhibitory effects on 17,20-lyase compared with the other CYP 
isoforms, thus indicating that (+)-89c is a selective 17,20-lyase inhibitor. 
 
Table 20. Inhibitory effect of (+)-89c on human 17,20-lyase (CYP17A1) and marker enzyme 
activities of microsomes expressing human CYP isoforms 
Enzyme inhibition IC50 (nM) 
CYP isoforms 
17A1 
(17,20-lyase) 
1A2 2A6 2B6 2C8 
2C9 
(Arg) 
2C9 
(Cys) 
2C19 2D6 2E1 3A4 
19 28,000 >30,000 >30,000 >30,000 >30,000 >30,000 14,000 >30,000 >30,000 >30,000 
Marker enzyme activities are as follows; CYP1A2: 7-ethoxyresorufin O-deethylation; CYP2A6: coumarin 7-hydroxylation; 
CYP2B6: ethoxycoumarin O-deethylation; CYP2C8, 2C9(Arg), 2C9(Cys): tolbutamide hydroxylation; CYP2C19: 
(S)-mephenytoin 4'-hydroxylation; CYP2D6: (+)-bufuralol 1'-hydroxylation; CYP2E1: 4-nitrophenol hydroxylation; CYP3A4: 
testosterone 6β-hydroxylation. 
 
4.11. Docking experiments 
 
To determine the binding mode of (+)-89c, a docking study was conducted using a homology 
model for the catalytic domain of 17,20-lyase. In the docking experiment, it was postulated that 
(+)-89c was coordinated to the catalytic heme iron via the nitrogen of the imidazole ring moiety.  
The results of the docking study are shown in Figure 17, and suggest that the naphthalene ring of 
(+)-89c is contained in a hydrophobic pocket surrounded by Ala 113, Phe 114, Ile 205, Ala 302 and 
Ile 371. In addition, the carbamoyl oxygen of (+)-89c was shown to form a hydrogen bond with Thr 
101, while the hydroxy group formed a hydrogen bond with Thr 306. These results were consistent 
with our previous experiments on (-)-71b. Moreover, the superimposition of (+)-89c with 
17α-hydroxypregnenolone, a known substrate of 17,20-lyase, demonstrated that the naphthalene ring 
of (+)-89c and the B and C rings of the steroidal skeleton of 17α-hydroxypregnenolone are located in 
a similar position (Figure 18). 
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Figure 17. Docking study of (+)-89c in the homology model of 17,20-lyase. 
 
 
Figure 18. Overlay of (+)-89c (white) with 17α-hydroxypregnenolone (green) in the homology 
model of 17,20-lyase. 
 
4.12. Conclusions 
 
A novel naphthylmethylimidazole derivative (-)-71b and its related compounds were identified as 
17,20-lyase inhibitors. Based on the structure–activity relationship around the naphthalene scaffold 
and the results of a docking study of (-)-71b in the homology model of 17,20-lyase, the 
6,7-dihydro-5H-pyrrolo[1,2-c]imidazole derivative (+)-89c was synthesized and identified as a 
potent and highly selective 17,20-lyase inhibitor. Biological evaluation of (+)-89c at a dose of 1 
mg/kg in a male monkey model revealed marked reductions in both serum testosterone and 
dehydroepiandrosterone concentrations. Furthermore, asymmetric synthesis of (+)-89c has been 
heme
Thr 306
Thr 101
Ala 113
Phe 114
Ile 205
Ala 302
Ile 371
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established by developing the novel chelation-assisted enantioselective Reformatsky reaction using 
cinchona alkaloids as a chiral ligand. 
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5. Conclusions 
 
As discussed in the previous sections 2 through 4, (-)-19, (-)-74b and (+)-89c were identified as 
promising candidates for further development. The Figure 19 summarizes the selected flow of 
representative compounds, (-)-19, (-)-74b and (+)-89c, and their biological profiles. In terms of in 
vivo activity in a monkey model and selectivity between 17,20-lyase and the other CYP family 
enzymes, (+)-89c was identified as a potent and highly selective inhibitor of 17,20-lyase. 
 
 
Figure 19. Summary of biological profiles for selected compounds, (-)-19, (-)-74b and (+)-89c 
(orteronel). 
 
To rationalize the characteristic properties of (+)-89c identified as a highly selective 17,20-lyase 
inhibitor over the other CYPs, a homology model for the catalytic domain of CYP3A4 was also 
investigated and the docking experiment of (+)-89c was conducted. First, the impact of 
conformational change as a factor contributing to enzyme selectivity was examined for two different 
inhibitors, compounds (-)-71b (CYP3A4 IC50 = 7800 nM) and (+)-89c (CYP3A4 IC50 = >30,000 
nM) (Figure 20). In the homology model, it was shown that when (-)-71b is bound to the active site 
of CYP3A4, the naphthyl group is located in the pocket, as shown in Figure 20. However, in the case 
of (+)-89c, owing to the high rigidity of the molecule, it was difficult to superimpose (+)-89c with 
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(-)-71b for this model. Furthermore, we determined that when (+)-89c was coordinated to the heme 
iron via the nitrogen of the fused imidazole ring moiety, a part of the naphthyl group appeared to be 
out of the pocket, shown as a red dotted circle in Figure 20. Based on these observations and 
previously discussed SAR study in Table 15, the conformational rigidity of the fused imidazole ring 
moiety of (+)-89c may contribute to its selectivity of 17,20-lyase over CYP3A4. 
 
 
Figure 20. Docking study of (-)-71b (magenta) with (+)-89c (green) in the homology model of 
CYP3A4. 
 
Another potential factor that may affect enzyme selectivity is the lipophilicity of the inhibitors. 
As described above, CYP family of enzymes is known to prefer lipophilic molecules as substrates or 
inhibitors. Therefore, an index such as Clog P, which represents the lipophilicity of a molecule, may, 
at least in part, provide helpful information on enzyme selectivity. The Clog P values of compounds 
(-)-71b and (+)-89c were 1.5 and 0.3, respectively, and the correlation between the potency of 
inhibition for CYP3A4 and Clog P values of these two inhibitors were as expected; (+)-89c with a 
lower Clog P value showed less potent inhibition against CYP3A4 than (-)-71b with a higher Clog P 
value. Based on these data, the decreased inhibition of CYP3A4 by (+)-89c seemed to be partly due 
to a decrease in lipophilicity of the molecule. However, regarding the inhibition of 17,20-lyase, 
(+)-89c shows potent inhibition with a lower Clog P value; therefore, additional contributions such 
as hydrogen bond interactions proposed by docking experiments should be considered for further 
discussion. In summary, these observations suggested that two main factors, namely conformational 
rigidity of the fused imidazole ring moiety and the low Clog P value of (+)-89c, may account for the 
observed selectivity for 17,20-lyase versus CYP3A4. 
In general, ring systems such as imidazole and pyridine rings are known to be good ligands for 
heme iron, which is a component of CYP family enzymes. Therefore, difficulties are often 
encountered when developing CYP inhibitors with these rings, owing to their ability to bind 
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nonselectively to heme iron found in the CYP enzymes. The author believes that these findings 
regarding the selectivity of (+)-89c over the CYPs could be applied to other series of CYP inhibitors 
and the author's approach to (+)-89c may provide a new methodology in this field. Finally, (+)-89c 
(termed orteronel [TAK-700]) was selected as a candidate for further development, and clinical 
evaluation of orteronel has been investigated for the potential treatment of metastatic CRPC. 
 
In conclusion, this study provides an excellent example of medicinal chemistry effort with a 
novel strategy that is able to achieve high specificity for the inhibition of 17,20-lyase over the other 
CYP enzymes, and the following new insights were obtained throughout this study. 
 
1. SARs for the novel series of biphenylylmethylimidazole derivatives and 
naphthylmethylimidazole derivatives as 17,20-lyase inhibitors were explored and compounds 
(-)-19, (-)-74b and orteronel as selective and orally active 17,20-lyase inhibitors were 
discovered by the novel approach using the homology model of 17,20-lyase. 
 
2. Asymmetric synthesis of (-)-19, (-)-74b and orteronel were examined, and especially, 
enantioselective Reformatsky reaction using cinchonine as a chiral ligand was developed in 
the case of orteronel. 
 
3. Orteronel was identified as a potent, highly selective and nonsteroidal inhibitor of 17,20-lyase 
and selected as a candidate for clinical evaluation.
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6. Experimental 
 
Melting points were determined using a BUCHI Melting Point B-545 apparatus and are 
uncorrected. Infrared (IR) spectra were recorded using a SHIMADZU FT-IR-8200PC spectrometer. 
1
H NMR spectra were recorded using a Varian Gemini-200, Varian Mercury-300 spectrometer, or a 
Bruker AVANCE-300 spectrometer. 
13
C NMR spectra were recorded using a Bruker AVANCE-300 
spectrometer; chemical shifts are given in ppm with tetramethylsilane as an internal standard, and 
coupling constants (J) are measured in hertz (Hz). The following abbreviations are used: s = singlet, 
d = doublet, t = triplet, m = multiplet, br s = broad singlet. LCMS was performed on the 
Agilent1200Sl and Agilent6130MS apparatus with 5 mM aqueous AcONH4 solution/acetonitrile 
mobile phase. Reactions were followed by TLC on Silica Gel 60 F254 precoated TLC plates (Merck, 
Darmstadt, Germany). Column chromatography was performed using Silica Gel 60 (E. Merck, 
Darmstadt, Germany). Compounds 4a–b, 5a–b, 13a–d, 22a–b, 22d–e, 42 were commercially 
available, compounds 6,
 49
 22c,
 50
 29,
 51
 , 39
 52
 and 60
 80
 were prepared in the same manner as 
described previously, and compound 11 was easily prepared from compound 6 and trityl chloride in 
the usual manner.  
 
6.1.1. General procedure for method A and 
1-[1,1'-biphenyl]-3-yl-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (7) 
 
n-BuLi in hexane (1.6 M; 6.4 mL, 10.2 mmol) was added to a cooled (−78°C) solution of 4a 
(2.11 g, 9.05 mmol) in THF (30 mL) and the mixture was stirred at −78°C for 1 h. A solution of 6 
(400 mg, 2.89 mmol) in THF (10 mL) was added to the mixture and the solution was allowed to 
warm to rt. The reaction was quenched with aqueous NH4Cl solution and the aqueous phase was 
extracted with AcOEt. The extract was dried over MgSO4 and concentrated under reduced pressure. 
The residue was chromatographed on silica gel (CH2Cl2/MeOH = 20:1) and recrystallized from 
AcOEt–hexane to give 7 (450 mg, 1.54 mmol, 53%) as a colorless powder. Melting point (mp) 180–
183°C (AcOEt–hexane). 
1
H NMR (CDCl3+CD3OD) δ: 0.83 (3H, d, J = 6.6 Hz), 0.99 (3H, d, J = 6.6 
Hz), 2.55–2.73 (1H, m), 6.97 (1H, d, J = 1.0 Hz), 7.28–7.50 (7H, m), 7.54–7.62 (2H, m), 7.72–7.77 
(1H, m). IR (KBr): 3200, 1005, 799 cm
−1
. Anal. Calcd for C19H20N2O: C, 78.05; H, 6.89; N, 9.58. 
Found: C, 77.84; H, 6.86; N, 9.36. Compounds 8–10 were prepared in the same manner as described 
for the preparation of 7. 
  
 56 
 
6.1.2. 1-(1H-Imidazol-4-yl)-1-(4'-methoxy-[1,1'-biphenyl]-3-yl)-2-methyl-1-propanol (8) 
 
Yield 74%. Mp 74–77°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.82 (3H, d, J = 6.9 Hz), 0.98 
(3H, d, J = 6.9 Hz), 2.50–2.74 (1H, m), 3.83 (3H, s), 6.89–6.99 (3H, m), 7.26–7.55 (6H, m), 7.71–
7.76 (1H, m). IR (KBr): 2969, 1516, 1480, 1248, 1181 cm
−1
. Anal. Calcd for C20H22N2O2: C, 74.51; 
H, 6.88; N, 8.69. Found: C, 74.45; H, 7.17; N, 8.40. 
 
6.1.3. 1-[1,1'-Biphenyl]-4-yl-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (9) 
 
Yield 83%. Mp 182–183°C (AcOEt–hexane). 
1
H NMR (CDCl3+CD3OD) δ: 0.83 (3H, d, J = 6.8 
Hz), 0.99 (3H, d, J = 6.8 Hz), 2.57–2.74 (1H, m), 6.98 (1H, d, J = 1.2 Hz), 7.30–7.47 (3H, m), 7.50–
7.65 (7H, m). IR (KBr): 3142, 2965, 1487, 826, 762 cm
−1
. Anal. Calcd for C19H20N2O·0.1H2O: C, 
77.57; H, 6.92; N, 9.52. Found: C, 77.57; H, 6.95; N, 9.61. 
 
6.1.4. 1-(1H-Imidazol-4-yl)-1-(4'-methoxy[1,1'-biphenyl]-4-yl)-2-methyl-1-propanol (10) 
 
Yield 39%. Mp 200–201°C (AcOEt). 
1
H NMR (CDCl3+CD3OD) δ: 0.83 (3H, d, J = 6.6 Hz), 0.98 
(3H, d, J = 6.6 Hz), 2.52–2.76 (1H, m), 3.85 (3H, s), 6.92–7.02 (3H, m), 7.38–7.62 (7H, m). IR 
(KBr): 3218, 1497, 1252, 1038, 1007, 816 cm
−1
. Anal. Calcd for C20H22N2O2: C, 74.51; H, 6.88; N, 
8.69. Found: C, 74.64; H, 6.89; N, 8.53. 
 
6.1.5. General procedure for method B and 
1-(3-bromophenyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol (12a) 
 
n-BuLi (1.6 M; 50 mL, 80 mmol) was added to a cooled (−78°C) solution of 1,3-dibromobenzene 
(29.02 g, 123 mmol) in diethylether (250 mL) and the mixture was stirred at −78°C for 30 min. A 
solution of 11 (20.0 g, 53 mmol) in THF (100 mL) was added and the solution was allowed to warm 
to −50°C. After stirring at −50°C for a further 30 min, the reaction was quenched with aq NH4Cl 
solution. The mixture was extracted with AcOEt and dried over MgSO4. After removal of the solvent, 
the residue was recrystallized from AcOEt–hexane to give 12a (25.30 g, 47 mmol, 90%) as a 
colorless powder. Mp 164–165°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.72 (3H, d, J = 6.8 Hz), 
0.90 (3H, d, J = 6.8 Hz), 2.22–2.44 (1H, m), 3.65 (1H, s), 6.73 (1H, d, J = 1.6 Hz), 7.06–7.19 (7H, 
m), 7.26–7.39 (11H, m), 7.46 (1H, dt, J = 7.8, 1.3 Hz), 7.59 (1H, t, J = 1.8 Hz). IR (KBr): 1493, 
1472, 1445, 702 cm
−1
. Anal. Calcd for C32H29N2OBr: C, 71.51; H, 5.44; N, 5.21. Found: C, 71.43; H, 
5.60; N, 5.38. Compound 12b was prepared in the same manner as described for the preparation of 
12a. 
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6.1.6. 1-(4-Bromophenyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol (12b) 
 
Yield 82%. Mp 145–146°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.71 (3H, d, J = 6.6 Hz), 0.89 
(3H, d, J = 6.6 Hz), 2.30–2.44 (1H, m), 3.50 (1H, s), 6.72 (1H, d, J = 1.2 Hz), 7.09–7.16 (6H, m), 
7.30–7.38 (14H, m). IR (KBr): 1489, 1445, 1159, 1009, 909, 812, 747, 735, 702, 660 cm
−1
. Anal. 
Calcd for C32H29N2OBr: C, 71.51; H, 5.44; N, 5.21. Found: C, 71.54; H, 5.48; N, 5.20. 
 
6.1.7. 1-(4'-Fluoro-[1,1'-biphenyl]-3-yl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 
(14a) 
 
Under N2 atmosphere, a mixture of 12a (1.01 g, 1.88 mmol), 4-fluorophenylboronic acid (413 mg, 
2.95 mmol) and Pd(PPh3)4 (0) (190 mg, 0.16 mmol) in dimethyloxyethane (DME)/2 M Na2CO3 (20 
mL/8 mL) was refluxed for 18 h. The resulting mixture was extracted with AcOEt and the organic 
layer was dried over MgSO4 and concentrated under reduced pressure. The residue was 
chromatographed on silica gel (hexane/AcOEt = 4:1) and recrystallized from AcOEt–hexane to give 
14a (705 mg, 1.28 mmol, 68%) as a pale yellow powder. Mp 141–143°C (AcOEt–hexane). 
1
H NMR 
(CDCl3) δ: 0.75 (3H, d, J = 6.8 Hz), 0.93 (3H, d, J = 6.8 Hz), 2.35–2.52 (1H, m), 3.70 (1H, s), 6.78 
(1H, d, J = 1.0 Hz), 7.04–7.18 (8H, m), 7.22–7.38 (12H, m), 7.44–7.55 (3H, m), 7.63 (1H, s). IR 
(KBr): 1512, 1480, 1233, 1159 cm
−1
. Anal. Calcd for C38H33N2OF: C, 82.58; H, 6.02; N, 5.07. 
Found: C, 82.43; H, 5.83; N, 4.91. Compounds 14b–f were prepared in the same manner as 
described for the preparation of 14a. 
 
6.1.8. 1-(4'-Chloro[1,1'-biphenyl]-3-yl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 
(14b) 
 
Yield 70%. Mp 157°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.75 (3H, d, J = 6.7 Hz), 0.94 (3H, 
d, J = 6.7 Hz), 2.35–2.55 (1H, m), 3.70 (1H, s), 6.78 (1H, d, J = 1.4 Hz), 7.05–7.60 (23H, m), 7.65 
(1H, s). IR (KBr): 1493, 1476, 1445, 909 cm
−1
. Anal. Calcd for C38H33N2OCl·H2O: C, 79.94; H, 
5.86; N, 4.91. Found: C, 79.85; H, 5.85; N, 4.80. 
 
6.1.9. 1-(4'-Fluoro-[1,1'-biphenyl]-4-yl)-1-(1-trityl-1H-imidazol-4-yl)-2-methyl-1-propanol 
(14c) 
 
Yield 80%. Mp 213–214°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.77 (3H, d, J = 6.6 Hz), 0.92 
(3H, d, J = 6.6 Hz), 2.42–2.49 (1H, m), 3.53 (1H, s), 6.78 (1H, s), 7.06–7.15 (7H, m), 7.33–7.57 
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(17H, m). IR (KBr): 1493, 1445, 1223, 1159, 818, 748, 733, 702 cm
−1
. Anal. Calcd for C38H33N2OF: 
C, 81.52; H, 6.08; N, 5.00. Found: C, 81.58; H, 6.08; N, 4.92. 
 
6.1.10. 1-(4'-Chloro-[1,1'-biphenyl]-4-yl)-1-(1-trityl-1H-imidazol-4-yl)-2-methyl-1-propanol 
(14d) 
 
Yield 85%. Mp 211–212°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.76 (3H, d, J = 7.0 Hz), 0.92 
(3H, d, J = 7.0 Hz), 2.42–2.49 (1H, m), 3.53 (1H, s), 6.78 (1H, s), 7.13–7.15 (6H, m), 7.32–7.59 
(18H, m). IR (KBr): 1485, 1445, 1094, 1005, 909, 812, 747, 733, 700 cm
−1
. Anal. Calcd for 
C38H33N2OCl: C, 79.69; H, 5.88; N, 4.89. Found: C, 79.48; H, 6.14; N, 4.72. 
 
6.1.11. N-{4'-[1-Hydroxy-2-methyl1-(1-trityl-1H-imidazol-4-yl)propyl][1,1'-biphenyl]-3-yl} 
acetamide (14e) 
 
Yield 96%. 
1
H NMR (CDCl3) δ: 0.76 (3H, d, J = 6.6 Hz), 0.92 (3H, d, J = 6.6 Hz), 2.20 (3H, s), 
2.38–2.56 (1H, m), 3.55 (1H, s), 6.77 (1H, d, J = 1.2 Hz), 7.06–7.20 (6H, m), 7.24–7.76 (18H, m). 
IR (KBr): 3063, 1674, 1557, 1483, 1445 cm
−1
. FAB-MS m/z: 592.2935 (calcd for C40H38N3O2: 
592.2964). 
 
6.1.12. N-{4'-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl][1,1'-biphenyl]-4-yl} 
acetamide (14f) 
 
Yield 32%. Mp 244–248°C (AcOEt). 
1
H NMR (CDCl3) δ: 0.77 (3H, d, J = 6.6 Hz), 0.93 (3H, d, J 
= 6.6 Hz), 2.20 (3H, s), 2.30–2.56 (1H, m), 3.53 (1H, s), 6.77 (1H, d, J = 1.4 Hz), 7.08–7.14 (6H, m), 
7.27–7.38 (10H, m), 7.43–7.58 (8H, m). IR (KBr): 2971, 1671, 1535, 1493 cm
−1
. Anal. Calcd for 
C40H37N3O2: C, 81.19; H, 6.30; N, 7.10. Found: C, 81.01; H, 6.37; N, 6.99. 
 
6.1.13. 1-(4'-Fluoro[1,1'-biphenyl]-3-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (15) 
 
A mixture of 14a (620 mg, 1.12 mmol) and pyridine hydrochloride (270 mg, 2.34 mmol) in 
MeOH (20 mL) was stirred at 60°C for 4 h. The mixture was made alkaline with aq NaHCO3 
solution and concentrated under reduced pressure. The resulting mixture was extracted with AcOEt 
and the combined organic layers were dried over MgSO4. After removal of the solvent, the residue 
was chromatographed on silica gel (CH2Cl2/MeOH = 40:1) and recrystallized from AcOEt–hexane 
to give 15 (274 mg, 0.88 mmol, 79%) as a colorless powder. Mp 154–156°C (AcOEt–hexane). 
1
H 
NMR (CDCl3+CD3OD) δ: 0.82 (3H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.8 Hz), 2.40–2.80 (1H, m), 
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6.70–7.16 (3H, m), 7.30–7.59 (6H, m), 7.72 (1H, s). IR (KBr): 3187, 1514, 1236, 1005, 795 cm
−1
. 
Anal. Calcd for C19H19N2OF: C, 73.53; H, 6.17; N, 9.03. Found: C, 73.48; H, 5.94; N, 9.02. 
Compounds 16–20 were prepared in the same manner as described for the preparation of 15. 
 
6.1.14. 1-(4'-Chloro[1,1'-biphenyl]-3-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (16) 
 
Yield 76%. Mp 169°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.82 (3H, d, J = 6.8 Hz), 0.98 (3H, 
d, J = 6.8 Hz), 2.50–2.78 (1H, m), 6.99 (1H, d, J = 1.0 Hz), 7.33–7.44 (4H, m), 7.45–7.56 (4H, m), 
7.78 (1H, s). IR (KBr): 2969, 1476, 1092, 1013 cm
−1
. Anal. Calcd for C19H19N2OCl: C, 69.83; H, 
5.86; N, 8.57. Found: C, 69.98; H, 5.98; N, 8.50. 
 
6.1.15. 1-(4'-Fluoro[1,1'-biphenyl]-4-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (17) 
 
Yield 69%. Mp 198–199°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.85 (3H, d, J = 7.0 Hz), 1.00 
(3H, d, J = 7.0 Hz), 2.60–2.74 (1H, m), 3.42 (1H, br s), 7.02–7.16 (3H, m), 7.48–7.66 (7H, m), 9.16 
(1H, br s). IR (KBr): 3241, 1493, 1397, 1242, 1009, 814, 781, 762, 623, 511 cm
−1
. Anal. Calcd for 
C19H19N2OF: C, 75.53; H, 6.17; N, 9.03. Found: C, 73.43; H, 6.09; N, 9.03. 
 
6.1.16. 1-(4'-Chloro[1,1'-biphenyl]-4-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (18) 
 
Yield 76%. Mp 197–198°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.83 (3H, d, J = 7.0 Hz), 0.98 
(3H, d, J = 7.0 Hz), 2.58–2.75 (1H, m), 3.38 (1H, br s), 7.00 (1H, s), 7.37 (2H, d, J = 8.4 Hz), 7.48–
7.64 (7H, m), 9.24 (1H, br s). IR (KBr): 3200, 1485, 1364, 1190, 1094, 1028, 1005, 808, 781 cm
−1
. 
Anal. Calcd for C19H19N2OCl: C, 69.83; H, 5.86; N, 8.57. Found: C, 69.80; H, 5.85; N, 8.65. 
 
6.1.17. N-{4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl][1,1'-biphenyl]-3-yl}acetamide 
(19) 
 
Yield 48%. 
1
H NMR (CDCl3+CD3OD) δ: 0.82 (3H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.8 Hz), 2.17 
(3H, s), 2.51–2.74 (1H, m), 6.96 (1H, d, J = 1.0 Hz), 7.25–7.39 (3H, m), 7.42–7.56 (5H, m), 7.68 
(1H, s). IR (KBr): 3210, 2971, 1672, 1557, 1483 cm
−1
. Anal. Calcd for C21H23N3O2 · 0.75 H2O: C, 
69.50; H, 6.80; N, 11.58. Found: C, 69.12; H, 6.91; N, 11.45. FAB-MS m/z: 350.1825 (calcd for 
C21H24N3O2: 350.1869). 
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6.1.18. N-{4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl][1,1'-biphenyl]-4-yl}acetamide 
(20) 
 
Yield 21%. Mp 199–201°C (AcOEt). 
1
H NMR (CDCl3+CD3OD) δ: 0.82 (3H, d, J = 6.8 Hz), 0.98 
(3H, d, J = 6.8 Hz), 2.17 (3H, s), 2.49–2.70 (1H, m), 6.96 (1H, d, J = 0.8 Hz), 7.44–7.60 (9H, m). IR 
(KBr): 3173, 1667, 1534, 1499 cm
−1
. Anal. Calcd for C21H23N3O2·0.1AcOEt: C, 71.75; H, 6.70; N, 
11.73. Found: C, 71.70; H, 6.65; N, 11.90. 
 
6.1.19. General procedure for method C and 
4-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl] phenylboronic acid (21) 
 
n-BuLi (1.6 M; 14 mL, 23 mmol) was added to a cooled (−78°C) solution of 1,4-dibromobenzene 
(5.10 g, 22 mmol) in diethylether (30 mL) and THF (40 mL) and the mixture was stirred at −78°C 
for 15 min. A solution of 12b (6.50 g, 17 mmol) in THF (30 mL) was added dropwise to the mixture. 
After stirring at −78°C for 15 min, n-BuLi (1.6 M; 20 mL, 33 mmol) was added dropwise. The 
resulting mixture was further stirred at −78°C for 15 min and trimethoxyborane (15 mL, 134 mmol) 
was added. The mixture was allowed to warm to rt and further stirred for 1 h. HCl (1 N) was added 
to the reaction mixture and the solution was extracted with AcOEt. The combined organic layers 
were concentrated under reduced pressure. The residue was redissolved in AcOEt and the solution 
was washed with 1 N NaOH and brine, before being dried over MgSO4. Concentration of the solvent 
under reduced pressure gave crude 21 (4.00 g) as a colorless amorphous solid. This compound was 
used for the next step without further purification. 
 
6.1.20. 4'-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl[1,1'-biphenyl]-3
-carboxamide (23a) 
 
Under N2 atmosphere a mixture of crude 21 (3.44 g), 3-bromophenyl-N-methylcarboxamide 22a 
(1.10 g, 5.14 mmol) and Pd(PPh3)4 (0) (210 mg, 0.18 mmol) in DME (20 mL) and 2 M Na2CO3 
solution (20 mL) was refluxed for 16 h. The resulting mixture was extracted with AcOEt and the 
combined organic layers were dried over MgSO4 and concentrated under reduced pressure. The 
residue was chromatographed on silica gel (hexane/AcOEt = 1:2) to give 23a (1.00 g, 1.69 mmol, 
33%) as a pale yellow amorphous solid. 
1
H NMR (CDCl3) δ: 0.76 (3H, d, J = 6.7 Hz), 0.93 (3H, d, J 
= 6.7 Hz), 2.30–2.54 (1H, m), 3.02 (3H, d, J = 4.8 Hz), 3.58 (1H, s), 6.33 (1H, br s), 6.78 (1H, d, J = 
1.4 Hz), 7.04–7.20 (6H, m), 7.22–7.38 (9H, m), 7.39–7.76 (8H, m), 7.98 (1H, t, J = 1.4 Hz). IR 
(KBr): 3295, 2969, 1644, 1549, 1121 cm
−1
. FAB-MS m/z: 592.2999 (calcd for 
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C40H38N3O2:592.2964). Compounds 23b–e were prepared in the same manner as described for the 
preparation of 23a. 
 
6.1.21. 4'-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl[1,1'-biphenyl]-3
-sulfonamide (23b) 
 
Yield 24%. Mp 148–149°C (AcOEt). 
1
H NMR (CDCl3) δ: 0.76 (3H, d, J = 6.8 Hz), 0.93 (3H, d, J 
= 6.8 Hz), 2.36–2.58 (1H, m), 2.69 (3H, d, J = 5.6 Hz), 3.57 (1H, s), 4.38–4.50 (1H, m), 6.79 (1H, s), 
7.08–7.20 (6H, m), 7.28–7.40 (10H, m), 7.48–7.65 (5H, m), 7.80 (2H, d, J = 8.0 Hz), 8.07 (1H, s). 
IR (KBr): 2969, 1495, 1472, 1445, 1327, 1161 cm
−1
. Anal. Calcd for C39H37N3O3S: C, 74.61; H, 
5.94; N, 6.69. Found: C, 74.71; H, 6.00; N, 6.69. 
 
6.1.22. N-{4'-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl][1,1'-biphenyl]-3-yl}-N'
-methylurea (23c) 
 
Yield 34%. 
1
H NMR (CDCl3) δ: 0.75 (3H, d, J = 6.7 Hz), 0.92 (3H, d, J = 6.7 Hz), 2.38–2.56 (1H, 
m), 2.78 (3H, d, J = 4.6 Hz), 3.52 (1H, s), 5.00–5.20 (1H, m), 6.79 (1H, d, J = 1.0 Hz), 6.90 (1H, br 
s), 7.06–7.18 (6H, m), 7.22–7.39 (14H, m), 7.42 (2H, d, J = 8.6 Hz), 7.51 (2H, d, J = 8.6 Hz). IR 
(KBr): 2967, 1669, 1557 cm
−1
. Anal. Calcd for C40H38N4O2·0.2AcOEt: C, 78.48; H, 6.39; N, 8.97. 
Found: C, 78.45; H, 6.53; N, 8.99. 
 
6.1.23. 2-Methyl-1-[4-(2-pyridinyl)phenyl]-1-(1-trityl-1H-imidazol-4-yl)-1-propanol (23d) 
 
Yield 72%. Mp 226–227°C (chloroform–MeOH–hexane). 
1
H NMR (CDCl3) δ: 0.75 (3H, d, J = 
6.8 Hz), 0.93 (3H, d, J = 6.4 Hz), 2.39–2.53 (1H, m), 3.60 (1H, s), 6.78 (1H, d, J = 1.4 Hz), 7.10–
7.35 (17H, m), 7.58–7.63 (2H, m), 7.71–7.78 (2H, m), 7.89–7.93 (2H, m), 8.66–8.69 (1H, m). IR 
(KBr): 1588, 1491, 1466, 1447, 1435, 1003, 781, 747, 702 cm
−1
. 
 
6.1.24. N-{6-(4-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]phenyl)-2-pyridinyl}
acetamide (23e) 
 
Yield 23%. Mp 137°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 0.74 (3H, d, J = 6.8 Hz), 0.92 (3H, 
d, J = 6.8 Hz), 2.20 (3H, s), 2.34–2.58 (1H, m), 3.60 (1H, s), 6.77 (1H, d, J = 1.4 Hz), 7.06–7.20 (6H, 
m), 7.28–7.42 (10H, m), 7.44 (1H, dd, J = 0.8, 7.9 Hz), 7.59 (2H, d, J = 8.4 Hz), 7.75 (1H, t, J = 7.9 
Hz), 7.83 (2H, d, J = 8.4 Hz), 8.05–8.16 (2H, m). IR (KBr): 2969, 1732, 1690, 1447 cm
−1
. Anal. 
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Calcd for C39H36N4O2·1.1AcOEt: C, 75.58; H, 6.55; N, 8.12. Found: C, 75.52; H, 6.46; N, 8.17. 
Compounds 24–28 were prepared in the same manner as described for the preparation of 15. 
 
6.1.25. 4'-[1-Hydroxy1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl[1,1'-biphenyl]-3- 
carboxamide (24) 
 
Yield 42%. 
1
H NMR (CDCl3+CD3OD) δ: 0.81 (3H, d, J = 6.9 Hz), 0.98 (3H, d, J = 6.9 Hz), 
2.40–2.80 (1H, m), 3.00 (3H, s), 6.96 (1H, s), 7.30 (1H, d, J = 1.4 Hz), 7.38–7.60 (5H, m), 7.60–7.74 
(2H, m), 7.93 (1H, s). IR (KBr): 3277, 2969, 1645, 1547 cm
−1
. Anal. Calcd for 
C21H23N3O2·0.75H2O: C, 69.50; H, 6.80; N, 11.58. Found: C, 69.53; H, 7.16; N, 11.28. 
 
6.1.26. 4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl[1,1'-biphenyl]-3- 
sulfonamide (25) 
 
Yield 52%. 
1
H NMR (CDCl3+CD3OD) δ: 0.81 (3H, d, J = 6.6 Hz), 0.98 (3H, d, J = 6.6 Hz), 
2.20–2.70 (4H, m), 6.98 (1H, d, J = 1.2 Hz), 7.48–7.65 (6H, m), 7.74–7.83 (2H, m), 8.04 (1H, t, J = 
1.9 Hz). IR (KBr): 3287, 2971, 1474, 1308, 1161 cm
−1
. Anal. Calcd for C20H23N3O3S·0.5H2O: C, 
60.89; H, 6.13; N, 10.65. Found: C, 61.10; H, 6.31; N, 10.78. 
 
6.1.27. N-{4'-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl][1,1'-biphenyl]-3-yl}-N'- 
methylurea (26) 
 
Yield 61%. 
1
H NMR (CDCl3+CD3OD) δ: 0.77 (3H, d, J = 6.6 Hz), 0.94 (3H, d, J = 6.6 Hz), 
2.40–2.70 (1H, m), 2.71 (3H, s), 6.89 (1H, s), 7.02–7.50 (9H, m). IR (KBr): 3260, 1665, 1557 cm
−1
. 
Anal. Calcd for C20H24N4O2·0.5AcOEt: C, 66.65; H, 7.12; N, 14.13. Found: C, 66.89; H, 7.00; N, 
14.28. 
 
6.1.28. 1-(1H-Imidazol-4-yl)-2-methyl-1-[4-(2-pyridinyl)phenyl]-1-propanol (27) 
 
Yield 26%. 
1
H NMR (CDCl3) δ: 0.82 (3H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.6 Hz), 2.57–2.70 (1H, 
m), 6.95 (1H, d, J = 1.2 Hz), 7.18–7.24 (1H, m), 7.49 (1H, d, J = 1.2 Hz), 7.62–7.79 (4H, m), 7.91 
(2H, d, J = 8.4 Hz), 8.66 (1H, d, J = 4.8 Hz). IR (KBr): 1590, 1468, 1435, 829, 781, 733 cm
−1
. Anal. 
Calcd for C18H19N3O·0.4H2O: C, 71.93; H, 6.64; N, 13.98. Found: C, 71.69; H, 6.55; N, 13.98. 
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6.1.29. N-{6-(4-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]phenyl)-2-pyridyl}acetamide 
(28) 
 
Yield 42%. Mp 206–208°C (AcOEt–MeOH). 
1
H NMR (CDCl3+CD3OD) δ: 0.81 (3H, d, J = 6.7 
Hz), 0.98 (3H, d, J = 6.7 Hz), 2.22 (3H, s), 2.52–2.74 (1H, m), 6.97 (1H, d, J = 1.0 Hz), 7.44 (1H, d, 
J = 7.8 Hz), 7.52 (1H, d, J = 1.0 Hz), 7.59 (2H, d, J = 8.4 Hz), 7.76 (1H, t, J = 7.8 Hz), 7.83 (2H, d, J 
= 8.4 Hz), 8.09 (1H, d, J = 7.8 Hz). IR (KBr): 3177, 2967, 1651, 1559, 1451 cm
−1
. Anal. Calcd for 
C20H22N4O2·0.3AcOEt: C, 67.57; H, 6.53; N, 14.87. Found: C, 67.39; H, 6.63; N, 14.89. 
 
6.1.30. 4-Bromophenyl(1-trityl-1H-imidazol-4-yl)methanol (30) 
 
Compound 30 was prepared in the same manner as described for the preparation of 12a. Yield 
56%. Mp 214–215°C (AcOEt–MeOH–THF–hexane). 
1
H NMR (CDCl3) δ: 3.56 (1H, br s), 5.71 (2H, 
d, J = 4.4 Hz), 6.58 (1H, s), 7.07–7.13 (7H, m), 7.25–7.44 (12H, m). IR (KBr): 1493, 1445, 1128, 
1011, 909, 747, 733, 702 cm
−1
. Anal. Calcd for C29H23N2OBr: C, 70.31; H, 4.68; N, 5.65. Found: C, 
69.93; H, 4.86; N, 5.31. 
 
6.1.31. 4-Bromophenyl(1-trityl-1H-imidazol-4-yl)methanone (31) 
 
A mixture of 30 (30.0 g, 60.6 mmol) and MnO2 (52.6 g, 606 mmol) in CH2Cl2 (1000 mL) was 
stirred at rt for 26 h. The mixture was filtered through Celite, and the filtrate was concentrated in 
vacuo. The residue was recrystallized from AcOEt–Et2O–hexane to give 31 (23.3 g, 47.2 mmol, 
78%) as a colorless powder. Mp 145–146°C (AcOEt–Et2O–hexane). 
1
H NMR (CDCl3) δ: 7.10–7.19 
(6H, m), 7.31–7.41 (9H, m), 7.52 (1H, d, J = 1.4 Hz), 7.68 (2H, d, J = 8.4 Hz), 7.77 (1H, d, J = 1.4 
Hz), 8.21 (2H, d, J = 8.4 Hz). IR (KBr): 1644, 1520, 1213, 887, 756, 747, 702 cm
−1
. 
 
6.1.32. N-[4'-[(1-Trityl-1H-imidazol-4-yl)carbonyl][1,1'-biphenyl]-3-yl]acetamide (32) 
 
Compound 32 was prepared in the same manner as described for the preparation of 14a. Yield 
76%. Mp 198–199°C (AcOEt–hexane). 
1
H NMR (CDCl3) δ: 2.20 (3H, s), 7.14–7.21 (6H, m), 7.36–
7.44 (12H, m), 7.54–7.77 (6H, m), 8.33 (2H, d, J = 8.4 Hz). IR (KBr): 1671, 1645, 1603, 1553, 1524, 
756, 702 cm
−1
. Anal. Calcd for C37H29N3O2: C, 81.15; H, 5.34; N, 7.67. Found: C, 80.89; H, 5.58; N, 
7.45. 
 
 
 64 
 
6.1.33. N-[4'-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)ethyl][1,1'-biphenyl]-3-yl]acetamide 
(33a) 
 
Methylmagnesium bromide (1.0 M in THF, 4.4 mL, 4.38 mmol) was added dropwise to a cooled 
(0°C) solution of 32 (800 mg, 1.46 mmol) in THF (14 mL). After being stirred for 20 min at 0°C, the 
reaction was quenched with saturated NH4Cl solution. The resulting mixture was extracted with 
AcOEt and the combined organic layers were washed with brine and dried over MgSO4. After 
removal of the solvent in vacuo, the residue was recrystallized from AcOEt–MeOH–hexane to give 
33a (823 mg, 1.46 mmol, quant.) as a colorless powder. Mp 157–158°C (AcOEt–MeOH–hexane). 
1
H NMR (CDCl3) δ: 1.81 (3H, s), 2.20 (3H, s), 3.37 (1H, s), 6.79 (1H, d, J = 1.4 Hz), 7.12–7.20 (8H, 
m), 7.31–7.52 (16H, m), 7.65 (1H, br s). IR (KBr): 1672, 1553, 1483, 1445, 909, 747, 733, 700 cm
−1
. 
Anal. Calcd for C38H33N3O2 · 0.5AcOEt: C, 79.05; H, 6.14; N, 6.91. Found: C, 79.13; H, 6.33; N, 
6.71. Compounds 33b,c were prepared in the same manner as described for the preparation of 33a. 
 
6.1.34. N-[4'-[1-Hydroxy-1-(1-trityl-1H-imidazol-4-yl)propyl][1,1'-biphenyl]-3-yl]acetamide 
(33b) 
 
Yield 86%. 
1
H NMR (CDCl3) δ: 0.86 (3H, t, J = 7.6 Hz), 2.12–2.20 (5H, m), 3.35 (1H, s), 6.77 
(1H, s), 7.13–7.22 (6H, m), 7.26–7.48 (18H, m), 7.66 (1H, s). IR (KBr): 1674, 1609, 1557, 1485, 
1445, 747, 733, 702 cm
−1
. Anal. Calcd for C39H35N3O2 · 0.5AcOEt: C, 79.20; H, 6.32; N, 6.76. 
Found: C, 79.23; H, 6.40; N, 6.93. 
 
6.1.35. N-[4'-[Cyclopropyl(hydroxy)(1-trityl-1H-imidazol-4-yl)methyl][1,1'-biphenyl]-3-yl] 
acetamide (33c) 
 
Yield 61%. Mp 230–231°C (AcOEt–MeOH–hexane). 
1
H NMR (CDCl3) δ: 0.41–0.49 (4H, m), 
1.47–1.55 (1H, m), 2.20 (3H, s), 3.26 (1H, s), 6.82 (1H, d, J = 1.4 Hz), 7.11–7.41 (19H, m), 7.50–
7.53 (5H, m), 7.65 (1H, s). IR (KBr): 1671, 1591, 1559, 1483, 1445, 731, 702 cm
−1
. Anal. Calcd for 
C40H35N3O2: C, 81.47; H, 5.98; N, 7.13. Found: C, 81.25; H, 6.01; N, 6.92. Compounds 34, 36, and 
37 were prepared in the same manner as described for the preparation of 15. 
 
6.1.36. N-[4'-[1-Hydroxy-1-(1H-imidazol-4-yl)ethyl][1,1'-biphenyl]-3-yl]acetamide (34) 
 
Yield 59%. 
1
H NMR (CDCl3+CD3OD) δ: 1.89 (3H, s), 2.16 (3H, s), 6.89 (1H, s), 7.27–7.52 (8H, 
m), 7.69 (1H, s). IR (KBr): 3031, 1672, 1609, 1591, 1559, 1483, 1397, 1312, 791 cm
−1
. Anal. Calcd 
for C19H19N3O2·0.3H2O: C, 69.83; H, 6.05; N, 12.86. Found: C, 69.98; H, 6.05; N, 12.61. 
 65 
 
6.1.37. N-[4'-[Cyclopropyl(hydroxy)-1H-imidazol-4-ylmethyl][1,1'-biphenyl]-3-yl]acetamide 
(36) 
 
Yield 39%. 
1
H NMR (CDCl3+CD3OD) δ: 0.47–0.60 (4H, m), 1.57–1.64 (1H, m), 2.17 (3H, s), 
7.00 (1H, s), 7.36–7.58 (8H, m), 7.71 (1H, s). IR (KBr): 3148, 1667, 1591, 1555, 1485, 831, 791 
cm
−1
. Anal. Calcd for C21H21N3O2·0.5CHCl3·0.7H2O: C, 61.53; H, 5.50; N, 10.01. Found: C, 61.46; 
H, 5.67; N, 9.81. 
 
6.1.38. N-[4'-(1H-Imidazol-4-ylcarbonyl)[1,1'-biphenyl]-3-yl]acetamide (37) 
 
Yield 88%. Mp 253–254°C (AcOEt–MeOH–hexane). 
1
H NMR (CDCl3+CD3OD) δ: 2.19 (3H, s), 
7.34–7.47 (2H, m), 7.47–7.59 (1H, m), 7.72–7.84 (5H, m), 8.04 (2H, d, J = 8.4 Hz). IR (KBr): 1671, 
1638, 1599, 1559, 1437, 1399, 1345, 768 cm
−1
. Anal. Calcd for C18H15N3O2: C, 70.81; H, 4.95; N, 
13.76. Found: C, 70.72; H, 4.70; N, 13.58. 
 
6.1.39. N-[4'-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl][1,1'-biphenyl]-3-yl]acetamide (35) 
 
Under H2 atmosphere, a mixture of 33b (1.31 g, 2.27 mmol) and 10% Pd/C (1.31 g) in 1 N HCl 
(2.3 mL) and EtOH (22 mL) was vigorously stirred at rt for 8.5 h. The mixture was made alkaline 
with NaHCO3 (210 mg) and filtered through Celite. After removal of the solvent in vacuo, the 
residue was chromatographed on silica gel (CHCl3/MeOH = 10:1 to 4:1) to give 35 (640 mg, 1.91 
mmol, 84%) as a colorless amorphous solid. 
1
H NMR (CDCl3+CD3OD) δ: 0.89 (3H, t, J = 7.6 Hz), 
2.17–2.32 (5H, m), 6.91 (1H, s), 7.30–7.53 (8H, m), 7.69 (1H, s). IR (KBr): 3148, 1667, 1609, 1591, 
1557, 1485, 831, 791 cm
−1
. Anal. Calcd for C20H21N3O2·0.4H2O: C, 70.11; H, 6.41; N, 12.26. 
Found: C, 70.43; H, 6.48; N, 12.01. 
 
6.1.40. N-[4'-[1-Hydroxy(1H-imidazol-4-yl)methyl][1,1'-biphenyl]-3-yl]acetamide (38) 
 
Sodium borohydride (NaBH4) (172 mg, 4.55 mmol) was added to a cooled (0°C) solution of 37 
(500 mg, 1.97 mmol) in MeOH (40 mL) and the mixture was stirred at rt for 3 h. The mixture was 
diluted with H2O and the aqueous phase was extracted with AcOEt. The combined organic layers 
were dried over MgSO4 and concentrated under reduced pressure. The residue was chromatographed 
on silica gel (CH2Cl2/MeOH = 10:1 to 4:1) and recrystallized from AcOEt–diethylether–hexane to 
give 38 (461 mg, 1.50 mmol, 76%) as a colorless powder. Mp 227–228°C (AcOEt–diethylether–
hexane). 
1
H NMR (CDCl3+CD3OD) δ: 2.17 (3H, s), 5.85 (1H, s), 6.74 (1H, s), 7.38–7.59 (8H, m), 
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7.74 (1H, s). IR (KBr): 1667, 1651, 1607, 1561, 1485, 1325, 793, 775 cm
−1
. Anal. Calcd for 
C18H17N3O2·0.3H2O: C, 69.13; H, 5.67; N, 13.44. Found: C, 69.21; H, 5.81; N, 13.21. 
 
6.1.41. Optical resolution of 19 
 
Optical resolution of 19 (2.00 g) was performed using preparative HPLC on a Chiralpak AD 
column (Daicel Chemical Industries, 50 mmID × 500 mmL, eluent: hexane/EtOH = 50:50, flow rate: 
70 mL/min, temperature: 25°C) to yield (−)-19 (970 mg, >99.9% ee) and (+)-19 (920 mg, 99.9% ee), 
respectively. The HPLC retention time of (−)-19 was 10.8 min and that of (+)-19 was 26.3 min under 
the analytical condition (Chiralpak AD column, 4.6 mmID × 250 mmL, eluent: hexane/EtOH = 
50:50, flow rate: 0.5 mL/min, temperature: rt). [(−)-19: Anal. Calcd for C21H23N3O2 · 0.5H2O · 
0.1AcOEt: C, 69.99; H, 6.81; N, 11.44. Found: C, 70.22; H, 7.13; N, 11.27. (+)-19: Anal. Calcd for 
C21H23N3O2 · 0.75H2O: C, 69.50; H, 6.80; N, 11.58. Found: C, 69.68; H, 7.00; N, 11.43. [α]D
20
 = 
+16.5 (c 0.912, MeOH). 
 
6.1.42. Optical resolution of 28 
 
Optical resolution of 28 (3.00 g) was performed using preparative HPLC on a Chiralpak AD 
column (50 mmID × 500 mmL, eluent: hexane/EtOH = 30:70, flow rate: 70 mL/min, temperature: 
25°C) to yield (−)-28 (1410 mg, 99.8% ee) and (+)-28 (1180 mg, >99.9% ee), respectively. The 
HPLC retention time of (−)-28 was 8.6 min and that of (+)-28 was 23.9 min under the analytical 
condition (Chiralpak AD column, 4.6 mmID × 250 mmL, eluent: hexane/EtOH = 30:70, flow rate: 
0.5 mL/min, temperature: rt). (−)-28: [α]D
20
 = −8.3 (c 0.362, MeOH). (+)-28: [α]D
20
 = +6.9 (c 0.376, 
MeOH). 
 
6.1.43. Optical resolution of 35 
 
Optical resolution of 35 (280 mg) was performed using preparative HPLC on a Chiralpak AD 
column (50 mmID × 500 mmL, eluent: hexane/EtOH/diethylamine = 85:15:0.1, flow rate: 60 
mL/min, temperature: 25°C) to yield (−)-35 (53 mg, >99.9% ee) and (+)-35 (67 mg, 99.6% ee), 
respectively. The HPLC retention time of (−)-35 was 43.0 min and that of (+)-35 was 59.2 min under 
the analytical condition (Chiralpak AD column, 4.6 mmID × 250 mmL, eluent: hexane/EtOH = 
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85:15, flow rate: 1.0 mL/min, temperature: rt). (−)-35: [α]D
20
 = −2.24 (c 1.03, EtOH). (+)-35: [α]D
20
 = 
+1.69 (c 1.06, EtOH). 
 
6.1.44. Asymmetric synthesis of N-[4'-[(1S)-1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl] 
-1,1'-biphenyl-3-yl] acetamide ((−)-17): synthesis of 4-[(2R)-2- 
(tert-butyldimethylsilyloxy)propanoyl]morpholine (40) 
 
Imidazole (12.26 g, 180.1 mmol) was added dropwise to a cooled (0°C) solution of 
(2R)-2-hydroxy-1-(morpholin-4-yl)propan-1-one 39 (24.09 g, 151.3 mmol)
49
 in 
N,N-dimethylformamide (DMF) (150 mL), followed by tert-butyldimethylsilyl chloride (TBSCl) 
(23.06 g, 153.0 mmol) and the mixture was stirred at 0°C for 30 min, allowed to warm to rt and 
stirred for a further 16 h. The reaction mixture was poured into water and the aqueous phase was 
extracted with AcOEt. The combined organic phase was washed with water and brine, dried over 
MgSO4 and evaporated to give 40 (40.70 g, 98%) as a pale yellow oil. This compound was used 
without purification in the next step. IR (KBr): 1651, 1119, 831 cm
−1
. 
1
H NMR (CDCl3) δ: 0.11 (6H, 
s), 0.91 (9H, s), 1.41 (3H, d, J = 6.6 Hz), 3.60–4.00 (8H, m), 4.57 (1H, q, J = 6.6 Hz). 
 
6.1.45. (2R)-1-(4-Bromophenyl)-2-[[tert-butyl(dimethyl)silyl]oxy]propan-1-one (41) 
 
n-BuLi (1.6 M; 62.9 mL, 101 mmol) was added to a cooled (−78°C) solution of 
1,4-dibromobenzene (25.6 g, 109 mmol) in THF (350 mL) and the mixture was stirred at −78°C for 
20 min. A solution of 40 (22.0 g, 80.5 mmol) in THF (50 mL) was added to the mixture and the 
solution was stirred at −78°C for 45 min. The reaction was quenched with aq NH4Cl and the mixture 
was extracted with AcOEt. The combined organic layers were washed with brine and dried over 
MgSO4. After removal of the solvent in vacuo, the residue was chromatographed on silica gel 
(hexane/AcOEt = 40:1) to give 41 (25.3 g, 73.7 mmol, 92%) as a pale yellow oil. 
1
H NMR (CDCl3) 
δ: 0.02 (3H, s), 0.07 (3H, s), 0.87 (9H, s), 1.50 (3H, d, J = 7.0 Hz), 4.84 (1H, q, J = 7.0 Hz), 7.56–
7.61 (2H, m), 7.94–8.00 (2H, m). IR (KBr): 1684, 1586, 1256, 1146, 1071, 920, 835, 777 cm
−1
. 
 
6.1.46. (2R)-1-(4-Bromophenyl)-2-hydroxypropan-1-one (43) 
 
Tetrabutylammonium fluoride (21.5 g, 21.5 mmol) was added to a cooled (0°C) solution of 41 
(25.7 g, 74.9 mmol) in THF (250 mL) and the mixture was stirred at 0°C for 15 min. The mixture 
was diluted with satd aq NH4Cl solution and the aqueous phase was extracted with diisopropylether. 
The combined organic layers were washed with brine and dried over MgSO4. After removal of the 
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solvent in vacuo, the residue was chromatographed on silica gel (hexane/AcOEt = 4:1) to give 43 
(14.1 g, 61.6 mmol, 82%) as a pale yellow oil. The optical purity of the obtained 43 was 96% ee as 
determined by HPLC using a Chiralpak AD column with hexane/EtOH = 85:15 as an eluent. 
1
H 
NMR (CDCl3) δ: 1.44 (3H, d, J = 7.0 Hz), 3.70 (1H, d, J = 6.6 Hz), 5.05–5.18 (1H, m), 7.64–7.69 
(2H, m), 7.77–7.82 (2H, m). IR (KBr): 1717, 1485, 1402, 1358, 1175, 1073, 1011, 824 cm
−1
. 
 
6.1.47. Alternative method for (2R)-1-(4-bromophenyl)-2-hydroxypropan-1-one (43); 
asymmetric oxidation with AD-mix-β™ 
 
40% sodium bis(trimethylsilyl)amide solution (NaHMDS) in THF–cumene (2.46 g, 4.70 mmol) 
at −70°C was added to a solution of 1-(4-bromophenyl)propan-1-one 42 (500 mg, 2.35 mmol) in 
THF (10 mL) and stirred for 30 min. A solution of TBSCl (429 mg, 2.84 mmol) in hexane (2 mL) 
was added to the mixture and stirred at −70°C for 30 min, allowed to warm to rt, and stirred for an 
additional 100 min. The mixture was diluted with water and the aqueous phase was extracted with 
AcOEt. The organic layers were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The remaining residue was dissolved in tert-butanol (tert-BuOH) (15 mL) and 
H2O (12 mL) and the mixture was cooled to 5°C, followed by the addition of methanesulfonamide 
(226 mg, 2.37 mmol) and AD-mix-β (3.32 g, 2.37 mmol). After being stirred at 5°C for 22 h and at rt 
for a further 15 h, sodium sulfite (2.35 g, 18.6 mmol) was added. The mixture was stirred for an 
additional 2 h and diluted with water. The aqueous phase was extracted with AcOEt and the extract 
was washed with brine and dried over MgSO4. After removal of the solvent, the residue was 
chromatographed on silica gel (hexane/AcOEt = 10:1 to 4:1) to give 43 (468 mg, 2.04 mmol, 87%) 
as a pale yellow oil. The optical purity of the obtained 43 was 98% ee as determined by HPLC 
(Chiralpak AD). 
 
6.1.48. (2R,3S)-3-(4-Bromophenyl)-4-methylpentane-2,3-diol (44) 
 
Solution 43 (100 mg, 0.44 mmol; 96.3% ee) in THF (3 mL) was added dropwise to a cooled 
(0°C) solution of i-PrMgBr (0.75 M in THF; 2.9 mL, 2.2 mmol) and the mixture was stirred at 0°C 
for 4.5 h. The reaction was quenched with satd aq NH4Cl and the aqueous phase was extracted with 
AcOEt. The combined organic layers were washed with brine, dried over MgSO4 and concentrated 
in vacuo. The residue was chromatographed on silica gel (hexane/AcOEt = 3:1) to give 44 (70.8 mg, 
0.6 mmol, 59%) with some by-products. This compound was used without further purification in the 
next step. 
1
H NMR (CDCl3) δ: 0.82 (3H, d, J = 7.0 Hz), 0.88 (3H, d, J = 6.6 Hz), 1.01 (3H, d, J = 6.2 
Hz), 1.57 (1H, s), 2.23–2.36 (1H, m), 2.41 (1H, s), 4.25 (1H, dt, J = 6.2, 6.2 Hz), 7.22–7.27 (2H, m), 
7.44–7.51 (2H, m). IR (KBr): 2975, 1489, 1393, 1076, 1009, 986, 882, 818 cm
−1
. 
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6.1.49. (3S)-3-(4-Bromophenyl)-3-hydroxy-4-methylpentane-2-one (45) 
 
Dimethyl sulfoxide (DMSO) (10.9 mL, 154 mmol) was added dropwise to a cooled (–70°C) 
solution of oxalyl chloride (6.71 mL, 38.4 mmol) in CH2Cl2 (150 mL). After stirring for 10 min, a 
solution of 43 (10.5 g, 38.4 mmol) in CH2Cl2 (100 mL) was added dropwise, and the reaction 
mixture was stirred at a temperature of −50 to −40°C for 30 min. The mixture was then cooled to 
−70°C, and triethylamine (53.5 mL, 384 mmol) was added dropwise, and the solution was allowed 
to warm to rt. The resulting mixture was diluted with satd aq NH4Cl solution and extracted with 
CH2Cl2. The combined organic layers were washed with brine and dried over MgSO4. After removal 
of the solvent in vacuo, the residue was chromatographed on silica gel (hexane/AcOEt = 10:1) to 
give 45 (8.72 g, 32.2 mmol, 84%) as a pale yellow amorphous solid. 
1
H NMR (CDCl3) δ: 0.88 (6H, 
d, J = 6.6 Hz), 2.14 (3H, s), 2.69–2.82 (1H, m), 4.44 (1H, s), 7.40–7.45 (2H, m), 7.47–7.53 (2H, m). 
IR (KBr): 2971, 1709, 1487, 1358, 1169, 1142, 1009, 816 cm
−1
. Anal. Calcd for C12H15O2Br: C, 
53.15; H, 5.58; N, 0.00; Br, 29.47. Found: C, 52.94; H, 5.59; N, 0.07. 
 
6.1.50. (3S)-1-Bromo-3-(4-bromophenyl)-3-hydroxy-4-methylpentane-2-one (46) 
 
Pyridinium bromide perbromide (11.2 g, 34.9 mmol) was added to a stirred solution of 45 (7.89 g, 
29.1 mmol) in THF (150 mL) and the mixture was stirred at rt for 12 h. The reaction mixture was 
diluted with aqueous sodium thiosulfate solution and the aqueous phase was extracted with AcOEt. 
The combined organic layers were washed with brine and dried over MgSO4. After removal of the 
solvent in vacuo, the residue was chromatographed on silica gel (hexane/AcOEt = 10:1) to give 46 
(6.58 g, 18.8 mmol, 65%) as a pale yellow powder. 
1
H NMR (CDCl3) δ: 0.78 (3H, d, J = 7.0 Hz), 
0.95 (3H, d, J = 7.0 Hz), 2.72–2.85 (1H, m), 4.11 (1H, d, J = 14.2 Hz), 4.19 (1H, d, J = 14.2 Hz), 
7.37–7.44 (2H, m), 7.48–7.55 (2H, m). IR (KBr): 2969, 1726, 1487, 1076, 1026, 1009, 814 cm
−1
. 
 
6.1.51. (1S)-1-(4-Bromophenyl)-1-(1H-imidazol-4-yl)-2-methylpropan-1-ol (47) 
 
Trimethylsilyl trifluoromethanesulfonate (TMSOTf) (8.01 mL, 44.3 mmol) was added dropwise 
to a cooled (0°C) solution of 46 (6.20 g, 17.7 mmol) and 2,6-lutidine (6.18 mL, 53.1 mmol) in 
anhydrous THF (50 mL), and the reaction mixture was stirred at 0°C for 30 min and allowed to 
warm to rt. After stirring for a further 90 min, the mixture was diluted with 1 N HCl followed by 
extraction with AcOEt. The combined organic layers were washed with satd NaHCO3 solution 
followed by brine, before drying over MgSO4. The solution was concentrated in vacuo to give crude 
(3S)-1-bromo-3-(4-bromophenyl)-4-methyl-3-[(trimethylsilyl)oxy]pentane-2-one as a colorless 
amorphous solid. This material, without further purification, was mixed with THF (6 mL) and 
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formamidine acetate (2.95 g, 28.3 mmol) and added to a saturated ammonia solution in MeOH (30 
mL); the resulting mixture was stirred at rt for 22 h. After removing excess NH3 and MeOH, the 
residue was chromatographed on silica gel (CH2Cl2/MeOH = 50:1 to 10:1) to give 47 (3.89 g, 13.2 
mmol, 74%) as a pale yellow amorphous solid. The optical purity of the obtained 47 was 90% ee as 
determined by HPLC (Chiralpak AD). 
1
H NMR (CDCl3) δ: 0.78 (3H, d, J = 6.6 Hz), 0.95 (3H, d, J = 
7.0 Hz), 2.50–7.64 (1H, m), 6.95 (1H, d, J = 1.2 Hz), 7.43 (4H, s), 7.55 (1H, d, J = 1.2 Hz). IR 
(KBr): 2971, 1485, 1395, 1009, 814, 733 cm
−1
. 
 
6.1.52. (1S)-1-(4-Bromophenyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propan-1-ol (48) 
 
Trityl chloride (1.00 g, 3.59 mmol) was added to a cooled (0°C) mixture of 47 (1.01 g, 3.42 
mmol, 90.0% ee) and triethylamine (0.715 mL, 5.13 mmol) in DMF (10 mL), and the reaction 
mixture was stirred at rt for 2.5 h. After being diluted with H2O, the mixture was extracted with 
AcOEt. The combined organic layers were washed with H2O and brine successively, followed by 
drying over MgSO4. The solution was concentrated in vacuo and the obtained residue was 
recrystallized from hexane–AcOEt to give 48 (1.16 g, 2.16 mmol, 63%) as a colorless powder. The 
optical purity of the obtained 48 was 99% ee as determined by HPLC (Chiralpak AD). 
Recrystallization of 48 with 99% ee from hexane–AcOEt provided needle crystals with 99.5% ee for 
X-ray crystallographic analysis. The spectral data of 48 were identical to those of the racemate 12b 
except for elemental analysis and optical rotation. Anal. Calcd for C32H29N2OBr: C, 71.51; H, 5.44; 
N, 5.21; Br, 14.87. Found: C, 71.45; H, 5.66; N, 5.02. [α]D
20
 = +34.6 (c 1.00, MeOH). 
 
6.1.53. N-[4'-[(1S)-1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-propyl]-1,1'-biphenyl- 
3-yl]acetamide (49) 
 
Compound 49 was prepared from 48 (300 mg, 0.56 mmol, 99% ee) and 
3-acetamidephenylboronic acid (130 mg) and Pd(PPh3)4 (0) (32 mg, 0.028 mmol) as a colorless 
amorphous solid (288 mg, 0.49 mmol, 87%) using the same method described for the preparation of 
14a. The optical purity of 49 was 99% ee as determined by HPLC (Chiralpak AD). The spectral data 
of 49 were identical to those of the racemate 14e except for optical rotation. [α]D
20
 = +46.6 (c 0.49, 
MeOH). 
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6.1.54. N-[4'-[(1S)-1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,1'-biphenyl-3-yl] 
acetamide (S-(−)-19) 
 
A solution of 49 (86.3 mg, 0.143 mmol) and 10% Pd/C (85 mg) in EtOH (10 mL) was vigorously 
stirred at 70°C for 9 h under H2 (4 atm) atmosphere. The mixture was filtered, and the filtrate was 
concentrated under reduced pressure. The residue was chromatographed on silica gel 
(CH2Cl2/MeOH = 10:1) to give (−)-19 (30.7 mg, 0.088 mmol, 61%) as a colorless amorphous solid. 
The optical purity of the obtained (−)-19 was 99% ee as determined by HPLC (Chiralpak AD). The 
spectral data of (−)-19 were identical to those of the racemate 19 except for optical rotation. [α]D
20
 = 
−15.7 (c 1.10, MeOH). FAB-MS m/z: 350.1834 (calcd for C21H24N3O2:350.1869). 
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6.2.1. 2,6-Dibromonaphthalene (50) 
 
Bromine (78.8 g, 493 mmol) was added dropwise to a cooled (0°C) solution of 
triphenylphosphine (129 g, 493 mmol) in anhydrous CH3CN (200 mL) and the solution was stirred 
for 30 min at rt. A solution of 6-bromo-2-naphthol (100 g, 448 mmol) in anhydrous acetonitrile 
(CH3CN) (200 mL) was added, and the reaction mixture was stirred for a further 2 h at 70°C. After 
removal of the solvent (bath temp was increased to 140°C), the residue was heated to 300°C for 1 h. 
After being cooled to 100°C, the black tar was dissolved in toluene (100 mL), and cooled to rt while 
stirring. The resulting solution was washed with 1 N NaOH and water, followed by drying over 
MgSO4. The solvent was removed in vacuo and the residue was dissolved in MeOH (50 mL). The 
precipitate was filtered and washed with MeOH (200 mL) and diisopropylether (iPr2O), successively, 
to give 50 (37.2 g, 29%) as a grey powder. The analytical sample was obtained by recrystallization 
from AcOEt (light brown plates). 
1
H NMR (CDCl3) δ: 7.51–7.62 (4H, m), 7.94 (2H, s). IR (KBr): 
1568, 1481, 1175, 1134, 1065, 885, 853, 816 cm
−1
. Anal. Calcd for C10H6Br2: C, 42.00; H, 2.11. 
Found: C, 42.28; H, 2.18. 
 
6.2.2. 1-(6-Bromo-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol (51) 
 
n-BuLi (1.6 M; 59.0 mL, 94.4 mmol) was added dropwise to a cooled (−50°C) solution of 50 
(27.0 g, 94.4 mmol) in anhydrous THF (1300 mL) , and the solution was stirred for 20 min at −50°C. 
A solution of 11 (23.9 g, 62.9 mmol) in anhydrous THF (200 mL) was added dropwise over 20 min, 
and the reaction mixture was stirred for 20 min at −50°C. After dilution with water, the organic 
phase was separated. The aqueous phase was extracted with AcOEt. The extracts were washed with 
brine and dried over MgSO4, and then concentrated in vacuo. The residue was washed with hot 
AcOEt to give 51 (34.4 g, 93%) as a light brown powder. The analytical sample was obtained by 
recrystallization from THF–hexane (colorless powder). 
1
H NMR (CDCl3) δ: 0.72 (3H, d, J = 6.7 Hz), 
0.95 (3H, d, J = 6.7 Hz), 2.45–2.58 (1H, m), 3.75 (1H, s), 6.80 (1H, d, J = 1.4 Hz), 7.10–7.15 (6H, 
m), 7.29–7.35 (10H, m), 7.50 (1H, dd, J = 1.8, 8.7 Hz), 7.57 (1H, dd, J = 1.8, 8.8 Hz), 7.63–7.69 (2H, 
m), 7.94 (1H, d, J = 1.8 Hz), 8.02 (1H, s). IR (KBr): 3241, 2967, 1493, 1445, 1169, 1017, 826, 812, 
756, 747, 700 cm
−1
. Anal. Calcd for C36H31N2OBr: C, 73.59; H, 5.32; N, 4.77. Found: C, 73.89; H, 
5.11; N, 4.63. 
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6.2.3. 1-{6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthyl}-1-ethanone 
(52) 
 
n-BuLi (1.6 M; 16.4 mL, 26.2 mmol) was added dropwise to a cooled (−70°C) solution of 51 (7.0 
g, 11.9 mmol) in anhydrous THF (150 mL) , and the solution was stirred for 20 min at −70°C. A 
solution of N-methoxy-N-methylacetamide (2.45 g, 23.8 mmol) in anhydrous THF (10 mL) was 
added, and the reaction mixture was stirred for 20 min at −70°C. After dilution with water, the 
resulting mixture was extracted with AcOEt (×2). The combined organic layers were washed with 
brine, dried over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (hexane/THF = 6:1–3:1) to give 52(3.53 g, 54%) as a colorless powder. 
The analytical sample was obtained by recrystallization from i-Pr2O (colorless powder). 
1
H NMR 
(CDCl3) δ: 0.74 (3H, d, J = 6.8 Hz), 0.97 (3H, d, J = 6.8 Hz), 2.48–2.61 (1H, m), 2.72 (3H, s), 3.75 
(1H, br s), 6.83 (1H, d, J = 1.4 Hz), 7.10–7.17 (6H, m), 7.30–7.37 (10H, m), 7.65 (1H, dd, J = 1.6, 
8.8 Hz), 7.84 (1H, d, J = 8.8 Hz), 7.87 (1H, d, J = 8.8 Hz), 8.01 (1H, dd, J = 1.6, 8.8 Hz), 8.07 (1H, 
s), 8.42 (1H, s). IR (KBr): 3519, 2963, 1671, 1275, 1231, 1140, 747, 700 cm
−1
. Anal. Calcd for 
C38H34N2O2: C, 82.88; H, 6.22; N, 5.09. Found: C, 82.96; H, 6.17; N, 5.37. 
 
6.2.4. 1-{6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthyl}-1-ethanone (53) 
 
A mixture of 52 (350 mg, 0.64 mmol) and pyridine hydrochloride (148 mg, 1.28 mmol) in MeOH 
(4 mL) and CHCl3 (2 mL) was stirred at 60°C for 3 h. The mixture was diluted with aq NaHCO3 
solution and the resulting mixture was extracted with AcOEt. The combined organic layers were 
washed with brine, dried over MgSO4. After removing the solvent, the residue was purified by 
column chromatography on silica gel (CH2Cl2/MeOH = 20:1–10:1) to give 53 (159 mg, 81%) as a 
colorless powder. The analytical sample was obtained by recrystallization from AcOEt as a colorless 
powder. Mp 180.0–182.0°C. 
1
H NMR (CDCl3 + CD3OD) δ: 0.81 (3H, d, J = 6.7 Hz), 1.02 (3H, d, J 
= 6.7 Hz), 2.73–2.86 (4H, m), 7.05 (1H, d, J = 1.1 Hz), 7.56 (1H, d, J = 1.1 Hz), 7.73 (1H, dd, J = 
1.7, 8.7 Hz), 7.89 (1H, d, J = 8.7 Hz), 7.92 (1H, d, J = 8.7 Hz), 7.99 (1H, dd, J = 1.7, 8.7 Hz), 8.11 
(1H, s), 8.46 (1H, s). IR (KBr): 3235, 2969, 1672, 1306, 1289, 1044, 895, 824, 789 cm
−1
. LCMS 
(API): m/z 309.2 [M+H]
+
. Anal. Calcd for C19H20N2O2·0.1AcOEt: C, 73.46; H, 6.61; N, 8.83. 
Found: C, 73.29; H, 6.57; N, 8.84. 
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6.2.5. 1-[6-[(Diphenylmethylene)amino]-2-naphthyl]-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1
-propanol (54) 
 
A mixture of 51 (14.0 g, 23.8 mmol), benzophenoneimine (5.18 g, 28.6 mmol), tert-BuONa (5.72 
g, 59.5 mmol), Pd2(dba)3 (440 mg, 0.48 mmol), and R-(+)-BINAP (872 mg, 1.40 mmol) in 
anhydrous toluene (140 mL) was heated at 80°C for 18 h under Ar atmosphere. After dilution with 
AcOEt, the resulting mixture was passed through Celite. The filtrate was concentrated in vacuo, and 
the residue was purified by column chromatography on silica gel (hexane/THF = 1:1) and 
recrystallized from AcOEt–hexane (×2) to give 54 (14.3 g, 87%) as a yellow powder. 
1
H NMR 
(CDCl3) δ: 0.74 (3H, d, J = 6.7 Hz), 0.93 (3H, d, J = 6.7 Hz), 2.42–2.56 (1H, d), 3.65 (1H, br s), 6.79 
(1H, d, J = 1.4 Hz), 6.87 (1H, dd, J = 2.0, 8.6 Hz), 7.10–7.57 (28H, m), 7.76 (1H, d, J = 2.0 Hz), 
7.80 (1H, d, J = 1.4 Hz), 7.86 (1H, s). IR (KBr): 3453, 2969, 1493, 1445, 1256, 1163, 1005, 812, 748 
cm
−1
. Anal. Calcd for C49H41N3O·0.3THF: C, 84.98; H, 6.17; N, 5.92. Found: C, 84.87; H, 6.27; N, 
5.74. 
 
6.2.6. 1-(6-Amino-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol (55) 
 
Sodium acetate (4.02 g, 49.0 mmol) and hydroxylamine hydrochloride (2.52 g, 36.3 mmol) were 
added to a solution of 7 (14.0 g, 20.4 mmol) in anhydrous THF (100 mL) and MeOH (100 mL) and 
the mixture was stirred for 40 min at rt. After concentration in vacuo, the residue was diluted with 
0.2 N NaOH, and the resulting mixture was extracted with AcOEt (×2). The combined organic layers 
were washed with brine and dried over MgSO4 followed by concentration in vacuo to give 55 
(orange-colored oil), which was used in the next reaction without further purification. The analytical 
sample was obtained by recrystallization from AcOEt (pale yellow powder). 
1
H NMR (CDCl3) δ: 
0.75 (3H, d, J = 6.8 Hz), 0.93 (3H, d, J = 6.8 Hz), 2.44–2.57 (1H, m), 3.62 (1H, br s), 6.79 (1H, d, J 
= 1.4 Hz), 6.89–6.94 (2H, m), 7.11–7.18 (6H, m), 7.29–7.36 (10H, m), 7.44 (1H, dd, J = 1.8, 8.8 Hz), 
7.50 (1H, d, J = 8.8 Hz), 7.61 (1H, d, J = 8.4 Hz), 7.86 (1H, d, J = 1.2 Hz). IR (KBr): 3370, 3092, 
2963, 1634, 1485, 1445, 760, 747, 700 cm
−1
. Anal. Calcd for C36H33N3O·0.2AcOEt: C, 81.66; H, 
6.44; N, 7.76. Found: C, 81.55; H, 6.51; N, 7.66. 
 
6.2.7. N-{6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthyl}acetamide 
(56a) 
 
Pyridine (5.0 mL, 61.2 mmol) and acetic anhydride (3.9 mL, 40.8 mmol) were added to a crude 
mixture of 55 in anhydrous CH2Cl2 (100 mL) and stirred for 40 min at rt. After dilution with 
saturated NaHCO3 (200 mL), the mixture was extracted with CH2Cl2 (×3). The combined organic 
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layers were dried over MgSO4 and concentrated in vacuo. The residue was recrystallized from 
AcOEt to give 56a (10.9 g, 95% from 7) as a pale yellow powder. 
1
H NMR (CDCl3 + CD3OD) δ: 
0.75 (3H, d, J = 6.7 Hz), 0.95 (3H, d, J = 6.7 Hz), 2.20 (3H, s), 2.57–2.71 (1H, m), 6.87 (1H, d, J = 
1.4 Hz), 7.10–7.15 (6H, m), 7.32–7.54 (12H, m), 7.68–7.77 (2H, m), 7.92 (1H, s), 8.15 (1H, s), 9.60 
(1H, br s). IR (KBr): 3058, 2969, 1686, 1493, 1298, 1011, 747, 700 cm
−1
. Anal. Calcd for 
C38H35N3O2·0.3AcOEt: C, 79.51; H, 6.37; N, 7.10. Found: C, 79.50; H, 6.47; N, 7.28. 
 
6.2.8. N-{6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthyl}acetamide (57a) 
 
Compound 57a was prepared in the same manner as described for the preparation of 53. Yield 
84%, colorless powder. Mp 186.0–188.0°C. 
1
H NMR (CDCl3 + CD3OD) δ: 0.79 (3H, d, J = 6.8 Hz), 
1.0 (3H, d, J = 6.8 Hz), 2.17 (3H, s), 2.63–2.76 (1H, m), 6.99 (1H, s), 7.43–7.54 (3H, m), 7.65–7.74 
(2H, m), 7.91 (1H, s), 8.11 (1H, s). IR (KBr): 3248, 2971, 1669, 1557, 1495, 1391, 1296, 818 cm
−1
. 
LCMS (API): m/z 324.2 [M+H]
+
. Anal. Calcd for C19H21N3O2: C, 70.57; H, 6.55; N, 12.99. Found: 
C, 70.58; H, 6.90; N, 12.94. 
 
6.2.9. N'-{6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthyl}-N-methylurea 
(57b) 
 
Phenyl chloroformate (0.50 mL, 4.01 mmol) was added dropwise to a cooled (0°C) solution of 55 
(1.40 g, 2.67 mmol) and pyridine (0.65 mL, 8.01 mmol) in anhydrous THF (10 mL) and stirred for 
30 min at 0°C. After pouring into phosphate buffer (pH 7.0), the resulting mixture was extracted 
with AcOEt (×2). The combined organic layers were washed with brine and dried over MgSO4, 
followed by concentrating in vacuo to give the carbamate (red viscous oil) which was used for the 
next reaction without further purification. Methylamine hydrochloride (360 mg, 5.34 mmol) and 10 
N NaOH (0.54 mL, 5.4 mmol) were added to a stirred solution of the carbamate in DMSO (5 mL), 
and the reaction mixture was stirred for 1 h at rt. After dilution with 0.5 N NaOH, the resulting 
mixture was extracted with AcOEt (×2). The combined organic layers were washed with brine and 
dried over MgSO4 followed by concentrating in vacuo. The residue was purified by column 
chromatography on silica gel (hexane/AcOEt = 1:2–1:4) to give 56b (984 mg) as a pale yellow 
powder, which contained a small amount of impurities. 56b (850 mg) was used as a starting material. 
Using the same procedure as described for the synthesis of 53, 57b (278 mg, 31% from 55) was 
obtained as colorless amorphous solid. 
1
H NMR (CDCl3 + CD3OD) δ: 0.79 (3H, d, J = 6.9 Hz), 0.97 
(3H, d, J = 6.9 Hz), 2.74–2.87 (1H, m), 2.79 (3H, s), 7.03 (1H, s), 7.38 (1H, dd, J = 2.2, 8.8 Hz), 
7.55–7.66 (3H, m), 7.72 (1H, d, J = 9.0 Hz), 7.87 (1H, d, J = 2.0 Hz), 7.94 (1H, s). IR (KBr): 3320, 
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2971, 1655, 1555, 1493, 1248 cm
−1
. LCMS (API): m/z 339.2 [M+H]
+
. Anal. Calcd for 
C19H22N4O2·H2O: C, 64.03; H, 6.79; N, 15.72. Found: C, 64.06; H, 6.72; N, 15.63. 
 
6.2.10. 6-Bromo-1-chloro-2-naphthol (58b) 
 
Sulfuryl chloride (6.48 mL, 80.7 mmol) was added dropwise to a cooled (0°C) solution of 
6-bromo-2-naphthol (15.0 g, 67.2 mmol) in anhydrous Et2O (80 mL) and stirred for 1 h at rt. After 
removal of the solvent in vacuo, the residue was diluted with AcOEt. The solution was washed with 
water and brine, and then dried over MgSO4. After concentration in vacuo, the residue was 
recrystallized from i-Pr2O–hexane (×2) to give 58b (8.89 g, 51%) as a light brown powder. 
1
H NMR 
(CDCl3) δ: 5.90 (1H, s), 7.27 (1H, d, J = 9.0 Hz), 7.61 (1H, d, J = 9.0 Hz), 7.63 (1H, dd, J = 2.2, 9.0 
Hz), 7.92 (1H, d, J = 9.0 Hz), 7.94 (1H, d, J = 2.2 Hz). IR (KBr): 3491, 3432, 1589, 1200, 1184, 939, 
806 cm
−1
. Anal. Calcd for C10H6OBrCl: C, 46.64; H, 2.35. Found: C, 46.44; H, 2.35. 
 
6.2.11. 1-Methyl-2-naphthol (59) 
 
A mixture of 2-hydroxy-1-naphthaldehyde (20.0 g, 116 mmol), hydrazine monohydrate (16.9 mL, 
348 mmol) and KOH (20 g) in triethyleneglycol (150 mL) was slowly heated to 170°C in a 
round-bottomed flask equipped with Dean-Stark apparatus. The mixture was then heated at 170°C 
for 90 min and at 190°C for a further 20 min. After cooling to rt, the mixture was poured into water 
and acidified with concentrated HCl. The precipitate was filtered, washed with water, and dried in 
vacuo to give 59 (16.3 g, 89%) as a pale yellow powder. The analytical sample was obtained by 
recrystallization from i-Pr2O–hexane (colorless needles). 
1
H NMR (CDCl3) δ: 2.52 (3H, s), 4.91 (1H, 
br s), 7.04 (1H, d, J = 8.8 Hz), 7.29–7.37 (1H, m), 7.44–7.52 (1H, m), 7.60 (1H, d, J = 8.8 Hz), 7.75 
(1H, d, J = 8.0 Hz), 7.90 (1H, d, J = 8.4 Hz). IR (KBr): 3295, 1514, 1354, 1227, 1213, 806, 742 cm
−1
. 
Anal. Calcd for C11H10O: C, 83.51; H, 6.37. Found: C, 83.55; H, 6.46. 
 
6.2.12. 6-Bromo-1-methyl-2-naphthol (58c) 
 
A solution of bromine (16.1 g, 101 mL) in AcOH (30 mL) was added dropwise to a cooled 
(10°C) solution of 59 (16.0 g, 101 mmol) in AcOH (50 mL); the temperature of the solution was 
maintained at 10–20°C. After stirring for 15 min at 15–20°C, the mixture was poured into water. The 
precipitate was filtered, washed with water, and dried in vacuo to give 58c (23.7 g, 99%) as a reddish 
powder. 
1
H NMR (CDCl3) δ: 2.49 (3H, s), 4.94 (1H, s), 7.05 (1H, d, J = 8.8 Hz), 7.50 (1H, d, J = 8.8 
Hz), 7.52 (1H, dd, J = 2.2, 9.0 Hz), 7.76 (1H, d J = 9.0 Hz), 7.89 (1H, d, J = 2.2 Hz). IR (KBr): 3245, 
 77 
 
1591, 1497, 1356, 1341, 1198, 1080, 893, 878, 810 cm
−1
. Anal. Calcd for C11H9OBr: C, 55.72; H, 
3.83. Found: C, 55.70; H, 3.81. 
 
6.2.13. (7-Bromo-3-methoxy-2-naphthyl)methanol (61) 
 
Trimethoxyborane (1.60 mL, 13.6 mmol) was added dropwise to a solution of lithium 
borohydride (2.96 g, 136 mmol) and 60
62
 (40.0 g, 136 mmol) in anhydrous THF (150 mL), and the 
solution was refluxed for 90 min. After cooling to 0°C, water was carefully added, and the mixture 
was acidified with 6 N HCl followed by extraction with AcOEt (×2). The combined organic layers 
were washed with 1 N NaOH (×2) and brine, and then dried over MgSO4. The solvent was removed 
in vacuo to give 61 as a colorless powder, which was used for the next reaction without further 
purification. The analytical sample was obtained by recrystallization from AcOEt–hexane (colorless 
needles). 
1
H NMR (CDCl3) δ: 3.97 (3H, s), 4.82 (2H, s), 7.09 (1H, s), 7.49 (1H, dd, J = 1.8, 8.8 Hz), 
7.60 (1H, d, J = 8.8 Hz), 7.65 (1H, s), 7.91 (1H, d, J = 1.8 Hz). IR (KBr): 3239, 1497, 1248, 1215, 
1065, 1049, 839 cm
−1
. Anal. Calcd for C12H11O2Br: C, 53.96; H, 4.15. Found: C, 53.76; H, 3.93. 
 
6.2.14. 7-Bromo-3-methoxy-2-naphthaldehyde (62) 
 
A suspension of 61 and MnO2 (200 g) in CH2Cl2 (600 mL) was refluxed for 1 h. The mixture was 
filtered through Celite, and the filtrate was concentrated in vacuo to give 62 (33.9 g, 94% from 60) 
as a yellow powder. The analytical sample was obtained by recrystallization from AcOEt–hexane 
(colorless plates). 
1
H NMR (CDCl3) δ: 4.01 (3H, s), 7.13 (1H, s), 7.58 (2H, s), 7.98 (1H, s), 8.20 (1H, 
s), 10.55 (1H, s). IR (KBr): 2882, 1680, 1620, 1250, 1157 cm
−1
. Anal. Calcd for C12H9O2Br: C, 
54.37; H, 3.42. Found: C, 54.41; H, 3.46. 
 
6.2.15. 6-Bromo-2-methoxy-3-methylnaphthalene (63) 
 
A mixture of 62 (13.0 g, 49.0 mmol), hydrazine monohydrate (7.13 mL, 147 mmol) and KOH 
(13.0 g) in triethyleneglycol (100 mL) was slowly heated to 160°C in a round-bottomed flask 
equipped with Dean-Stark apparatus. Evolution of N2 gas started at 100°C. The mixture was heated 
at 160°C for 20 min and then at 180°C for a further 10 min. After cooling to rt, the mixture was 
poured into water. The precipitate was washed with water and dried in vacuo to give 63 (12.1 g, 
98%) as pale yellow plates. The analytical sample was obtained by recrystallization from AcOEt–
hexane (colorless plates). 
1
H NMR (CDCl3) δ: 2.35 (3H, s), 3.91 (3H, s), 7.01 (1H, s), 7.40–7.45 (2H, 
m), 7.56 (1H, d, J = 8.4 Hz), 7.82 (1H, s). IR (KBr): 2978, 1590, 1490, 1256, 1157, 1119, 1019, 903, 
851 cm
−1
. Anal. Calcd for C12H11OBr: C, 57.39; H, 4.42. Found: C, 57.27; H, 4.47. 
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6.2.16. 6-Bromo-3-methyl-2-naphthol (58d) 
 
BBr3 (1 M solution in CH2Cl2; 55.0 mL) was added dropwise to a cooled (−70°C) solution of 63 
(11.5 g, 45.8 mmol) in anhydrous CH2Cl2 (120 mL), and the mixture was slowly heated to rt. After 
stirring for 2 h at rt, the reaction was quenched with water at 0°C. The resulting mixture was 
extracted with CH2Cl2 (×2). The combined organic layers were washed with brine, dried over 
MgSO4, and then concentrated in vacuo. The residue was purified by column chromatography on 
silica gel (hexane/AcOEt = 2:1) and washed with hexane to give 58d (9.67 g, 89%) as a pale yellow 
powder. The analytical sample was obtained by recrystallization from AcOEt–hexane (pale yellow 
prisms). 
1
H NMR (CDCl3) δ: 2.40 (3H, s), 5.12 (1H, s), 7.02 (1H, s), 7.40 (1H, dd, J = 1.8, 8.8 Hz), 
7.46–7.50 (2H, m), 7.82 (1H, s). IR (KBr): 3562, 1589, 1512, 1232, 1186, 1153, 1103, 920, 905, 860 
cm
−1
. Anal. Calcd for C11H9OBr: C, 55.72; H, 3.83. Found: C, 55.65; H, 3.63. 
 
6.2.17. 2-Bromo-6-(tert-butyldimethylsilyloxy)naphthalene (64a) 
 
TBSCl (37.0 g, 246 mmol) was added to a cooled (0°C) solution of 6-bromo-2-naphthol (50.0 g, 
224 mmol) and imidazole (22.9 g, 336 mmol) in DMF (200 mL), and the solution was stirred for 2 h 
at rt. After dilution with water, the resulting mixture was extracted with AcOEt (×2). The combined 
organic layers were washed with water and brine, and then dried over MgSO4. After removal of the 
solvent in vacuo, the residue was recrystallized from MeOH (20 mL) to give 64a (71.3 g, 94%) as 
colorless plates. 
1
H NMR (CDCl3) δ: 0.24 (6H, s), 1.01 (9H, s), 7.08 (1H, dd, J = 2.4, 8.8 Hz), 7.15 
(1H, d, J = 2.4 Hz), 7.46 (1H, dd, J = 1.8, 8.8 Hz), 7.54 (1H, d, J = 8.8 Hz), 7.61 (1H, d, J = 8.8 Hz), 
7.90 (1H, d, J = 1.8 Hz). IR (KBr): 2957, 2930, 2857, 1256, 874, 797, 783 cm
−1
. Anal. Calcd for 
C16H21OBrSi: C, 56.97; H, 6.27; Br, 23.69. Found: C, 56.94; H, 6.26. Compounds 64b–d were 
prepared using the same method as described for the preparation of 64a. 
 
6.2.18. 6-Bromo-2-[(tert-butyldimethylsilyl)oxy]-1-chloronaphthalene (64b) 
 
Yield 98%, pale yellow oil. 
1
H NMR (CDCl3) δ: 0.27 (6H, s), 1.07 (9H, s), 7.14 (1H, d, J = 8.8 
Hz), 7.56 (1H, d, J = 8.8 Hz), 7.60 (1H, dd, J = 2.0, 9.0 Hz), 7.93 (1H, d, J = 2.0 Hz), 8.07 (1H, d, J 
= 9.0 Hz). IR (KBr): 2930, 1588, 1487, 1352, 1271, 1246, 960, 839 cm
−1
. 
 
6.2.19. 6-Bromo-2-[(tert-butyldimethylsilyl)oxy]-1-methylnaphthalene (64c) 
 
Yield 85%, pale yellow plates. 
1
H NMR (CDCl3) δ: 0.23 (6H, s), 1.05 (9H, s), 2.49 (3H, s), 7.07 
(1H, d, J = 8.8 Hz), 7.48 (1H, d, J = 8.8 Hz), 7.51 (1H, dd, J = 2.2, 9.2 Hz), 7.77 (1H, d, J = 9.2 Hz), 
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7.89 (1H, d, J = 2.2 Hz). IR (KBr): 2926, 1460, 1258, 928, 841, 781 cm
−1
. Anal. Calcd for 
C17H23OBrSi: C, 58.11; H, 6.60; Br, 22.74. Found: C, 57.97; H, 6.56. 
 
6.2.20. 6-Bromo-2-[(tert-butyldimethylsilyl)oxy]-3-methylnaphthalene (64d) 
 
Yield 98%, pale yellow powder. 
1
H NMR (CDCl3) δ: 0.28 (6H, s), 1.04 (9H, s), 2.35 (3H, s), 7.05 
(1H, s), 7.40 (1H, dd, J = 2.0, 8.6 Hz), 7.48–7.52 (2H, m), 7.81 (1H, d, J = 1.8 Hz). IR (KBr): 2928, 
2856, 1587, 1460, 1254, 840, 781 cm
−1
. Anal. Calcd for C17H23OBrSi: C, 58.11; H, 6.60; Br, 22.74. 
Found: C, 58.23; H, 6.64. 
 
6.2.21. 1-(6-tert-Butyldimethylsilyloxy-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1- 
propanol (65a) 
 
n-BuLi (1.6 M; 55.6 mL, 88.9 mmol) was added dropwise to a cooled (−70°C) solution of 64a 
(30.0 g, 88.9 mmol) in anhydrous THF (300 mL), and the solution was stirred for 20 min at −70°C. 
A solution of 11 (22.6 g, 59.3 mmol) in anhydrous THF (150 mL) was added dropwise over 30 min, 
and the reaction mixture was stirred for 20 min at −70°C. After dilution with water, the organic 
phase was separated and the aqueous phase was extracted with AcOEt. The extracts were washed 
with brine and dried over MgSO4. After removal of the solvent in vacuo, the residue was purified by 
column chromatography on silica gel (hexane/AcOEt = 1:1) and recrystallized from iPr2O–hexane to 
give 65a (34.8 g, 92%) as a colorless powder. 
1
H NMR (CDCl3) δ: 0.23 (6H, s), 0.75 (3H, d, J = 6.8 
Hz), 0.95 (3H, d, J = 6.6 Hz), 1.02 (9H, s), 2.45–2.59 (1H, m), 3.66 (1H, s), 6.80 (1H, d, J = 1.4 Hz), 
7.04 (1H, dd, J = 2.4, 8.8 Hz), 7.11–7.16 (6H, m), 7.30–7.34 (11H, m), 7.49 (1H, dd, J = 1.6, 8.6 Hz), 
7.60 (1H, d, J = 8.6 Hz), 7.68 (1H, d, J = 8.8 Hz), 7.94 (1H, s). IR (KBr): 3158, 2955, 2930, 1601, 
1480, 1260, 843, 700 cm
−1
. Anal. Calcd for C42H46N2O2Si: C, 78.95; H, 7.26; N, 4.38. Found: C, 
79.05; H, 7.26; N, 4.47. Compounds 65b–d were prepared using the same method as described for 
the preparation of 65a. 
 
6.2.22. 1-(6-{[tert-Butyl(dimethyl)silyl]oxy}-5-chloro-2-naphthyl)-2-methyl-1-(1-trityl-1H- 
imidazol-4-yl)propan-1-ol (65b) 
 
Yield 84%, colorless powder. 
1
H NMR (CDCl3) δ: 0.25 (6H, s), 0.74 (3H, d, J = 6.8 Hz), 0.95 
(3H, d, J = 6.6 Hz), 1.07 (9H, s), 2.45–2.59 (1H, m), 3.70 (1H, s), 6.80 (1H, d, J = 1.2 Hz), 7.07–
7.16 (7H, m), 7.29–7.34 (10H, m), 7.59 (1H, dd, J = 1.8, 8.8 Hz), 7.61 (1H, d, J = 8.8 Hz), 7.99 (1H, 
d, J = 1.8 Hz), 8.07 (1H, d, J = 8.8 Hz). IR (KBr): 3155, 2957, 1599, 1474, 1360, 1252, 1020, 964, 
841, 700 cm
−1
. 
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6.2.23. 1-(6-{[tert-Butyl(dimethyl)silyl]oxy}-5-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1H- 
imidazol-4-yl)propan-1-ol (65c) 
 
Yield 89%, colorless powder. 
1
H NMR (CDCl3) δ: 0.22 (6H, s), 0.75 (3H, d, J = 6.6 Hz), 0.95 
(3H, d, J = 6.6 Hz), 1.05 (9H, s), 2.44–2.60 (4H, m), 3.64 (1H, s), 6.80 (1H, d, J = 1.2 Hz), 7.03 (1H, 
d, J = 8.8 Hz), 7.10–7.16 (6H, m), 7.28–7.34 (10H, m), 7.55 (1H, d, J = 8.8 Hz), 7.56 (1H, dd, J = 
1.8, 9.0 Hz), 7.81 (1H, d, J = 9.0 Hz), 7.92 (1H, d, J = 1.8 Hz). IR (KBr): 3200, 2961, 1472, 1242, 
839, 702 cm
−1
. Anal. Calcd for C43H48N2O2Si: C, 79.10; H, 7.41; N, 4.29. Found: C, 79.11; H, 7.44; 
N, 4.40. 
 
6.2.24. 1-(6-{[tert-Butyl(dimethyl)silyl]oxy}-7-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1H- 
imidazol-4-yl)-1-propanol (65d) 
 
Yield 93%, pale yellow powder. 
1
H NMR (CDCl3) δ: 0.27 (6H, s), 0.75 (3H, d, J = 6.6 Hz), 0.94 
(3H, d, J = 6.6 Hz), 1.05 (9H, s), 2.35 (3H, s), 2.45–2.58 (1H, m), 3.67 (1H, s), 6.80 (1H, d, J = 1.2 
Hz), 7.06 (1H, s), 7.11–7.15 (6H, m), 7.30–7.7.33 (10H, m), 7.44 (1H, dd, J = 1.8, 8.6 Hz), 7.53–
7.57 (2H, m), 7.86 (1H, s). IR (KBr): 3198, 1472, 1445, 1250, 1163, 1124, 914, 700 cm
−1
. Anal. 
Calcd for C43H48N2O2Si: C, 79.10; H, 7.41; N, 4.29. Found: C, 79.12; H, 7.39; N, 4.44. 
 
6.2.25. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthol (66a) 
 
Tetrabutylammonium fluoride (1 M in THF; 100 mL) was added to a cooled (0°C) solution of 
65a (35.0 g, 54.8 mmol) in anhydrous THF (100 mL), and the reaction mixture was stirred for 1 h at 
rt. After removal of the solvent in vacuo, the residue was diluted with water. The precipitate was 
filtered, washed with water and AcOEt, and then dried in vacuo (100°C) to give 66a (28.3 g, 98%) 
as a colorless powder. The analytical sample was obtained by recrystallization from THF–hexane 
(colorless powder). 
1
H NMR (CDCl3 + CD3OD) δ: 0.76 (3H, d, J = 6.8 Hz), 0.95 (3H, d, J = 6.6 Hz), 
2.27–2.71 (1H, m), 6.86 (1H, d, J = 1.4 Hz), 7.05–7.17 (7H, m), 7.31–7.38 (11H, m), 7.48 (1H, dd, J 
= 1.8, 8.6 Hz), 7.58 (1H, d, J = 8.8 Hz), 7.67 (1H, d, J = 8.6 Hz), 7.85 (1H, s). IR (KBr): 3598, 2965, 
1603, 1445, 1250, 1223, 1171, 702 cm
−1
. LCMS (API): m/z 523.1 [M−H]
−
. Anal. Calcd for 
C36H32N2O2·0.5H2O·0.5THF: C, 80.11; H, 6.55; N, 4.92. Found: C, 80.27; H, 6.55, N, 4.92. 
Compounds 66b–d were prepared using the same method as described for the preparation of 66a. 
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6.2.26. Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthol (66b) 
 
Yield 89%, colorless powder. 
1
H NMR (CDCl3 + CD3OD) δ: 0.73 (3H, d, J = 7.0 Hz), 0.97 (3H, 
d, J = 6.6 Hz), 2.48–2.61 (1H, m), 6.86 (1H, d, J = 1.4 Hz), 6.90 (1H, d, J = 9.2 Hz), 7.12–7.17 (6H, 
m), 7.31–7.47 (12H, m), 7.85 (1H, s), 7.94 (1H, d, J = 9.2 Hz). IR (KBr): 3533, 2971, 1485, 1350, 
1310, 1001, 758, 702 cm
−1
. LCMS (API): m/z 557.1 [M−H]
−
. Anal. Calcd for 
C36H31N2O2Cl·0.5THF: C, 76.69; H, 5.93; N, 4.71. Found: C, 76.51; H, 5.92; N, 4.62. 
 
6.2.27. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthol (66c) 
 
Yield 95%, colorless powder. 
1
H NMR (CDCl3) δ: 0.69 (3H, d, J = 6.6 Hz), 1.03 (3H, d, J = 6.6 
Hz), 2.30–2.43 (1H, m), 2.43 (3H, s), 3.89 (1H, s), 6.04 (1H, d, J = 8.8 Hz), 6.49 (1H, d, J = 8.8 Hz), 
6.85–6.93 (2H, m), 7.21–7.25 (6H, m), 7.37–7.48 (10H, m), 7.55 (1H, d, J = 8.8 Hz), 7.56 (1H, d, J 
= 1.0 Hz). IR (KBr): 3511, 2976, 1485, 1445, 1348, 1169, 1001, 758, 702 cm
−1
. LCMS (API): m/z 
539.1 [M+H]
+
. Anal. Calcd for C37H34N2O2·0.5THF: C, 81.50; H, 6.66; N, 4.87. Found: C, 81.54; H, 
6.67; N, 4.82. 
 
6.2.28. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthol (66d) 
 
Yield 98%, colorless plates. 
1
H NMR (DMSO-d6) δ: 0.61 (3H, d, J = 6.8 Hz), 0.71 (3H, d, J = 6.6 
Hz), 2.27 (3H, s), 2.54–2.64 (1H, m), 5.04 (1H, s), 6.83 (1H, d, J = 1.4 Hz), 7.03–7.08 (6H, m), 7.29 
(1H, d, J = 1.4 Hz), 7.33–7.41 (10H, m), 7.45–7.50 (2H, m), 7.69 (1H, dd, J = 1.4, 8.8 Hz), 7.84 (1H, 
s), 9.26 (1H, br s). IR (KBr): 3603, 2966, 1670, 1447, 1244, 1159, 760, 748, 704 cm
−1
. Anal. Calcd 
for C37H34N2O2·0.6DMF: C, 80.00; H, 6.61; N, 6.25. Found: C, 80.03; H, 6.59; N, 6.19. 
 
6.2.29. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthyl 
trifluoromethanesulfonate (67a) 
 
Trifluoromethanesulfonic anhydride (9.1 mL, 54.1 mmol) was added dropwise to a cooled (0°C) 
solution of 66a (27.0 g, 51.5 mmol) in anhydrous pyridine (200 mL) and stirred for 1 h at 0°C. After 
dilution with water, the resulting mixture was extracted with AcOEt (×2). The combined organic 
layers were washed with brine, dried over MgSO4, and then concentrated in vacuo. The residue was 
purified by column chromatography on silica gel (hexane/AcOEt = 1:1) and recrystallized from 
i-Pr2O to give 70 (26.1 g, 77%) as a colorless powder. The mother liquor was concentrated, and the 
residue was recrystallized from i-Pr2O to give 67a (3.54 g, 10%) as a colorless powder. 
1
H NMR 
(CDCl3) δ: 0.73 (3H, d, J = 6.6 Hz), 0.96 (3H, d, J = 6.6 Hz), 2.47–2.60 (1H, m), 3.72 (1H, br s), 
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6.82 (1H, d, J = 1.4 Hz), 7.10–7.17 (6H, m), 7.30–7.35 (11H, m), 7.65 (1H, dd, J = 1.7, 8.6 Hz), 7.70 
(1H, d, J = 2.6 Hz), 7.77 (1H, d, J = 8.6 Hz), 7.88 (1H, d, J = 9.0 Hz), 8.11 (1H, s). IR (KBr): 3164, 
2965, 1431, 1412, 1242, 1211, 1142, 909, 897, 748, 702 cm
−1
. Anal. Calcd for C37H31N2O4SF3: C, 
67.67; H, 4.76; N, 4.27. Found: C, 67.75; H, 4.51; N, 4.34. Compounds 67b–d were prepared using 
the same method as described for the preparation of 67a. 
 
6.2.30. 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthyl 
trifluoromethanesulfonate (67b) 
 
Yield 94%, colorless powder. 
1
H NMR (CDCl3) δ: 0.72 (3H, d, J = 6.6 Hz), 0.97 (3H, d, J = 6.6 
Hz), 2.48–2.61 (1H, m), 3.75 (1H, s), 6.82 (1H, d, J = 1.6 Hz), 7.09–7.16 (6H, m), 7.30–7.37 (10H, 
m), 7.40 (1H, d, J = 9.2 Hz), 7.75 (1H, dd, J = 1.8, 8.8 Hz), 7.81 (1H, d, J = 9.2 Hz), 8.15 (1H, d, J = 
1.8 Hz), 8.19 (1H, d, J = 8.8 Hz). IR (KBr): 3194, 2965, 1422, 1221, 1134, 828, 702 cm
−1
. Anal. 
Calcd for C37H30N2O4SClF3: C, 64.30; H, 4.37; N, 4.05. Found: C, 64.03; H, 4.19; N, 4.03. 
 
6.2.31. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthyl 
trifluoromethanesulfonate (67c) 
 
Yield 61%, colorless powder. 
1
H NMR (CDCl3) δ: 0.73 (3H, d, J = 6.6 Hz), 0.96 (3H, d, J = 6.6 
Hz), 2.48–2.63 (1H, m), 2.67 (3H, s), 3.70 (1H, s), 6.82 (1H, d, J = 1.4 Hz), 7.10–7.16 (6H, m), 
7.29–7.35 (11H, m), 7.69–7.74 (2H, m), 7.95 (1H, d, J = 8.8 Hz), 8.07 (1H, d, J = 1.8 Hz). IR (KBr): 
3208, 2973, 1408, 1219, 1140, 897, 702 cm
−1
. Anal. Calcd for C38H33N2O4SF3: C, 68.05; H, 4.96; N, 
4.18. Found: C, 68.22; H, 4.97; N, 4.19. 
 
6.2.32. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthyl 
trifluoromethanesulfonate (67d) 
 
Yield 74%, yellow powder. 
1
H NMR (CDCl3) δ: 0.72 (3H, d, J = 7.0 Hz), 0.96 (3H, d, J = 7.0 
Hz), 2.46–2.59 (1H, m), 2.51 (3H, s), 3.72 (1H, s), 6.80 (1H, d, J = 1.6 Hz), 7.09–7.16 (6H, m), 
7.29–7.36 (10H, m), 7.56 (1H, dd, J = 1.8, 8.6 Hz), 7.67–7.73 (3H, m), 8.02 (1H, s). IR (KBr): 3219, 
2966, 1408, 1215, 1140, 1055, 895, 748, 700 cm
−1
. Anal. Calcd for C38H33N2O4SF3: C, 68.05; H, 
4.96; N, 4.18. Found: C, 68.16; H, 4.98; N, 4.01. 
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6.2.33. Methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate (68a) 
 
A degassed solution of 67a (15.0 g, 22.8 mmol) and triethylamine (6.36 mL, 45.6 mmol) in 
anhydrous DMF (90 mL) and MeOH (30 mL) was added to Pd(OAc)2 (256 mg, 1.14 mmol) and 
dppf (632 mg, 1.14 mmol), and vigorously stirred for 14 h at 70°C under CO atmosphere (1 atm). 
After dilution with water, the resulting mixture was extracted with AcOEt (×2). The combined 
organic layers were washed with water and brine, and then dried over MgSO4. After removal of the 
solvent in vacuo, the residue was purified by column chromatography on silica gel (hexane/THF = 
1:2) and recrystallized from hexane–AcOEt to give 68a (12.3 g, 95%) as a light brown powder. 
1
H 
NMR (CDCl3) δ: 0.74 (3H, d, J = 7.0 Hz), 0.97 (3H, d, J = 6.6 Hz), 2.47–2.61 (1H, m), 3.75 (1H, s), 
3.97 (3H, s), 6.82 (1H, d, J = 1.2 Hz), 7.10–7.16 (6H, m), 7.29–7.35 (10H, m), 7.62 (1H, dd, J = 1.8, 
8.6 Hz), 7.81 (1H, d, J = 3.2 Hz), 7.85 (1H, d, J = 3.2 Hz), 8.02 (1H, dd, J = 1.8 Hz, 8.6 Hz), 8.07 
(1H, s), 8.55 (1H, s). IR (KBr): 3542, 2965, 1707, 1441, 1279, 1231, 747, 700 cm
−1
. Anal. Calcd for 
C38H34N2O3·0.1AcOEt: C, 80.41; H, 6.09; N, 4.87. Found: C, 80.07; H, 6.06; N, 4.95. Compounds 
68b–d were prepared using the same method as described for the preparation of 68a. 
 
6.2.34. Methyl-1-chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2- 
naphthoate (68b) 
 
Yield 89%, colorless powder. 
1
H NMR (CDCl3) δ: 0.72 (3H, d, J = 7.0 Hz), 0.97 (3H, d, J = 6.0 
Hz), 2.44–2.61 (1H, m), 3.79 (1H, s), 3.98 (3H, s), 6.82 (1H, d, J = 1.4 Hz), 7.09–7.14 (6H, m), 
7.31–7.38 (10H, m), 7.70 (1H, dd, J = 1.8, 9.0 Hz), 7.75 (s, 2H), 8.09 (1H, d, J = 1.4 Hz), 8.34 (1H, 
d, J = 9.2 Hz). IR (KBr): 3162, 1732, 1240, 1012, 747, 700 cm
−1
. Anal. Calcd for C38H33N2O3Cl: C, 
75.92; H, 5.53; N, 4.66. Found: C, 75.88; H, 5.58; N, 4.65. 
 
6.2.35. Methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2- 
naphthoate (68c) 
 
Yield 81%, colorless powder. 
1
H NMR (CDCl3) δ: 0.74 (3H, d, J = 7.0 Hz), 0.76 (3H, d, J = 6.0 
Hz), 2.48–2.62 (1H, m), 2.91 (3H, s), 3.74 (1H, s), 3.94 (3H, s), 6.82 (1H, d, J = 1.4 Hz), 7.10–7.15 
(6H, m), 7.30–7.34 (10H, m), 7.64–7.70 (2H, m), 7.80 (1H, d, J = 8.8 Hz), 8.02 (1H, d, J = 1.4 Hz), 
8.08 (1H, d, J = 9.2 Hz). IR (KBr): 3162, 2969, 1719, 1445, 1240, 1173, 747, 700 cm
−1
. Anal. Calcd 
for C39H36N2O3: C, 80.66; H, 6.25; N, 4.82. Found: C, 80.47; H, 6.26; N, 4.72. 
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6.2.36. Methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2- 
naphthoate (68d) 
 
Yield 88%, pale yellow powder. 
1
H NMR (CDCl3) δ: 0.73 (3H, d, J = 6.8 Hz), 0.95 (3H, d, J = 
6.6 Hz), 2.45–2.59 (1H, m), 2.71 (3H, s), 3.73 (1H, s), 3.94 (3H, s), 6.80 (1H, d, J = 1.6 Hz), 7.10–
7.16 (6H, m), 7.29–7.36 (10H, m), 7.54 (1H, dd, J = 1.6, 8.6 Hz), 7.61 (1H, s), 7.76 (1H, d, J = 8.6 
Hz), 7.96 (1H, s), 8.44 (1H, s). IR (KBr): 3223, 2968, 1724, 1445, 1283, 1267, 748, 700 cm
−1
. Anal. 
Calcd for C39H36N2O3·0.4AcOEt: C, 79.17; H, 6.41; N, 4.55. Found: C, 79.17; H, 6.23; N, 4.61. 
 
6.2.37. Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate (69) 
 
Compound 68a (1.40 g, 2.47 mmol) was used as a starting material. Using the same procedure 
described for the synthesis of 53, 69 (751 mg, 94%) was obtained as a pale yellow powder after 
recrystallization from AcOEt. Mp 167.0–169.0°C. 
1
H NMR (CDCl3 + CD3OD) δ: 0.80 (3H, d, J = 
7.0 Hz), 1.02 (3H, d, J = 6.6 Hz), 2.69–2.82 (1H, m), 3.97 (3H, s), 7.02 (1H, d, J = 1.2 Hz), 7.52 (1H, 
d, J = 1.2 Hz), 7.68 (1H, dd, J = 1.0, 8.4 Hz), 7.87 (2H, d, J = 8,4 Hz), 8.01 (1H, dd, J = 1.0, 8.4 Hz), 
8.08 (1H, s), 8.55 (1H, s). IR (KBr): 3542, 2965, 1707, 1441, 1279, 1231, 747, 700 cm
−1
. LCMS 
(API): m/z 325.1 [M+H]
+
. Anal. Calcd for C19H20N2O3·0.2AcOEt: C, 69.54; H, 6.37; N, 8.19. 
Found: C, 69.53; H, 6.43; N, 8.26. 
 
6.2.38. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide (70a) 
 
A solution of 68a (2.0 g, 3.53 mmol) in THF (20 mL) and MeOH (4 mL) and 4 N NaOH (4 mL) 
was stirred for 2 h at 60°C. After cooling to 0°C, the solution was neutralized with concentrated HCl 
and extracted with AcOEt (×2). The combined organic layers were washed with brine and 
concentrated in vacuo. The residue was dried with toluene azeotropically (×2) to give the 
carboxylate as a light brown powder, which was used for the next reaction without further 
purification. A mixture of the carboxylate, ammonium bicarbonate (558 mg, 7.06 mmol), DPPA 
(0.91 mL, 4.24 mmol) and triethylamine (0.98 mL, 7.06 mmol) in anhydrous DMF (10 mL) was 
stirred for 12 h at rt. After dilution with water, the mixture was extracted with AcOEt (×2). The 
combined organic layers were washed with water and brine, and then dried over MgSO4. After 
removal of the solvent in vacuo, the residue was purified by column chromatography on silica gel 
(hexane/THF = 1:2) and washed with hexane–AcOEt to give 70a (1.96 g, quant.) as a colorless 
powder. The analytical sample was obtained by recrystallizaion from THF–hexane (colorless 
powder). 
1
H NMR (CDCl3 + CD3OD) δ: 0.74 (3H, d, J = 7.0 Hz), 0.97 (3H, d, J = 7.0 Hz), 2.55–
2.68 (1H, m), 6.86 (1H, d, J = 1.2 Hz), 7.09–7.14 (6H, m), 7.27–2.38 (10H, m), 7.63 (1H, d, J = 1.7, 
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8.5 Hz), 7.82–7.85 (3H, m), 8.04 (1H, s), 8.33 (1H, s). IR (KBr): 3407, 3189, 2965, 1644, 1443, 748, 
700 cm
−1
. Anal. Calcd for C37H33N3O2·1.0THF: C, 78.94; H, 6.62; N, 6.74. Found: C, 78.83; H, 
6.57; N, 6.94. 
 
6.2.39. General procedure for the synthesis of the carbamoyl derivatives: 
6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 
(70b) 
 
Using the same procedure as described for the synthesis of 70a, 68a (8.0 g, 14.1 mmol) was 
hydrolyzed to give the carboxylate (light brown powder). A solution of the carboxylate, methylamine 
(2 M solution in THF; 8.45 mL), EDCI·HCl (3.24 g, 16.9 mmol), HOBt·H2O (2.59 g, 16.9 mmol) 
and triethylamine (2.36 mL, 16.9 mmol) in anhydrous DMF (80 mL) was stirred for 12 h at rt. After 
dilution with water, the mixture was extracted with AcOEt (×2). The combined organic layers were 
washed with water and brine, and then dried over MgSO4. After removal of the solvent in vacuo, the 
residue was washed with AcOEt to give 70b (8.0 g, quant.) as a pale yellow powder. The analytical 
sample was obtained by recrystallization from THF–hexane (pale yellow powder). 
1
H NMR (CDCl3 
+ CD3OD) δ: 0.75 (3H, d, J = 6.6 Hz), 0.97 (3H, d, J = 7.0 Hz), 2.60–2.74 (1H, m), 3.01 (3H, d, J = 
4.4 Hz), 6.89 (1H, s), 7.10–7.14 (6H, m), 7.27–7.38 (10H, m), 7.65 (1H, dd, J = 1.4, 8.8 Hz), 7.82–
7.86 (3H, m), 8.03 (1H, s), 8.28 (1H, s). IR (KBr): 3345, 2969, 1657, 1443, 1302, 1011, 747, 700 
cm
−1
. Anal. Calcd for C38H35N3O2·0.3THF: C, 80.03; H, 6.58; N, 7.14. Found: C, 79.81; H, 6.46; N, 
7.05. Compounds 70c–h were prepared using the same method as described for the preparation of 
70b. 
 
6.2.40. N-Ethyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 
(70c) 
 
Yield 83%, colorless powder. 
1
H NMR (CDCl3) δ: 0.73 (3H, d, J = 3.3 Hz), 0.96 (3H, d, J = 6.6 
Hz), 1.28 (3H, t, J = 7.2 Hz), 2.47–2.60 (1H, m), 3.48–3.61 (2H, m), 3.79 (1H, s), 6.32 (1H, t, J = 
5.5 Hz), 6.82 (1H, d, J = 1.4 Hz), 7.09–7.16 (6H, m), 7.28–7.34 (10H, m), 7.61 (1H, dd, J = 1.8, 8.8 
Hz), 7.75–7.84 (3H, m), 8.05 (1H, s), 8.23 (1H, s). IR (KBr): 3308, 2967, 1638, 1535, 1308, 1009, 
747, 700 cm
−1
. Anal. Calcd for C39H37N3O2·0.1AcOEt: C, 80.41; H, 6.47; N, 7.14. Found: C, 80.26; 
H, 6.54; N, 7.09. 
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6.2.41. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-propyl-2-naphthamide 
(70d) 
 
Yield 92%, colorless powder. 
1
H NMR (CDCl3) δ: 0.73 (3H, d, J = 6.8 Hz), 0.96 (3H, d, J = 6.8 
Hz), 1.02 (3H, t, J = 7.2 Hz), 1.60–1.78 (2H, m), 2.53 (1H, quintet, J = 6.8 Hz), 3.48 (2H, q, J = 7.2 
Hz), 3.76 (1H, s), 6.28 (1H, t, J = 7.2 Hz), 6.81 (1H, d, J = 1.4 Hz), 7.07–7.20 (6H, m), 7.28–7.37 
(10H, m), 7.62 (1H, dd, J = 1.8, 8.6 Hz), 7.75–7.86 (3H, m), 8.06 (1H, s), 8.23 (1H, s). IR (KBr): 
3326, 2967, 1642, 1599, 1541, 1445, 1308, 1157 cm
−1
. Anal. Calcd for C40H39N3O2: C, 80.91; H, 
6.62; N, 7.08. Found: C 80.84; H, 6.86; N, 7.08. 
 
6.2.42. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-isopropyl-2- 
naphthamide (70e) 
 
Yield 91%, colorless powder. 
1
H NMR (CDCl3) δ: 0.73 (3H, d, J = 6.8 Hz), 0.96 (3H, d, J = 6.8 
Hz), 1.31 (6H, d, J = 6.6 Hz), 2.53 (1H, quintet, J = 6.8 Hz), 3.76 (1H, s), 4.27–4.43 (1H, m), 6.06 
(1H, d, J = 7.4 Hz), 6.81 (1H, d, J = 1.4 Hz), 7.07–7.18 (6H, m), 7.28–7.38 (10H, m), 7.61 (1H, dd, J 
= 1.8, 8.6 Hz), 7.74–7.85 (3H, m), 8.06 (1H, s), 8.22 (1H, s). IR (KBr): 3301, 2971, 1640, 1601, 
1537, 1447, 1289, 1171 cm
−1
. Anal. Calcd for C40H39N3O2·0.25H2O: C, 81.30; H, 6.65; N, 7.02. 
Found: C, 80.33; H, 6.68; N, 6.88. 
 
6.2.43. 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2- 
naphthamide (70f) 
 
Yield 75%, colorless powder. 
1
H NMR (CDCl3) δ: 0.71 (3H, d, J = 7.0 Hz), 0.96 (3H, d, J = 6.6 
Hz), 2.46–2.60 (1H, m), 3.07 (3H, d, J = 4.8 Hz), 3.81 (1H, s), 6.24 (1H, d, J = 4.8 Hz), 6.82 (1H, d, 
J = 0.6 Hz), 7.09–7.14 (6H, m), 7.31–7.34 (10H, m), 7.57 (1H, d, J = 8.4 Hz), 7.69–7.73 (2H, m), 
8.05 (1H, s), 8.22 (1H, d, J = 8.8 Hz). IR (KBr): 3376, 2969, 1634, 1157, 1134, 702 cm
−1
. Anal. 
Calcd for C38H34N3O2Cl: C, 76.05; H, 5.71; N, 7.00. Found: C, 75.87; H, 5.71; N, 6.97. 
 
6.2.44. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,1-dimethyl-2- 
naphthamide (70g) 
 
Yield 95%, colorless powder. 
1
H NMR (CDCl3) δ: 0.72 (3H, d, J = 6.6 Hz), 0.95 (3H, d, J = 6.6 
Hz), 2.47–2.61 (1H, m), 2.70 (3H, s), 3.02 (3H, d, J = 4.8 Hz), 3.75 (1H, s), 5.89 (1H, br s), 6.81 (1H, 
d, J = 1.2 Hz), 7.09–7.14 (6H, m), 7.28–7.35 (10H, m), 7.59–7.68 (2H, m), 7.93–7.99 (2H, m). IR 
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(KBr): 3407, 3250, 2971, 1634, 1495, 1157, 816, 702 cm
−1
. Anal. Calcd for C39H37N3O2: C, 80.80; H, 
6.43; N, 7.25. Found: C, 80.41; H, 6.33; N, 7.18. 
 
6.2.45. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,3-dimethyl-2- 
naphthamide (70h) 
 
Yield 86%, colorless powder. 
1
H NMR (CDCl3 + CD3OD) δ: 0.72 (3H, d, J = 6.6 Hz), 0.95 (3H, 
d, J = 6.6 Hz), 2.54 (3H, s), 2.52–2.65 (1H, m), 2.99 (3H, d, J = 4.0 Hz), 6.85 (1H, d, J = 1.6 Hz), 
7.10–7.15 (6H, m), 7.32–7.38 (10H, m), 7.53 (1H, dd, J = 1.6, 8.6 Hz), 7.58 (1H, s), 7.69 (1H, d, J = 
8.6 Hz), 7.78 (1H, s), 7.89 (1H, s). IR (KBr): 3412, 3277, 2966, 1645, 1011, 746, 702 cm
−1
. Anal. 
Calcd for C39H37N3O2·0.1AcOEt: C, 80.41; H, 6.47; N, 7.14. Found: C, 80.36; H, 6.31; N, 7.14. 
Compounds 71a–h were prepared using the method as described for the preparation of 53. 
 
6.2.46. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide (71a) 
 
Yield 88%, a colorless amorphous solid. 
1
H NMR (CDCl3 + CD3OD) δ: 0.78 (3H, d, J = 6.6 Hz), 
1.00 (3H, d, J = 7.0 Hz), 2.66–2.80 (1H, m), 7.00 (1H, d, J = 1.0 Hz), 7.49 (1H, d, J = 1.0 Hz), 7.63 
(1H, d, J = 1.8, 8.8 Hz), 7.77–7.81 (3H, m), 8.04 (1H, s), 8.29 (1H, s). IR (KBr): 3200, 2969, 1659, 
1393, 816 cm
−1
. LCMS (API): m/z 310.1 [M+H]
+
. Anal. Calcd for C18H19N3O2·H2O: C, 66.04; H, 
6.47; N, 12.84. Found: C, 66.65; H, 6.45; N, 12.86. 
 
6.2.47. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide (71b) 
 
Yield 88%, colorless powder. Mp 217.0–219.0°C. 
1
H NMR (CDCl3 + CD3OD) δ: 0.78 (3H, d, J 
= 7.0 Hz), 1.01 (3H, d, J = 6.6 Hz), 2.67–2.80 (1H, m), 3.00 (3H, s), 7.00 (1H, d, J = 1.2 Hz), 7.49 
(1H, d, J = 1.0 Hz), 7.63 (1H, dd, J = 1.8, 8.8 Hz), 7.74–7.79 (2H, m), 7.83 (1H, d, J = 8.4 Hz), 8.03 
(1H, s), 8.22 (1H, s). 
13
C NMR (DMSO-d6) δ: 16.7, 17.4, 26.3, 36.6, 77.4, 112.0, 123.1, 123.8, 125.9, 
126.7, 127.5, 127.9, 130.6, 131.1, 133.6, 134.2, 147.2, 147.5, 166.7. IR (KBr): 3565, 3351, 3318, 
2973, 1638, 1628, 1549, 1308, 993, 812 cm
−1
. LCMS (API): m/z 324.2 [M+H]
+
. Anal. Calcd for 
C19H21N3O2: C, 70.57; H, 6.55; N, 12.99. Found: C, 70.46; H, 6.67; N, 12.87. 
 
6.2.48. N-Ethyl-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide (71c) 
 
Yield 92%, pale yellow amorphous solid. 
1
H NMR (CDCl3 + CD3OD) δ: 0.77 (3H, d, J = 7.0 Hz), 
1.00 (3H, d, J = 7.0 Hz), 1.26 (3H, t, J = 7.2 Hz), 2.63–2.77 (1H, m), 3.42–3.56 (2H, m), 6.98 (1H, d, 
J = 1.2 Hz), 7.22 (1H, t, J = 5.5 Hz), 7.44 (1H, d, J = 1.2 Hz), 7.59 (1H, dd, J = 1.6, 8.6 Hz), 7.70–
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7.76 (3H, m), 8.01 (1H, s), 8.19 (1H, s). IR (KBr): 3310, 2971, 1638, 1561, 1306, 1146, 816 cm
−1
. 
LCMS (API): m/z 338.2 [M+H]
+
. Anal. Calcd for C20H23N3O2·0.75H2O: C, 68.45; H, 7.04; N, 11.97. 
Found: C, 68.62; H, 7.08; N, 11.93. 
 
6.2.49. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl-2-naphthamide (71d) 
 
Yield 77%, colorless amorphous powder solid. 
1
H NMR (CDCl3) δ: 0.78 (3H, d, J = 6.6 Hz), 
1.00 (3H, t, J = 7.2 Hz), 1.00 (3H, d, J = 6.6 Hz), 1.58–1.77 (2H, m), 2.68 (1H, quintet, J = 7.2 Hz), 
3.40–3.52 (2H, m), 3.49 (1H, s), 6.44 (1H, t, J = 5.5 Hz), 6.99 (1H, s), 7.45 (1H, s), 7.59–7.80 (4H, 
m), 8.05 (1H, s), 8.1 7 (1H, s). IR (KBr): 3400–3100, 2967, 1640, 1601, 1539, 1464, 1308, 1144 
cm
−1
. LCMS (API): m/z 352.3 [M+H]
+
. Anal. Calcd for C21H25N3O2·0.2H2O: C, 71.04; H, 7.21; N, 
11.83. Found: C, 70.83; H, 7.29; N, 11.78. 
 
6.2.50. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropyl-2-naphthamide (71e) 
 
Yield 73%, colorless amorphous solid. 
1
H NMR (CDCl3) δ: 0.77 (3H, d, J = 6.8 Hz), 1.00 (3H, d, 
J = 6.8 Hz), 1.29 (6H, d, J = 6.6 Hz), 2.67 (1H, quintet, J = 6.8 Hz), 3.48 (1H, s), 4.26–4.42 (1H, m), 
6.23 (1H, d, J = 7.8 Hz), 6.97 (1H, d, J = 1.2 Hz), 7.41 (1H, d, J = 1.2 Hz), 7.57–7.80 (4H, m), 8.04 
(1H, s), 8.14 (1H, s). IR (KBr): 3400–3100, 2973, 1626, 1601, 1537, 1456, 1294, 1173 cm
−1
. LCMS 
(API): m/z 352.3 [M+H]
+
. Anal. Calcd for C21H25N3O2·0.15H2O: C, 71.22; H, 7.20; N, 11.87. Found: 
C, 71.05; H, 7.34; N, 11.81. 
 
6.2.51. 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2- 
naphthamide (71f) 
 
Yield 93%, pale yellow amorphous solid. 
1
H NMR (CDCl3 + CD3OD) δ: 0.76 (3H, d, J = 6.6 Hz), 
0.99 (3H, d, J = 6.6 Hz), 2.64–2.78 (1H, m), 3.01 (3H, d, J = 1.4 Hz), 6.98 (1H, s), 7.41 (1H, dd, J = 
1.4, 8.6 Hz), 7.42 (1H, s), 7.69 (1H, d, J = 7.8 Hz), 7.72 (1H, dd, J = 1.4, 7.8 Hz), 8.01 (1H, s), 8.19 
(1H, d, J = 8.6 Hz). IR (KBr): 3242, 2970, 1630, 1553, 1333, 824 cm
−1
. LCMS (API): m/z 358.1 
[M+H]
+
. Anal. Calcd for C19H20N3O2·0.5H2O: C, 62.21; H, 5.77; N, 11.45. Found: C, 62.10; H, 5.84; 
N, 11.37. 
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6.2.52. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl-2-naphthamide 
(71g) 
 
Yield 91%, colorless amorphous solid. 
1
H NMR (CDCl3 + CD3OD) δ: 0.78 (3H, d, J = 7.0 Hz), 
0.99 (3H, d, J = 6.6 Hz), 2.65 (3H, s), 2.65–2.78 (1H, m), 2.98 (3H, s), 6.97 (1H, d, J = 1.2 Hz), 7.31 
(1H, d, J = 8.4 Hz), 7.42 (1H, d, J = 1.2 Hz), 7.61–7.67 (2H, m), 7.93–7.97 (2H, m). IR (KBr): 330, 
2975, 1634, 1559, 1410, 1159, 822 cm
−1
. LCMS (API): m/z 338.2 [M+H]
+
. Anal. Calcd for 
C20H23N3O2·0.75H2O: C, 68.45; H, 7.04; N, 11.97. Found: C, 68.20; H, 7.15; N, 11.83. 
 
6.2.53. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-2-naphthamide 
(71h) 
 
Yield 84%, pale yellow amorphous solid. 
1
H NMR (CDCl3 + CD3OD) δ: 0.77 (3H, d, J = 7.0 Hz), 
0.99 (3H, d, J = 6.6 Hz), 2.48 (3H, s), 2.61–2.74 (1H, m), 2.98 (3H, d, J = 3.0 Hz), 6.95 (1H, d, J = 
1.2 Hz), 7.37 (1H, d, J = 1.2 Hz), 7.50 (1H, dd, J = 1.8, 8.8 Hz), 7.54 (1H, s), 7.64 (1H, d, J = 8.8 
Hz), 7.72 (1H, s), 7.88 (1H, s). IR (KBr): 3192, 2968, 1643, 1539, 1408, 1304, 1155, 908, 818 cm
−1
. 
LCMS (API): m/z 338.2 [M+H]
+
. Anal. Calcd for C20H23N3O2·0.75H2O: C, 68.45; H, 7.04; N, 11.97. 
Found: C, 68.56; H, 7.12; N, 11.79. 
 
6.2.54. Methyl-1-(Bromomethyl)-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-
yl)propyl]-2-naphthoate (72) 
 
A mixture of 68c (34.61 g, 59.6 mmol), N-bromosuccinimide (12.28 g, 69.0 mmol) and 
2,2'-azobisisobutyronitrile (0.99 g, 6.0 mmol) in CCl4 (800 mL) was refluxed for 21 h. After 
removing the solvent, the mixture was diluted with aq NaHCO3 solution. The resulting mixture was 
extracted with AcOEt–THF and the combined organic layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel (AcOEt) to give a crude mixture of 68c and 72 (68c:72 = 1:7, 23.1 g, 
59%). The analytical sample was obtained by recrystallization from THF–AcOEt as a colorless 
powder. Mp 195°C decomp. 
1
H NMR (CDCl3) δ: 0.74 (3H, d, J = 6.8 Hz), 0.98 (3H, d, J = 6.8 Hz), 
2.55 (1H, septet, J = 6.8 Hz), 3.78 (1H, s), 3.99 (3H, s), 5.43 (1H, d, J = 9.8 Hz), 5.47 (1H, d, J = 9.8 
Hz), 6.82 (1H, d, J = 1.4 Hz), 7.10–7.35 (16H, m), 7.72 (1H, dd, J = 8.8, 1.8 Hz), 7.81 (1H, d, J = 
8.8 Hz), 7.92 (1H, d, J = 8.8 Hz), 8.10 (1H, d, J = 1.8 Hz), 8.18 (1H, d, J = 8.8 Hz). IR (KBr): 1725, 
1238, 702 cm
−1
. Anal. Calcd for C39H35N2O3Br: C, 71.01; H, 5.35; N, 4.25; Br, 12.11. Found: C, 
70.86; H, 5.42; N, 4.19. 
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6.2.55. 7-[1-Hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-yl)propyl]-1,2-dihydro-3H
-benzo[e]isoindol-3-one (73a) 
 
A solution of saturated NH3 in MeOH (50 mL) was added to a cooled (0°C) solution of 72 (5.58 
g, crude 8.5 mmol) in THF (50 mL), and stirred for 1 h at rt. After removal of the solvent, the residue 
was diluted with aq NaHCO3 solution. The resulting mixture was extracted with AcOEt–THF and 
the combined organic layers were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The residue was purified by column chromatography on silica gel (AcOEt/MeOH 
= 20:1) to give 73a (1.22 g, 26%) as a colorless powder. Mp 250°C decomp. 
1
H NMR (CDCl3 + 
CD3OD) δ: 0.74 (3H, d, J = 6.6 Hz), 0.98 (3H, d, J = 6.6 Hz), 2.59 (1H, septet, J = 6.6 Hz), 4.73 (2H, 
s), 6.85 (1H, s), 7.10–7.38 (16H, m), 7.78–7.90 (4H, m), 8.11 (1H, s). IR (KBr): 1690, 745, 702 cm
−1
. 
Anal. Calcd for C38H33N3O2·0.5H2O: C, 79.69; H, 5.98; N, 7.34. Found: C, 79.57; H, 6.27; N, 7.07. 
 
6.2.56. 7-[1-Hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-yl)propyl]-2-methyl-1,2- 
dihydro-3H-benzo[e]isoindol-3-one (73b) 
 
Using 72 (0.80 g, 1.2 mmol) was used as the starting material and the same procedure described 
for the synthesis of 73a with 40% methylamine solution, 73b (0.77 g, quant.) was obtained as a 
colorless powder. The analytical sample was obtained by recrystallization from THF as a colorless 
powder. Mp 250°C decomp. 
1
H NMR (CDCl3) δ: 0.74 (3H, d, J = 6.6 Hz), 0.97 (3H, d, J = 6.6 Hz), 
2.56 (1H, septet, J = 6.6 Hz), 3.29 (3H, s), 3.69 (1H, br s), 4.68 (2H, s), 6.83 (1H, d, J = 1.4 Hz), 
7.10–7.36 (16H, m), 7.76 (2H, s), 7.83 (2H, s), 8.11 (1H, s). IR (KBr): 3409, 1680, 704 cm
−1
. Anal. 
Calcd for C39H35N3O2: C, 81.08; H, 6.11; N, 7.27. Found: C, 80.69; H, 6.11; N, 7.12. 
 
6.2.57. 7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benzo[e]isoindol-3
-one (74a) 
 
Compound 73a (1.17 g, 2.1 mmol) was used as a starting material. Using the same procedure 
described for the synthesis of 53, 74a (0.50 g, 75%) was obtained as a colorless powder. The 
analytical sample was obtained by recrystallization from EtOH–H2O as a colorless powder. Mp 
230°C decomp. 
1
H NMR (CDCl3 + CD3OD) δ: 0.79 (3H, d, J = 6.6 Hz), 1.02 (3H, d, J = 6.6 Hz), 
2.76 (1H, septet, J = 6.6 Hz), 4.68 (2H, s), 7.04 (1H, s), 7.55 (1H, s), 7.70–7.77 (3H, m), 7.88 (1H, d, 
J = 8.4 Hz), 8.15 (1H, s). IR (KBr): 1684, 1472, 747 cm
−1
. LCMS (API): m/z 322.1 [M+H]
+
. Anal. 
Calcd for C19H19N3O2: C, 71.01; H, 5.96; N, 13.08. Found: C, 70.76; H, 6.04; N, 12.78. 
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6.2.58. 7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-1,2-dihydro-3H-benzo[e]
isoindol-3-one (74b) 
 
Using 73b was used as the starting material and the same procedure as described for the synthesis 
of 74a, 74b (0.28 g, 90%) was obtained as a colorless powder. The analytical sample was obtained 
by recrystallization from THF–MeOH (colorless powder). Mp 250°C decomp. 
1
H NMR (CDCl3 + 
CD3OD) δ: 0.80 (3H, d, J = 7.0 Hz), 1.02 (3H, d, J = 7.0 Hz), 2.78 (1H, septet, J = 7.0 Hz), 3.29 (3H, 
s), 4.73 (2H, s), 7.04 (1H, d, J = 1.2 Hz), 7.54 (1H, d, J = 1.2 Hz), 7.76–7.94 (4H, m), 8.17 (1H, s). 
13
C NMR (DMSO- d6) δ: 16.7, 17.4, 29.0, 36.7, 50.6, 77.4, 112.0, 119.0, 122.5, 124.3, 125.9, 126.5, 
128.6, 129.0, 133.9, 134.2, 140.5, 147.1, 147.7, 168.1. IR (KBr): 3193, 1667, 1003 cm
−1
. LCMS 
(API): m/z 336.2 [M+H]
+
. Anal. Calcd for C20H21N3O2·0.1H2O: C, 71.24; H, 6.34; N, 12.46. Found: 
C, 71.09; H, 6.48; N, 12.23. 
 
6.2.59. Methyl-3-(bromomethyl)-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1H-imidazol-4-
yl)propyl]-2-naphthoate (75) 
 
Using 68d (5.93 g, 10.2 mmol) as the starting material and the same procedure as described for 
the synthesis of 72, crude 75 (6.70 g, quant.) was obtained as a brown amorphous solid. 
1
H NMR 
(CDCl3) δ: 0.73 (3H, d, J = 6.6 Hz), 0.97 (3H, d, J = 6.6 Hz), 2.53 (1H, septet, J = 6.6 Hz), 3.74 (1H, 
s), 4.00 (3H, s), 5.12 (1H, d, J = 10.4 Hz), 5.15 (1H, d, J = 10.4 Hz), 6.81 (1H, d, J = 1.0 Hz), 7.09–
7.38 (16H, m), 7.65 (1H, dd, J = 8.4, 1.6 Hz), 7.78–7.84 (2H, m), 8.02 (1H, s), 8.50 (1H, s). IR 
(KBr): 2969, 1717, 1287, 702 cm
−1
. Anal. Calcd C39H35N2O3Br·2H2O: C, 67.34; H, 5.65; N, 4.03; Br, 
12.11.Found: C, 67.38; H, 5.50; N, 4.34. 
 
6.2.60. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2,3-dihydro-1H-benzo[f]isoindol-1
-one (77a) 
 
Using 75 (5.00 g, 7.3 mmol) as the starting material and the same procedure as described for the 
synthesis of 74a, 77a (1.46 g, 64%) was obtained as a colorless power. The analytical sample was 
obtained by recrystallization from EtOH as a colorless powder. Mp 204.0–208.0°C. 
1
H NMR (CDCl3 
+ CD3OD) δ: 0.80 (3H, d, J = 7.0 Hz), 1.02 (3H, d, J = 7.0 Hz), 2.76 (1H, septet, J = 7.0 Hz), 4.56 
(2H, s), 7.03 (1H, d, J = 1.2 Hz), 7.53 (1H, d, J = 1.2 Hz), 7.65 (1H, dd, J = 8.4, 1.6 Hz), 7.90–7.96 
(2H, m), 8.13 (1H, s), 8.31 (1H, s). IR (KBr): 3208, 1671 cm
−1
. LCMS (API): m/z 322.1 [M+H]
+
. 
Anal. Calcd for C19H19N3O2·C2H5OH: C, 68.64; H, 6.86; N, 11.44. Found: C, 68.30; H, 6.84; N, 
11.29. 
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6.2.61. 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-2,3-dihydro-1H-benzo[f]
isoindol-1-one (77b) 
 
Using 75 (0.99 g, 1.5 mmol) as the starting material and the same procedure as described for the 
synthesis of 74a, 77b (0.11 g, 22%) was obtained as a colorless power. The analytical sample was 
obtained by recrystallization from EtOH (colorless powder). Mp 260°C decomp. 
1
H NMR (CDCl3 + 
CD3OD) δ: 0.81 (3H, d, J = 6.6 Hz), 1.02 (3H, d, J = 6.6 Hz), 2.70–2.90 (1H, m), 3.27 (3H, s), 4.59 
(2H, s), 7.04 (1H, s), 7.54 (1H, s), 7.65–7.73 (1H, m), 7.92–7.96 (2H, m), 8.14 (1H, s), 8.27 (1H, s). 
13
C NMR (DMSO- d6) δ: 16.7, 17.4, 29.1, 36.6, 51.1, 77.4, 112.0, 121.8, 121.9, 123.4, 125.5, 128.0, 
130.0, 130.8, 134.1, 134.1, 134.2, 136.5, 147.2, 147.4, 167.1. IR (KBr): 3167, 1663, 1400, 1150, 810, 
625 cm
−1
. LCMS (API): m/z 336.2 [M+H]
+
. Anal. Calcd for C20H21N3O2: C, 71.62; H, 6.31; N, 12.53. 
Found: C, 71.22; H, 6.61; N, 12.46. 
 
6.2.62. Optical resolution of 74a 
 
Optical resolution of 74a (13.1 g) was performed using preparative HPLC on a Chiralpak AD 
column (50 mmID × 500 mmL, eluent: hexane/EtOH/diethylamine = 85:15:0.1, flow rate: 80–100 
mL/min, temperature: 35°C) to yield (−)-74a (5.27 g, 99.9% enantiomeric excess [ee]) as a colorless 
powder and (+)-74a (5.39 g, 99.7% ee) as colorless amorphous solid. (−)-74a: Mp 220.0–222.0°C. 
1
H NMR (DMSO- d6) δ : 0.66 (3H, d, J = 6.8 Hz), 0.75–0.97 (3H, m), 2.67–2.86 (1H, m), 4.71 (2H, 
s), 5.18 (1H, br s), 7.02 (1H, br s), 7.56 (1H, br s), 7.64 (1H, d, J = 8.3 Hz), 7.82–8.10 (3H, m), 8.25 
(1H, br s), 8.58 (1H, s), 11.82 (1H, br s). IR (KBr): 3185, 2976, 1686 cm
−1
. LCMS (API): m/z 322.1 
[M+H]
+
. Anal. Calcd for C19H19N3O2·0.5H2O: C, 69.07; H, 6.10; N, 12.72. Found: C, 69.37; H, 6.11; 
N, 12.68. [α]D
20
 =-41.2 (c 0.9520, MeOH). (+)-74a: The spectral data of (+)-74a were identical to 
those of the (−)-74a except for elemental analysis and optical rotation. LCMS (API): m/z 322.1 
[M+H]
+
. Anal. Calcd for C19H19N3O2·1.25H2O·0.25AcOEt: C, 65.65; H, 6.47; N, 11.48. Found: C, 
65.40; H, 6.68; N, 11.36. [α]D
20
 =+35.4 (c 1.0085, MeOH). 
 
6.2.63. Optical resolution of 74b 
 
Optical resolution of 74b (2.40 g) was performed using preparative HPLC on a Chiralpak AD 
column (50 mmID × 500 mmL, eluent: hexane/EtOH = 40:60, flow rate: 60 mL/min, temperature: 
rt) to yield (−)-74b (1.10 g, 99.9% ee) as a colorless powder and (+)-74b (1.00 g, 99.8% ee) as a 
colorless powder. (−)-74b: Mp 207.0–209.0°C. 
1
H NMR (DMSO- d6) δ : 0.65 (3H, d, J = 6.6 Hz), 
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0.83 (3H, d, J = 6.6 Hz), 2.65–2.87 (1H, m), 3.14 (3H, s), 4.78 (2H, s), 5.17 (1H, s), 7.04 (1H, s), 
7.42–7.76 (2H, m), 7.80–8.08 (3H, m), 8.26 (1H, s), 11.83 (1H, br s). The 
13
C NMR spectral data of 
(−)-74b was identical to those of the 74b. IR (KBr): 3148, 2971, 1669 cm
−1
. LCMS (API): m/z 336.2 
[M+H]
+
. Anal. Calcd for C20H21N3O2·0.75H2O: C, 68.85; H, 6.50; N, 12.04. Found: C, 68.71; H, 
6.38; N, 11.99. [α]D
20
 =-33.4 (c 0.226, MeOH). (+)-74b: The spectral data of (+)-74b were identical 
to those of the (−)-74b except for elemental analysis and optical rotation. Mp 207.0–209.0°C. LCMS 
(API): m/z 336.1 [M+H]
+
. Anal. Calcd for C20H21N3O2·0.75H2O: C, 68.85; H, 6.50; N, 12.04. 
Found: C, 68.99; H, 6.45; N, 11.95. [α]D
20
 =+34.5 (c 0.258, MeOH). 
 
6.2.64. 7-[(1R)-1-{1-[(4-Bromophenyl)sulfonyl]-1H-imidazol-4-yl}-1-hydroxy-2-methylpropyl]-
2-methyl-1,2-dihydro-3H-benzo[e]isoindol-3-one (78) 
 
4-Bromobenzenesulfonyl chloride (460 mg, 1.8 mmol) was added to a solution of (+)-74b (503 
mg, 1.5 mmol) in DMF (12 mL) and the mixture was stirred at rt for 3 h. The mixture was poured 
into water and the aqueous phase extracted with AcOEt. The combined organic layer was washed 
with 10% citric acid solution, H2O and brine, dried over MgSO4 and evaporated. The residue was 
crystallized from AcOEt–i-Pr2O to give 78 (730 mg, 88%). Analytical sample was obtained by 
recrystallization from THF–MeOH. Mp 170°C. IR (KBr): 3345, 1671, 745, 635 cm
−1
. 
1
H NMR 
(CDCl3) δ: 0.76 (3H, d, J = 6.6 Hz), 0.91 (3H, d, J = 6.6 Hz), 2.79 (1H, septet, J = 6.6 Hz), 2.96 (1H, 
s), 3.27 (3H, s), 4.66 (2H, s), 7.31 (1H, d, J = 1.4 Hz), 7.64–7.88 (8H, m), 7.94 (1H, d, J = 1.4 Hz), 
8.14 (1H, s). Anal. Calcd for C26H24BrN3O4S·MeOH: C, 55.29; H, 4.81; N, 7.13. Found: C, 55.48; H, 
4.75; N, 6.98. 
 
6.2.65. 6-Bromo-N,N-diisopropyl-2-naphthamide (79b) 
 
A solution of 6-bromo-2-naphthoic acid 79a (100 g, 398 mmol), thionylchloride (37.7 mL, 517 
mmol) and DMF (0.5 mL) in THF (1000 mL) was stirred at 60°C for 90 min. After cooling to rt, the 
solvent and excess amount of thionylchloride was evaporated. The resulting residue was dissolved in 
dry THF (400 mL) and the solution was added dropwise to a cooled (0°C) solution of 
diisopropylamine (112 mL, 799 mmol) and triethylamine (112 mL, 804 mmol) in THF (800 mL). 
After being stirred at rt for 1 h, about 50% of the solvent was evaporated. Then the mixture was 
diluted with AcOEt and the organic phase was washed with H2O, 1 N NaOH solution and brine, 
dried over MgSO4 and evaporated. The residue was washed with i-Pr2O to give 79b (117 g, 88%) as 
a colorless crystal. 
1
H NMR (CDCl3) δ: 1.36 (12H, br s), 3.71 (2H, br s), 7.44 (1H, dd, J = 1.2 Hz, 
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8.6 Hz), 7.58 (1H, dd, J = 2.2 Hz, 8.8 Hz), 7.70–7.79 (3H, m), 8.01 (1H, d, J = 1.2 Hz). IR (KBr): 
2968, 1620, 1435, 1369, 1333, 895, 814 cm
−1
. LCMS (API): m/z 334.1 [M+H]
+
. Anal. Calcd for 
C17H20NOBr: C, 61.09; H, 6.03; N, 4.19; Br, 23.91. Found: C, 61.22; H, 6.08; N, 4.12. 
 
6.2.66. 6-[(2R)-2-(tert-Butyldimethylsilyloxy)propanoyl]-N,N-diisopropyl-2-naphthamide (80a) 
 
Solution 79b (46.80 g, 140.0 mmol) in THF (400 mL) was added dropwise to a cooled (−70°C) 
solution of n-BuLi (1.6 mol/L in hexane; 96.3 mL, 154 mmol) in toluene (900 mL) and the mixture 
was stirred at −70°C for 30 min. A solution of 40 (34.45 g, 126.0 mmol) in toluene (50 mL) was 
added to the mixture and the solution was stirred at −78°C for 30 min. The reaction was quenched 
with aq NH4Cl and the mixture was warmed to rt. After extraction with AcOEt, the combined 
organic layers were dried over MgSO4 and evaporated to give 80a as a pale yellow oil. This 
compound was directly used without further purification in the next step. 
1
H NMR (CDCl3) δ: 0.06 
(3H, s), 0.12 (3H, s), 0.91 (9H, s), 1.10–1.60 (12H, m), 1.60 (3H, d, J = 7.0 Hz), 3.50–4.00 (2H, br 
m), 5.04 (1H, q, J = 7.0 Hz), 7.50 (1H, dd, J = 8.4, 1.4 Hz), 7.83 (1H, s), 7.91 (1H, d, J = 8.4 Hz), 
7.99 (1H, d, J = 8.4 Hz), 8.14 (1H, d, J = 8.4, 1.4 Hz), 8.72 (1H, s). IR (KBr): 1694, 1630, 1441, 
1335, 835 cm
−1
. 
 
6.2.67. 6-[(2R)-2-Hydroxypropanoyl]-N,N-diisopropyl-2-naphthamide (80b) 
 
TBAF (41.01 g, 157 mmol) was added to a cooled (−10°C) solution of 80a (25.7 g, 74.9 mmol) 
in THF (900 mL) and the mixture was stirred at 0°C for 1 h. The mixture was diluted with brine and 
the aqueous phase was extracted with AcOEt. The combined organic layers were washed with brine 
and dried over MgSO4. After removal of the solvent in vacuo, the residue was chromatographed on 
silica gel (hexane/AcOEt = 2:1–2:3) and washed with diethylether to give 80b (24.00 g, 58% from 
40) as a colorless solid. Mp 174°C. [α]D
20
 =+38.2 (c 0.726, MeOH). 
1
H NMR (CDCl3) δ: 1.10–1.70 
(12H, br m), 1.52 (3H, d, J = 6.9 Hz), 3.40–3.90 (2H, br), 3.84 (1H, d, J = 6.9 Hz), 5.32 (1H, quint, J 
= 6.9 Hz), 7.52 (1H, dd, J = 8.4, 1.8 Hz), 7.84 (1H, s), 7.95 (1H, d, J = 8.4 Hz), 8.00–8.04 (2H, m), 
8.45 (1H, s). IR (KBr): 3493, 1678, 1628, 1117, 826 cm
−1
. LCMS (API): m/z 328.1 [M+H]
+
. Anal. 
Calcd for C20H25NO3: C, 73.37; H, 7.70; N, 4.28. Found: C, 73.24; H, 7.60; N, 4.21. 
 
6.2.68. 6-[(1S,2R)-1,2-Dihydroxy-1-isopropylpropyl]-N,N-diisopropyl-2-naphthamide (81) 
 
A solution of i -propylmagnesium bromide (0.7 M in THF; 500 mL, 350 mmol) was added 
dropwise over 2 h to a cooled (−10°C) solution of 80b (20.08 g, 61.3 mmol) in THF (300 mL) and 
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the mixture was stirred at 0°C for 1 h. The reaction was quenched with satd aq NH4Cl and the 
aqueous layer was extracted with AcOEt. The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. The residue was crystallized from i -Pr2O to give 81 (12.35 g, 54%) as a 
colorless solid. The purity of the obtained 81 was >95% as determined by HPLC using a Chiralpak 
AD column. The analytical sample was obtained by recrystallization from AcOEt. Mp 200°C. [α]D
20
 
=+19.9 (c 0.545, MeOH). 
1
H NMR (CDCl3) δ: 0.87 (3H, d, J = 6.6 Hz), 0.95 (3H, d, J = 6.6 Hz), 
1.06 (3H, d, J = 6.6 Hz), 1.00–1.70 (12H, br m), 1.65 (1H, d, J = 4.2 Hz), 2.45 (1H, septet, J = 6.6 
Hz), 2.61 (1H, s), 3.50–4.00 (2H, br), 4.37 (1H, dq, J = 4.2, 6.6 Hz), 7.41 (1H, dd, J = 8.4, 1.8 Hz), 
7.48 (1H, dd, J = 8.4, 1.8 Hz), 7.77–7.90 (4H, m). IR (KBr): 3511, 2971, 1617, 1443, 1372, 1341 
cm
−1
. LCMS (API): m/z 372.2 [M+H]
+
. Anal. Calcd for C23H33NO3: C, 74.36; H, 8.95; N, 3.77. 
Found: C, 74.39; H, 8.77; N, 3.73. 
 
6.2.69. 7-[(1S,2R)-1,2-Dihydroxy-1-isopropylpropyl]-2-methyl-1,2-dihydro-3H-benzo[e]isoindo
l-3-one (84a) 
 
n-BuLi (1.6 mol/L, 103.8 mL, 166 mmol) was added dropwise to a cooled (−70°C) solution of 81 
(12.35 g, 33.2 mmol) and tetramethylethylenediamine (TMEDA) (60 mL) in THF (250 mL) and the 
mixture was stirred at −70°C for 2.5 h. To the mixture, DMF (25 mL) was added dropwise, and the 
reaction mixture was further stirred at −70°C for 1 h. After diluting with aq NH4Cl solution, the 
aqueous layer was extracted with AcOEt. The combined organic layers were washed with H2O and 
brine, dried over MgSO4. Removal of the solvent in vacuo gave a crude product of 82a and 82b 
(82a:82b = ca. 6:1) as amorphous solid. The crude product of 82a and 82b was dissolved in CH2Cl2 
(250 mL) and methylamine (2 M in THF, 67.5 mL, 135 mmol) was added. After adjusting the pH of 
the reaction mixture to 6–7 with acetic acid (ca. 9 mL), NaBH(OAc)3 (59.3 g, 280 mmol) was added 
dropwise to the reaction mixture, which was then stirred at rt for 62 h. After being diluted with 2 N 
HCl, the aqueous layer was washed with AcOEt. The aqueous layer was then made alkaline with 10 
N NaOH solution and extracted with AcOEt. The combined organic layers were dried over MgSO4 
and evaporated in vacuo to give a crude product of 83a and 83b. 
n-BuLi (1.6 M in hexane; 104 ml, 166 mmol) was added dropwise to a cooled (−60°C) solution 
of diisopropylamine (24.5 mL, 175 mmol) in THF (250 mL) and the mixture was stirred at −70°C 
for 10 min to prepare the LDA solution. A solution of the crude product of 83a and 83b in THF (70 
mL) was then added dropwise, and the reaction mixture was allowed to warm to 0°C over 2 h. After 
being diluted with aq NH4Cl solution, the aqueous layer was extracted with AcOEt. The combined 
organic layers were dried over MgSO4 and evaporated. The residue was purified by column 
chromatography on silica gel (AcOEt) and crystallized from THF–AcOEt to yield a mixture of 84a 
 96 
 
and 84b (4.33 g, 42%, 84a:84b = 93:7) as a colorless solid. The ratio of the obtained 84a and 84b 
was determined by HPLC using Chiralpak AD column. 
1
H NMR (CDCl3) δ: 0.89 (3H, d, J = 6.9 Hz), 
0.95 (3H, d, J = 6.9 Hz), 1.07 (3H, d, J = 6.3 Hz), 1.82 (1H, d, J = 6.3 Hz), 2.46 (1H, septet, J = 6.9 
Hz), 2.69 (1H, s), 3.29 (3H, s), 4.41 (1H, quint, J = 6.3 Hz), 4.70 (2H, s), 7.61 (1H, dd, J = 8.7, 1.8 
Hz), 7.80–7.97 (3H, m), 8.01 (1H, d, J = 1.8 Hz). IR (KBr): 3420, 1686, 826, 747 cm
−1
. LCMS 
(API): m/z 314.2 [M+H]
+
. Anal. Calcd for C19H23NO3·0.1AcOEt: C, 72.32; H, 7.45; N, 4.35. Found: 
C, 72.37; H, 7.61; N, 4.32. 
 
6.2.70. 7-[(1S)-1-Acetyl-1-hydroxy-2-methylpropyl]-2-methyl-1,2-dihydro-3H-benzo[e]isoindol
-3-one (85) 
 
Dimethyl sulfoxide (DMSO) (3.63 mL, 51.1 mmol) was added dropwise to a cooled (−70°C) 
solution of oxalylchloride (2.22 mL, 25.5 mmol) in CH2Cl2 (40 mL) and the mixture was stirred at 
−70°C for 1 h. A solution of 84a (4.00 g, 12.8 mmol, 84a:84b = 93:7) in CH2Cl2/DMSO (1:1, 12 
mL) was added dropwise, and the reaction mixture was warmed to −20°C over 1 h. After cooling to 
−70°C, triethylamine (10.7 mL, 76.6 mmol) was added dropwise to the mixture and the solution was 
allowed to warm to rt and stirred for a further 2 h. The resulting mixture was diluted with H2O and 
the combined organic layers were washed with H2O and dried over MgSO4. After removal of the 
solvent in vacuo, the resulting solid was washed with i -Pr2O and recrystallized from AcOEt to give 
85 (3.10 g, 33% from 81) as a colorless solid. The purity of the obtained 85 was >99% as determined 
by HPLC using a Chiralpak AD column. Mp 171°C. [α]D
20
 =-22.9 (c 0.615, MeOH). 
1
H NMR 
(CDCl3) δ: 0.94 (3H, d, J = 6.9 Hz), 0.96 (3H, d, J = 6.9 Hz), 2.20 (3H, s), 2.97 (1H, septet, J = 6.9 
Hz), 3.29 (3H, s), 4.63 (1H, s), 4.70 (2H, s), 7.77 (1H, dd, J = 8.7, 1.8 Hz), 7.84–7.92 (3H, m), 8.17 
(1H, d, J = 1.8 Hz). IR (KBr): 3335, 1705, 1667, 1171, 748 cm
−1
. LCMS (API): m/z 312.2 [M+H]
+
. 
Anal. Calcd for C19H21NO3·0.6AcOEt: C, 70.57; H, 7.14; N, 3.85. Found: C, 70.60; H, 7.16; N, 
4.12. 
 
6.2.71. 7-[(1S)-3-Bromo-1-hydroxy-1-isopropyl-2-oxopropyl]-2-methyl-1,2-dihydro-3H-benzo 
[e]isoindol-3-one (86) 
 
Pyridinium bromide perbromide (3.17 g, 9.9 mmol) was added to a cooled (0°C) solution of 85 
(2.80 g, 9.0 mmol) in THF (35 mL) and the mixture was stirred at rt for 66 h. The reaction mixture 
was diluted with aqueous sodium thiosulfate solution and the aqueous phase was extracted with 
AcOEt. The combined organic layers were washed with 10% aq citric acid solution and aq NaHCO3 
solution, and dried over MgSO4. After removal of the solvent in vacuo, the residue was 
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chromatographed on silica gel (hexane/AcOEt = 1:1–1:2) to give 86 (2.97 g, 85%) including starting 
material 85 as a colorless solid. This compound was used without further purification in the next step. 
1
H NMR (CDCl3) δ: 0.80 (3H, d, J = 6.6 Hz), 1.04 (3H, d, J = 6.6 Hz), 2.99 (1H, septet, J = 6.6 Hz), 
3.28 (3H, s), 3.97 (1H, s), 4.27 (1H, d, J = 15.0 Hz), 4.34 (1H, d, J = 15.0 Hz), 4.68 (2H, s), 7.72–
7.91 (4H, m), 8.19 (1H, d, J = 1.4 Hz). IR (KBr): 1670 cm
−1
. 
 
6.2.72. 7-{(1S,2Z)-3-Bromo-1-isopropyl-1,2-bis[(trimethylsilyl)oxy]prop-2-enyl}-2-methyl-1,2-
dihydro-3H-benzo[e]isoindol-3-one (87) 
 
TBAF (1 M solution in THF, 32 mL, 0.032 mmol) was added to a solution of 86 (0.63 g, 1.6 
mmol) and N,O-bis(trimethylsilyl)acetamide (2.4 mL, 9.7 mmol) in DMF (8 mL) and the reaction 
mixture was stirred at rt for 16 h. After being diluted with AcOEt, the mixture was washed with H2O, 
followed by brine, before drying over MgSO4. After removal of the solvent in vacuo, the residue was 
chromatographed on silica gel (hexane/AcOEt = 13:7–7:13) to give 87 (0.55 g, 54% from 85) as 
colorless amorphous solid. 
1
H NMR (CDCl3) δ: −0.14 (9H, s), 0.09 (9H, s), 0.85 (3H, d, J = 6.9 Hz), 
1.00 (3H, d, J = 6.9 Hz), 2.59 (1H, septet, J = 6.9 Hz), 3.31 (3H, s), 4.72 (2H, s), 5.90 (1H, s), 7.64 
(1H, dd, J = 9.0, 4.8 Hz), 7.78–7.94 (4H, m). IR (KBr): 1690, 1252, 843 cm
−1
. LRMS (FAB): m/z 
534 [M+H]
+
. 
 
6.2.73. 7-[(1S)-1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-1,2-dihydro-3H- 
benzo[e]isoindol-3-one [(−)-74b] 
 
Saturated ammonia solution in MeOH (1.5 mL) and formamidine acetate (31 mg, 0.3 mmol) was 
added to a cooled (−15°C) solution of 87 (160 mg, 0.30 mmol) in THF (0.5 mL) and the resulting 
mixture was stirred at −15°C for 30 min. The reaction mixture was allowed to warm to rt over 3 h 
and stirred at rt for a further 90 h. After removing excess NH3 and MeOH, the residue was diluted 
with brine. The aqueous layer was extracted with AcOEt/THF (1:1) and the combined organic layer 
was dried over MgSO4. After removal of the solvent in vacuo, the residue was chromatographed on 
silica gel (CH2Cl2/MeOH = 30:1–6:1) to give (−)-74b (54 mg, 54%). The optical purity of the 
obtained (−)-74b was >99% ee as determined by HPLC using a Chiralpak AD column. 
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6.3.1. Optical resolution of 1 using preparative HPLC 
 
Compound 71b (12.7 g, 39.3 mmol) was subjected to optical resolution by preparative HPLC 
using a Chiralpak AD column (50 mm × 500 mm) using hexane/ethanol (85/15) as an eluent, 
detected at 254 nm, to afford (-)-71b (6.09 g, 18.8 mmol, 48%) as a first elution and (+)-71b (6.02 g, 
18.6 mmol, 47%) as a second elution. (-)-71b: [α]D
25
 = −55.7 (c 0.908, MeOH); t R = 17.1 min 
(Chiralpak AD 4.6 mmID × 250 mmL, hexane/ethanol = 85/15, 0.8 mL/min, at 254 nm); >99.9% ee. 
Compound (+)-71b: [α]D
25
 = +56.1 (c 0.924, MeOH); tR = 29.0 min (Chiralpak AD 4.6 mmID × 
250mmL, hexane/ethanol = 85/15, 0.8 mL/min, at 254 nm); 99.8% ee. 
 
6.3.2. 6-[(1S)-1-{1-[(4-Bromophenyl)sulfonyl]-1H-imidazol-4-yl}-1-hydroxy-2-ethylpropyl]-N-
methylnaphthalene-2-carboxamide (88) 
 
To a solution of (-)-71b (210 mg, 0.65 mmol) and Et3N (0.226 mL, 1.62 mmol) in DMF (5 mL) 
was added dropwise 4-bromobenzenesulfonyl chloride (166 mg, 0.65 mmol) and the mixture was 
stirred at room temperature for 16 h. After being diluted with aqueous NaHCO3 solution, the 
appeared solid was filtered off, washed with H2O and dried in air. The obtained solid was 
recrystallized from AcOEt and tetrahydrofuran (THF) to give 88 (278 mg, 0.512 mmol, 79%) as a 
colorless powder. 
1
H NMR (DMSO-d6) δ : 0.62 (3H, d, J = 6.8 Hz), 0.73 (3H, d, J = 6.8 Hz), 2.64–
2.78 (1H, m), 2.82 (3H, d, J = 4.5 Hz), 5.55 (1H, s), 7.49 (1H, d, J = 1.5 Hz), 7.80–7.94 (6H, m), 
7.96–8.04 (2H, m), 8.09 (1H, s), 8.33 (1H, s), 8.37 (1H, d, J = 1.5 Hz), 8.54 (1H, q, J = 4.6 Hz). [α]D
25
 
= +57.6 (c 0.187, MeOH). 
 
6.3.3. 3-Bromo-1-(1H-imidazol-4-yl)-1-propanone hydrogen bromide (91) 
 
25% hydrogen bromide in acetic acid (100 mL) was added dropwise to a cooled (10°C) solution 
of 90 (29.0 g, 80.0 mmol) in acetic acid (130 mL) and the mixture was stirred for 2 h at room 
temperature. After being diluted with diisopropylether (i-Pr2O) the precipitate was collected by 
filtration and washed with i-Pr2O to give 91 (22.3 g, quant.) as a pale yellow powder. 
1
H NMR 
(CD3OD) δ: 3.54–3.81 (4H, m), 8.50 (1H, d, J = 1.2 Hz), 9.15 (1H, d, J = 1.2 Hz). 
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6.3.4. 5,6-Dihydro-7H-pyrrolo[1,2-c]imidazol-7-one (92) 
 
A solution of Et3N (15.3 mL, 110 mmol) in CH3CN (25 mL) was added dropwise to a hot (70°C) 
suspension of 91 (28.5 g, 100 mmol) in CH3CN (1100 mL) and the mixture was stirred at 70°C for 2 
h. Triethylamine (25 mL, 179 mmol) was then added to the mixture, and the solution was stirred at 
70°C for a further 30 min. After cooling to room temperature, the insoluble material was filtered off 
and the filtrate was concentrated under reduced pressure. The residue was dissolved in ethyl acetate 
and the insoluble material was again filtered off. The filtrate was concentrated under reduced 
pressure and the resulting residue was separated by chromatography on silica gel (CH2Cl2/5% 
ammonia in MeOH = 10:1) to give 92 (6.67 g, 61%) as a colorless powder. 
1
H NMR (CDCl3) δ: 3.24 
(2H, t, J = 6.5 Hz), 4.41 (2H, t, J = 6.5 Hz), 7.60 (1H, s), 7.74 (1H, s). IR(KBr): 3121, 1713, 1537, 
1489, 1412, 1319, 1204, 1109 cm
−1
. 
 
6.3.5. 6,6-Dimethyl-5,6-dihydro-7H-pyrrolo[1,2-c]imidazol-7-one (93) 
 
Potassium tert-butoxide (t-BuOK) (3.14 g, 28.0 mmol) was added dropwise to a cooled (0°C) 
solution of 92 (1.71 g, 14.0 mmol) in anhydrous tetrahydrofuran (THF) (60 mL), and the solution 
was stirred for 15 min at 0°C. To the mixture, MeI (1.74 ml, 28.0 mmol) was added dropwise, and 
the whole was stirred for 2 h at 0°C. After dilution with 20% aqueous ammonium chloride solution 
and addition of sodium chloride, the aqueous phase was extracted with THF and the extracts were 
dried over MgSO4. After removal of the solvent in vacuo, the residue was purified by column 
chromatography on silica gel (AcOEt) to give 93 (0.90 g, 43%) as a colorless powder. Mp 87°C 
(i-Pr2O). IR (KBr): 3112, 2971, 1713, 1535, 1211, 1113, 841, 654 cm
−1
. 
1
H NMR (CDCl3) δ: 1.37 
(6H, s), 4.15 (2H, s), 7.63 (1H, s), 7.71 (1H, s). Anal. Calcd for C8H10N2O: C, 63.98; H, 6.71; N, 
18.65. Found: C, 64.09; H, 6.98; N, 18.81. 
 
6.3.6. 6-Bromo-N-methyl-2-naphthamide (95a) 
 
Under an argon atmosphere, to a cooled (0°C) solution of 94 (60.26 g, 240 mmol), EDCI·HCl 
(55.21 g, 288 mmol), HOBt·H2O (44.1 g, 288 mmol) and N,N-diisopropylethylamine ((i-Pr)2NEt) 
(37.23 g, 288 mmol) in anhydrous N,N-dimethylformamide (DMF) (960 mL) was added dropwise to 
a solution of MeNH2 (2 M solution in THF; 192 mL, 384 mmol) and the whole was stirred at room 
temperature for 18 h. After dilution with water, the precipitate was filtered off, washed with H2O and 
i-Pr2O and dried under the reduced pressure to give 95a (60.6 g, 82%) as a colorless powder. 
1
H 
NMR (CDCl3 + CD3OD) δ: 3.04 (3H, s), 7.60 (1H, dd, J = 1.8 Hz, 8.6 Hz), 7.78 (2H, d, J = 8.6 Hz), 
7.85 (1H, dd, J = 1.8 Hz, 8.6 Hz), 8.03 (1H, d, J = 1.8 Hz), 8.25 (1H, s). IR (KBr): 3274, 1638, 1622, 
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1559, 1495, 1408, 1316, 1159 cm
−1
. Anal. Calcd for C12H10NOBr.0.1H2O: C, 54.20; H, 3.87; N, 
5.27; Br, 30.25. Found: C, 54.03; H, 3.72; N, 5.24. Compounds 95b–d were prepared in the same 
manner as described for the preparation of 95a. 
 
6.3.7. 6-Bromo-N-ethyl-2-naphthamide (95b) 
 
Yield 60%. 
1
H NMR (CDCl3) δ:1.30 (3H, t, J = 7.3 Hz), 3.56 (2H, dq, J = 5.6 Hz, 7.3 Hz), 6.29 
(1H, br s), 7.60 (1H, dd, J = 2.0 Hz, 8.8 Hz), 7.77 (2H, d, J = 8.8 Hz), 7.85 (1H, dd, J = 2.0 Hz, 8.8 
Hz), 8.03 (1H, d, J = 2.0 Hz), 8.24 (1H, s). IR (KBr): 3275, 2976, 1638, 1620, 1555, 1460, 1314, 
1186 cm
−1
. Anal. Calcd for C13H12NOBr.0.25H2O: C, 55.24; H, 4.46; N, 4.96; Br, 28.73. Found: C, 
55.54; H, 4.16; N, 4.80. 
 
6.3.8. 6-Bromo-N-cyclopropyl-2-naphthamide (95c) 
 
Yield 70%. 
1
H NMR (CDCl3) δ: 0.64–0.73 (2H, m), 0.87–0.97 (2H, m), 2.90–3.02 (1H, m), 6.42 
(1H, br s), 7.60 (1H, dd, J = 2.0 Hz, 8.8 Hz), 7.77 (2H, d, J = 8.8 Hz), 7.82 (1H, dd, J = 2.0 Hz, 8.8 
Hz), 8.03 (1H, d, J = 2.0 Hz), 8.21 (1H, d, J = 2.0 Hz). IR (KBr): 3254, 3061, 1632, 1618, 1541, 
1491, 1318, 1138 cm
−1
. Anal. Calcd for C14H12NOBr: C, 57.95; H, 4.17; N, 4.83; Br, 27.54. Found: 
C, 57.71; H, 4.12; N, 4.79. 
 
6.3.9. 6-Bromo-N-isopropyl-2-naphthamide (95d) 
 
Yield 70%. 
1
H NMR (CDCl3) δ:1.31 (6H, d, J = 6.6 Hz), 4.27–4.44 (1H, m), 6.09 (1H, d, J = 7.8 
Hz), 7.60 (1H, dd, J = 1.8 Hz, 8.8 Hz), 7.78 (2H, d, J = 8.8 Hz), 7.84 (1H, dd, J = 1.8 Hz, 8.8 Hz), 
8.03 (1H, d, J = 1.8 Hz), 8.22 (1H, s). IR (KBr):3262, 2973, 1634, 1620, 1557, 1468, 1352, 1186 
cm
−1
. Anal. Calcd for C14H14NOBr: C, 57.55; H, 4.83; N, 4.79; Br, 27.35. Found: C, 57.40; H, 4.65; 
N, 4.83. 
 
6.3.10. 6-Bromo-N,N-diisopropyl-2-naphthamide (95e) 
 
A solution of 6-bromo-2-naphthoic acid 94 (100 g, 398 mmol), thionylchloride (SOCl2) (37.7 mL, 
517 mmol) and DMF (0.5 mL) in THF (1000 mL) was stirred at 60°C for 90 min. After cooling to 
room temperature, the solvent and excess thionylchloride were evaporated. The resulting residue was 
dissolved in dry THF (400 mL) and the solution was added dropwise to a cooled (0°C) solution of 
diisopropylamine (112 mL, 799 mmol) and Et3N (112 mL, 804 mmol) in THF (800 mL). After 
stirring at room temperature for 1 h, about half the amount of solvent was evaporated. The mixture 
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was then diluted with AcOEt and the organic phase was washed with H2O, 1 N NaOH solution and 
brine, dried over MgSO4 and evaporated. The residue was washed with i-Pr2O to give 95e (117 g, 
88%) as a colorless crystal. 
1
H NMR (CDCl3) δ: 1.36 (12H, br s), 3.71 (2H, br s), 7.44 (1H, dd, J = 
1.2 Hz, 8.6 Hz), 7.58 (1H, dd, J = 2.2 Hz, 8.8 Hz), 7.70–7.79 (3H, m), 8.01 (1H, d, J = 1.2 Hz). IR 
(KBr) : 2968, 1620, 1435, 1369, 1333, 895, 814 cm
−1
. Anal. Calcd for C17H20NOBr: C, 61.09; H, 
6.03; N, 4.19; Br, 23.91. Found: C, 61.08; H, 5.88; N, 4.11. 
 
6.3.11. 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-2-naphthoic acid (89a) 
 
Under an argon atmosphere, 94 (1.51 g, 6.0 mmol) was dissolved in dry THF (50 mL) and the 
solution was cooled to −100°C in a liquid N2 and diethylether bath. A n-BuLi hexane solution (1.6 
M: 7.88 mL, 12.6 mmol) was added dropwise over 5 min with stirring and the mixture was stirred at 
the same temperature for 30 min and at −80°C for 10 min. After cooling to −100°C, a solution of 92 
(610 mg, 6.0 mmol) in dry THF (11 mL) was added dropwise over 5 min and the whole was stirred 
at the same temperature for 30 min. After being warmed up to −70°C over 30 min, the reaction was 
quenched with saturated aqueous ammonium chloride solution. The mixture was diluted with AcOEt 
and the organic layer was separated. The aqueous phase was concentrated to dryness under reduced 
pressure. The resulting residue was chromatographed on silica gel (CHCl3/MeOH/H2O = 65:25:4) 
and concentrated under the reduced pressure. The residue was dissolved in MeOH and concentrated 
again under the reduced pressure. The appeared precipitates were washed with diethylether to give 
89a (180 mg, 12%) as a colorless powder. Mp >250°C decomp (Et2O–MeOH). 
1
H NMR (CD3OD) 
δ: 2.87–3.13 (2H, m), 4.28–4.50 (2H, m), 6.94 (1H, s), 7.65 (1H, dd, J = 1.6 Hz, 8.6 Hz), 7.90 (1H, d, 
J = 8.4 Hz), 7.99 (1H, d, J = 8.6 Hz), 8.01 (1H, s), 8.06 (1H, dd, J = 1.4 Hz, 8.4 Hz), 8.09 (1H, s), 
8.57 (1H, s). IR (KBr): 3500–3000, 1698, 1609, 1551, 1480, 1397, 1325, 1086 cm
−1
. FAB-Ms MH+ 
295. 
 
6.3.12. 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-2-naphthamide (89b) 
 
To a cooled (0°C) solution of 89a (449 mg, 1.53 mmol), EDCI·HCl (321 mg, 1.67 mmol), 
ammonium salt of HOBt (301 mg, 1.98 mmol) in anhydrous DMF (7.6 mL) was added dropwise 
(i-Pr)2NEt (216 mg, 1.67 mmol) and the mixture was stirred at room temperature for 18 h. After 
being concentrated under the reduced pressure with silica gel (3 g), the residue was purified by 
column chromatography on silica gel (CHCl3/7%NH3 in MeOH = 19:1) and recrystallized from 
EtOH to give 89b (53 mg, 12%). Mp >186°C decomp (CHCl3–MeOH). 
1
H NMR (CDCl3 + CD3OD) 
δ: 2.94–3.00 (2H, m), 4.15–4.40 (2H, m), 6.82 (1H, s), 7.58 (1H, s), 7.66 (1H, dd, J = 1.8 Hz, 8.6 
Hz), 7.90 (2H, s), 7.95 (1H, d, J = 8.6 Hz), 8.07 (1H, s), 8.40 (1H, s). IR (KBr): 3345, 1663, 1618, 
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1599, 1493, 1414, 1080 cm
−1
. Anal. Calcd for C17H15N3O2·1.0H2O: C, 65.58; H, 5.50; N, 13.50. 
Found: C, 65.63; H, 5.50; N, 13.73. 
 
6.3.13. 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide 
(89c) 
 
Under an argon atmosphere, 95a (436 mg, 1.65 mmol) was dissolved in dry THF (30 mL) and the 
mixture was cooled to −65°C in a dry ice acetone bath. A n-BuLi hexane solution (1.6 M: 2.28 mL, 
3.63 mmol) was added with stirring and the mixture was stirred at the same temperature for 1.5 h. 
After stirring, a solution of 92 (183 mg, 1.5 mmol) in dry THF (3 mL) was added dropwise and the 
whole was stirred at the same temperature for 1.5 h. After dilution with saturated aqueous 
ammonium chloride solution, the mixture was concentrated under reduced pressure. The resulting 
residue was dissolved in ethanol and the insoluble material was filtered off. The filtrate was 
concentrated under reduced pressure and the resulting residue was chromatographed on silica gel 
(CHCl3/7% ammonia in MeOH = 19:1) and crystallized from CHCl3 and diethylether to give 89c 
(121 mg, 26%) as a colorless powder. Mp >185°C decomp (CHCl3 + diethylether). 
1
H NMR (CDCl3 
+ CD3OD) δ: 2.89–3.02 (2H, m), 3.04 (3H, s), 4.12–4.25 (1H, m), 4.27–4.43 (1H, m), 6.79 (1H, s), 
7.20 (1H, q, J = 4.6 Hz), 7.54 (1H, s), 7.63 (1H, dd, J = 1.8 Hz, 8.6 Hz), 7.83 (2H, s), 7.89 (1H, d, J 
= 8.6 Hz), 8.03 (1H, s), 8.28 (1H, s). IR (KBr): 3500–3000, 1644, 1605, 1559, 1497, 1464, 1318, 
1082 cm
−1
. Anal. Calcd for C18H17N3O2·0.1CHCl3: C, 68.09; H, 5.40; N, 13.16. Found: C, 68.14; H, 
5.20; N, 12.94. Compounds 89e–h and 89j were prepared in the same manner as described for the 
preparation of 89c. 
 
6.3.14. N-Ethyl-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-2-naphthamide 
(89e) 
 
Yield 29%. Mp 157–8°C (CHCl3–MeOH). 
1
H NMR (CDCl3 + CD3OD) δ: 1.29 (3H, t, J = 7.2 
Hz), 2.85–3.06 (2H, m), 3.46–3.60 (2H, m), 4.10–4.24 (1H, m), 4.27–4.41 (1H, m), 6.88 (1H, s), 
6.89 (1H, t, J = 5.2 Hz), 7.50 (1H, s), 7.62 (1H, dd, J = 1.6 Hz, 8.6 Hz), 7.81 (2H, s), 7.87 (1H, d, J = 
8.6 Hz), 8.02 (1H, s), 8.26(1H, s). IR (KBr): 3283, 1642, 1605, 1557, 1495, 1447, 1316, 1080 cm
−1
. 
Anal. Calcd for C19H19N3O2·0.25H2O: C, 70.03; H, 6.03; N, 12.89. Found: C, 69.94; H, 6.12; N, 
12.74. 
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6.3.15. N-Cyclopropyl-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-2- 
naphthamide (89f) 
 
Yield 30%. Mp 146–7°C (CHCl3–MeOH). 
1
H NMR (DMSO-d6) δ: 0.58–0.79 (4H, m), 2.75–3.00 
(3H, m), 4.12–4.32 (2H, m), 6.17 (1H, s), 6.66 (1H, s), 7.63 (1H, dd, J = 1.4 Hz, 8.8 Hz), 7.64 (1H, 
s), 7.90 (1H, dd, J = 1.4 Hz, 8.6 Hz), 7.98 (2H, d, J = 8.6 Hz), 8.05 (1H, s), 8.39 (1H, s), 8.61 (1H, d, 
J = 4.4 Hz). IR (KBr): 3258, 1644, 1630, 1603, 1541, 1495, 1316, 1080 cm
−1
. Anal. Calcd for 
C20H19N3O2·0.75H2O: C, 69.25; H, 5.96; N, 12.11. Found: C, 69.35; H, 6.22; N, 12.15. 
 
6.3.16. 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-isopropyl-2-naphthamide 
(89g) 
 
Yield 37%. Mp >165°C decomp (CHCl3–MeOH). 
1
H NMR (CDCl3 + CD3OD) δ: 1.31 (6H, d, J 
= 6.4 Hz), 2.87–3.06 (2H, m), 4.12–4.26 (1H, m), 4.27–4.44 (1H, m), 6.56 (1H, d, J = 7.8 Hz), 6.78 
(1H, s), 7.52 (1H, s), 7.64 (1H, dd, J = 1.8 Hz, 8.8 Hz), 7.82 (2H, s), 7.89 (1H, d, J = 8.8 Hz), 8.03 
(1H, s), 8.25 (1H, s). IR (KBr): 3277, 1640, 1628, 1603, 1557, 1493, 1350, 1080 cm
−1
. Anal. Calcd 
for C20H21N3O2·0.75H2O: C, 68.85; H, 6.50; N, 12.04. Found: C, 68.75; H, 6.43; N, 12.09. 
 
6.3.17. N,N-Diisopropyl-6-(7-hydroxy-6,7-dihydro-6,6-dimethyl-5H-pyrrolo[1,2-c] 
imidazol-7-yl)-2-naphthamide (89h) 
 
Yield 29%. Mp 250°C decomp (AcOEt). 
1
H NMR (CDCl3) δ: 0.8 (3H, s), 1.34 (3H, s), 1.00–1.80 
(6H, br), 3.50–4.00 (2H, br), 3.79 (1H, d, J = 10.2 Hz), 4.14 (1H, d, J = 10.2 Hz), 6.89 (1H, s), 7.41–
7.46 (2H, m), 7.72–7.86 (4H, m), 8.05 (1H, s). IR (KBr): 2965, 1630, 1335 cm
−1
. Anal. Calcd for 
C23H27N3O2·0.25H2O: C,72.32; H, 7.26; N, 11.00. Found: C, 72.56; H, 7.32; N, 10.72. 
 
6.3.18. 6-[1-Hydroxy-1-(1-methyl-1H-imidazol-5-yl)ethyl]-N-methylnaphthalene-2- 
carboxamide (89j) 
 
Yield 38%. 
1
H NMR (CDCl3 + CD3OD) δ: 1.95 (3H, s), 3.04 (3H, s), 3.25 (3H, s), 7.14 (1H, s), 
7.35 (1H, s), 7.41 (1H, dd, J = 1.8, 8.8 Hz), 7.80–7.90 (3H, m), 7.93 (1H, s), 8.28 (1H, s). IR (KBr): 
3241, 3048, 2975, 1640, 1622, 1603, 1553, 1505, 1410, 1321, 1271, 1248, 1167, 1117, 1073 cm
−1
. 
Anal. Calcd. for C18H19N3O2: C, 69.88; H, 6.19; N, 13.58. Found: C, 69.75; H, 6.19; N, 13.49. 
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6.3.19. 6-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide (89d) 
 
Under a hydrogen atmosphere (3–4 atom), a mixture of 89c (77 mg, 0.25 mmol), 1 N HCl (0.5 
ml) and 10% palladium carbon (Pd/C) (39 mg) was dissolved in MeOH (5 mL) and the mixture was 
vigorously stirred at room temperature for 12 h. After the filtration of the catalyst, the filtrate was 
neutralized with aqueous potassium carbonate solution (0.25 M, 1 mL, 0.25 mmol), the mixture was 
concentrated under reduced pressure. The resulting residue was chromatographed on silica gel 
(CHCl3/7% ammonia in MeOH = 19:1) and recrystallized from CHCl3–Et2O to give 89d (53 mg, 
72%) as a colorless powder. Mp 174–5°C (CHCl3–Et2O). 
1
H NMR (CDCl3) δ: 2.55–2.74 (1H, m), 
3.07 (3H, d, J = 5.0 Hz), 3.04–3.26 (1H, m), 4.01–4.27 (2H, m), 4.57 (1H, t, J = 7.6 Hz), 6.62 (1H, q, 
J = 5.0 Hz), 6.79 (1H, s), 7.39 (1H, dd, J = 1.6 Hz, 8.4 Hz), 7.55 (1H, s), 7.70 (1H, s), 7.77–7.95 (3H, 
m), 8.29 (1H, s). IR (KBr): 3210, 1644, 1605, 1553, 1489, 1410, 1321 cm
−1
. Anal. Calcd for 
C18H17N3O·0.25H2O: C, 73.08; H, 5.96; N, 14.20. Found: C, 72.99; H, 6.07; N, 13.99. 
 
6.3.20. 6-(7-Hydroxy-6,7-dihydro-6,6-dimethyl-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2- 
naphthamide (89i) 
 
n-BuLi (1.6 M in hexane; 3.3 mL, 5.28 mmol) was added dropwise to a cooled (−70°C) solution 
of methylamine (2 M in THF; 2.65 mL, 5.30 mmol) in anhydrous THF (4 mL) and the solution was 
stirred for 20 min at −70°C. This solution was transferred to a cooled (0°C) suspension of 89h (500 
mg, 1.23 mmol) in anhydrous THF (10 mL) and the reaction mixture was stirred for 16 h at room 
temperature. After dilution with brine (200 mL) and water (100 mL), the mixture was extracted with 
AcOEt and THF (1:1). The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. The residue was recrystallized from AcOEt to give 89i (137 mg, 33%) as a colorless powder. 
Mp 250°C decomp (AcOEt). 
1
H NMR (CDCl3) δ: 0.65 (3H, s), 1.33 (3H, s), 3.08 (3H, d, J = 4.8 Hz), 
3.78 (1H, d, J = 10.2 Hz), 4.14 (1H, d, J = 10.2 Hz), 6.55 (1H, br), 6.72 (1H, s), 7.45 (1H, s), 7.68–
7.82 (4H, m), 8.00 (1H, s), 8.26 (1H, s). IR (KBr): 3241, 1640, 810 cm
−1
. Anal. Calcd for 
C20H21N3O2: C, 71.18; H, 6.38; N, 12.21. Found: C, 71.08; H, 6.28; N, 12.23. 
 
6.3.21. Synthesis of 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2- 
naphthamide (89c) by improved method of route A 
 
Under an argon atmosphere, 2-bromobenzotrifluoride (33.05 g, 147 mmol) was dissolved in dry 
THF (600 mL) and the mixture was cooled to −65°C in a dry ice acetone bath. A n-BuLi hexane 
solution (1.6 M: 93.7 mL, 150 mmol) was added with stirring and the mixture was stirred at the 
same temperature for 30 min. After stirring, a cooled (10°C) solution of 95a (38.03 g, 144 mmol) in 
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dry THF (2.88 L) was added at not more than −55°C and the mixture was stirred for 20 min. An 
additional n-BuLi hexane solution (1.6 M: 94.5 mL, 151 mmol) was added at not more than −65°C 
and the mixture was further stirred for 30 min. To the mixture, a solution of 92 (14.66 g, 120 mmol) 
in a dry THF solution (240 mL) was added dropwise and the resulting solution was stirred at the 
same temperature for 1.5 h. After dilution with saturated aqueous ammonium chloride solution, the 
mixture was concentrated under reduced pressure. The resulting residue was dissolved in ethanol and 
the insoluble material was filtered off. The filtrate was concentrated under reduced pressure and the 
resulting residue was chromatographed on silica gel (CHCl3/7% ammonia in MeOH = 19:1 to 9:1) 
and recrystallized from MeOH to give 89c (16.44 g, 45%) as a colorless powder. The spectral data 
were identical to those of the authentic sample. 
 
6.3.22. N,N-Diisopropyl-6-[hydroxy(1-trityl-1H-imidazol-4-yl)methyl]-2-naphthamide (97) 
 
A solution of 95e (50.0 g, 150 mmol) in anhydrous THF (250 mL) was added dropwise to a 
cooled (−70°C) solution of n-BuLi (1.6 M in hexane; 98.3 mL, 158 mmol) in anhydrous toluene 
(1000 mL) over a 30 min period while the temperature of the reaction mixture was maintained at 
under −60°C. After stirring for 20 min at −70°C, a solution of 29 (38.9 g, 115 mmol) in anhydrous 
THF (200 mL) was added dropwise over a 20-min period, before stirring for 20 min at −70°C. After 
dilution with water, the organic layer was separated and the aqueous layer was extracted with AcOEt 
(×2). The extracts were washed with brine, dried over MgSO4, and concentrated in vacuo to give a 
crude mixture of 97 as a yellow viscous oil. This material was used for the next reaction without 
further purification. The analytical sample was obtained by recrystallization from MeOH (colorless 
powder). 
1
H NMR (CDCl3) δ: 1.28 (12H, br s), 3.73 (2H, br s), 4.73 (1H, s), 5.93 (1H, s), 6.59 (1H, 
d, J = 0.8 Hz), 7.06–7.13 (6H, m), 7.27–7.33 (9H, m), 7.36 (1H, dd, J = 1.5, 8.5 Hz), 7.42 (1H, d, J = 
1.4 Hz), 7.48 (1H, dd, J = 1.7, 8.7 Hz), 7.71–7.79 (3H, m), 7.88 (1H, s); IR (KBr) 3177, 2964, 1630, 
1445, 1337, 1126, 710, 702 cm
−1
. Anal. Calcd for C40H39N3O2·0.3MeOH: C, 80.22; H, 6.72; N, 6.96. 
Found: C, 80.38; H, 6.53; N, 7.05. 
 
6.3.23. N,N-Diisopropyl-6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide (98) 
 
A suspension of a crude mixture of 97 and MnO2 (150 g) in CH2Cl2 (300 mL) was stirred for 90 
min at room temperature. The mixture was filtered through Celite, and the solid was washed with 
THF. The filtrate was concentrated, and the residue was recrystallized from EtOH to give 98 (41.0 g, 
60% two steps) as a colorless powder. 
1
H NMR (CDCl3) δ: 1.26–1.82 (12H, br d), 3.72 (2H, br s), 
7.13–7.22 (6H, m), 7.34–7.42 (9H, m), 7.45 (1H, dd, J = 1.4, 8.4 Hz), 7.58 (1H, d, J = 1.4 Hz), 7.79–
7.80 (2H, m), 7.90 (1H, d, J = 8.8 Hz), 7.98 (1H, d, J = 8.4 Hz), 8.29 (1H, dd, J = 1.6, 8.8 Hz), 8.98 
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(1H, s); IR (KBr) 2972, 1643, 1624, 1520, 1443, 1371, 1333, 1175, 756, 704 cm
−1
. Anal. Calcd for 
C40H37N3O2: C, 81.19; H, 6.30; N, 7.10. Found: C, 81.04; H, 6.26; N, 7.11. 
 
6.3.24. Ethyl 2-{6-[(diisopropylamino)carbonyl]-2-naphthyl}-2-hydroxy-2-(1-trityl-1H- 
imidazol-4-yl) acetate (99) 
 
Ethyl acetate (14.9 mL, 152 mmol) was added dropwise to a cooled (−70°C) solution of LDA 
(freshly prepared from diisopropylamine [21.3 mL, 152 mmol] and n-BuLi [1.6 M in hexane, 95.0 
mL, 152 mmol]) in anhydrous THF (600 mL). After stirring for 30 min, a solution of 98 (60.0 g, 101 
mmol) in anhydrous THF (150 mL) was added dropwise. The reaction mixture was stirred for 30 
min at −70°C and then allowed to warm to −30°C. After cooling to −50°C, the reaction mixture was 
diluted with water and the organic phase was separated. The aqueous phase was extracted with THF–
toluene (1:1). The combined extracts were washed with brine, dried over MgSO4, and concentrated 
in vacuo to give 99 as a pale yellow oil. This material was used for the next reaction without further 
purification. The analytical sample was obtained by recrystallization from toluene (colorless 
powder): 
1
H NMR (CDCl3) δ: 1.14 (3H, t, J = 7.0 Hz), 1.34 (12H, br s), 3.17 (1H, d, J = 16.2 Hz), 
3.50 (1H, d, J = 16.2 Hz), 3.72 (2H, br s), 3.08 (2H, q, J = 7.0 Hz), 5.15 (1H, s), 6.84 (1H, d, J = 1.4 
Hz), 7.07–7.14 (6H, m), 7.26–7.34 (9H, m), 7.37 (1H, d, J = 1.4 Hz), 7.38 (1H, dd, J = 1.7, 8.3 Hz), 
7.68 (1H, dd, J = 1.8, 8.8 Hz), 7.74–7.84 (3H, m), 8.03 (1H, d, J = 1.0 Hz); IR (KBr) 3454, 2968, 
1705, 1636, 1371, 1337, 1213, 746, 704 cm
−1
. Anal. Calcd for C44H45N3O4: C, 77.73; H, 6.67; N, 
6.18. Found: C, 77.69; H, 6.67; N, 6.12. 
 
6.3.25. 6-[1,3-Dihydroxy-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,N-diisopropyl-2-naphthamide 
(100) 
 
Red-Al (65% in toluene; 110 mL, 355 mL) was added dropwise to a cooled (−15°C) solution of 
99 in anhydrous toluene (600 mL) over a 30-min period. The reaction mixture was stirred for 2.5 h at 
−10 to −0°C. The reaction was quenched with the addition of water (12 mL). After dilution with 
THF (300 mL), aqueous 15% NaOH solution (12 mL) and water (36 mL) were added, and the 
mixture was stirred until the suspension turned to a clear solution. After the addition of Celite (120 
g), the suspension was stirred for 10 min, and the solid was then filtered and washed with THF. The 
filtrate was concentrated (ca. 60% of the solvent was evaporated), and the solution was washed with 
10% citric acid solution, water, saturated NaHCO3, and brine followed by drying over MgSO4. After 
removal of the solvent in vacuo, the residue was recrystallized from hexane–AcOEt to give 100 
(63.7 g, 98%) as a colorless powder: 
1
H NMR (CDCl3) δ: 1.34 (12H, br s), 2.27–2.40 (1H, m), 2.48–
2.61 (1H, m), 3.70 (2H, t, J = 5.0 Hz), 3.83 (3H, br s), 4.54 (1H, s), 6.78 (1H, d, J = 1.6 Hz), 7.08–
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7.17 (6H, m), 7.28–7.40 (11H, m), 7.51 (1H, dd, J = 1.8, 8.4 Hz), 7.71–7.81 (3H, m), 7.97 (1H, s); 
IR (KBr) 3497, 3200, 2964, 1634, 1445, 1335, 748, 702 cm
−1
. Anal. Calcd for C42H43N3O3: C, 
79.09; H, 6.80; N, 6.59. Found: C, 78.83; H, 6.71; N, 6.59. 
 
6.3.26. 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N,N-diisopropyl-2- 
naphthamide (101) 
 
Methanesulfonyl chloride (9.21 mL, 119 mmol) was added dropwise to a cooled (0°C) solution 
of 100 (63.0 g, 98.8 mmol) and (i-Pr)2NEt (34.5 mL, 198 mmol) in anhydrous THF (400 mL) while 
keeping the temperature of the solution below 10°C. After stirring for 30 min, water was added and 
the resulting mixture was extracted with AcOEt (×2). The combined organic layers were washed 
with brine, dried over MgSO4, and concentrated in vacuo to give a crude mixture of the mesylate as 
a pink amorphous powder. The mesylate was dissolved in CH3CN (300 mL), and the solution was 
heated at 70°C for 20 min, during which time the spot of the mesylate disappeared on TLC. After the 
addition of MeOH (100 mL) and (i-Pr)2NEt (34.5 mL, 198 mmol), the mixture was heated at 70°C 
for 6 h. The mixture was concentrated in vacuo (about half of the solvent was evaporated), diluted 
with water, and extracted with AcOEt (×3). The combined organic layers were washed with brine 
(×2) and concentrated in vacuo. The remaining solid was filtered and washed with AcOEt to give 
101 (32.5 g, 87%) as a colorless powder. The analytical sample was obtained by recrystallization 
from EtOH and AcOEt (colorless powder): 
1
H NMR (CDCl3) δ: 1.18–1.50 (12H, br d), 2.78–2.97 
(2H, m), 3.69–3.77 (2H, br d), 4.01–4.09 (1H, m), 4.18–4.28 (1H, m), 6.58 (1H, s), 7.26 (1H, s), 
7.36 (1H, dd, J = 1.2, 5.6 Hz), 7.59 (1H, dd, J = 1.2, 5.8 Hz), 7.72–7.78 (3H, m), 7.99 (1H, s); IR 
(KBr) 3275, 2964, 1611, 1487, 1450, 1371, 1342, 800 cm
−1
. Anal. Calcd for C23H27N3O2·0.1EtOH: 
C, 72.93; H, 7.28; N, 11.00. Found: C, 72.73; H, 7.10; N, 11.05. 
 
6.3.27. 6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide 
(89c) by route B 
 
n-BuLi (1.6 M in hexane; 199 mL, 318 mmol) was added dropwise over 30 min to a cooled 
(−70°C) solution of methylamine (2 M in THF; 159 mL, 318 mmol) in anhydrous THF (300 mL) 
and the solution was stirred for 20 min at −70°C. This solution was transferred to a cooled (0°C) 
suspension of 101 (30 g, 79.5 mmol) in anhydrous THF (450 mL) via a Teflon needle, and 101 was 
completely dissolved. The reaction mixture was stirred for 16 h at room temperature. After dilution 
with brine (200 mL) and water (100 mL), the mixture was stirred for 10 min, and the precipitated 
compound 89c was separated by filtration. The organic layers of the filtrate were separated, and the 
aqueous layer was extracted with AcOEt and THF (1:1, ×2). The combined organic layers were dried 
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over MgSO4 and concentrated in vacuo. The residue was filtered and washed with AcOEt to give an 
additional amount of compound 89c. The two separately obtained portions of compound 89c were 
combined and dissolved in hot EtOH (150 mL) and MeOH (10 mL). The insoluble material was 
filtered, and the filtrate was concentrated, followed by recrystallization from EtOH and AcOEt to 
give 89c (19.2 g, 79%) as a colorless powder. The spectral data were identical to those of the 
authentic sample. 
 
6.3.28. Optical resolution of 89c using preparative HPLC 
 
Compound 89c (12.8 g, 41.6 mmol) was subjected to optical resolution by preparative HPLC 
using a Chiralpak AD column (50 mm × 500 mm) using hexane/ethanol (1/1) as an eluent, detected 
at 254 nm, to afford (−)-89c (6.40 g, 20.8 mmol, 50%) as a first elution and (+)-89c (6.32 g, 20.6 
mmol, 49%) as a second elution. The spectral data were identical to those of the racemic 89c except 
for optical rotation. 
Compound (−)-89c: [α]D
25
 = −82.7 (c 0.526, MeOH); t R = 9.9 min (Chiralpak AD 4.6 mmID × 
250mmL, hexane/ethanol = 1/1, 0.5 mL/min, at 254 nm); 99.8% ee. Compound (+)-89c: [α]D
25
 = 
+83.8 (c 0.474, MeOH); tR = 19.1 min (Chiralpak AD 4.6 mmID × 250 mmL, hexane/ethanol = 1/1, 
0.5 mL/min, at 254 nm); 99.8% ee. 
 
6.3.29. Preparation of Reformatsky reagent (102a) 
 
A catalytic amount of chlorotrimethylsilane (ca. 0.1 mL) was added to a suspension of zinc 
powder (1.04 g, 16.0 mmol) in anhydrous THF (8 mL), and the suspension was stirred for 20 min at 
room temperature, in which time the zinc powder a formed sponge-like precipitate. Ethyl 
bromoacetate (1.77 mL, 16.0 mmol) in anhydrous THF (20 mL) was added to the solution dropwise 
over a 20 min period while ensuring that the temperature of the solution remained below 30°C. The 
solution was stirred for a further 20 min to give 102a as a yellow solution. This solution was 
immediately used for the next reaction after acid-alkaline titration (0.50 M). 
 
6.3.30. Preparation of Reformatsky reagent (102b) 
 
A catalytic amount of chlorotrimethylsilane (ca. 0.1 mL) was added to a suspension of zinc 
powder (1.04 g, 16.0 mmol) in anhydrous THF (8 mL) and the suspension was stirred for 20 min at 
room temperature, in which time the zinc powder formed a spongy precipitate. After heating at 50°C, 
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tert-butyl bromoacetate (2.36 mL, 16.0 mmol) in anhydrous THF (20 mL) was added to the solution 
dropwise over a 20 min period while ensuring that the temperature of the solution was kept below 
60°C. The solution was stirred for a further 20 min and then allowed to cool to room temperature to 
give 102b as a yellow solution. This solution was used for the next reaction after acid-alkaline 
titration (0.35–0.50 M). 
 
6.3.31. Titration of Reformatsky reagent 
 
A THF solution of Reformatsky reagent (1.0 mL), 0.10 N HCl (20 mL), together with a few 
drops of aqueous Methyl Orange solution was added to a distilled water (10 mL). After stirring for 
10 min at room temperature, the solution was titrated with 0.10 N NaOH solution. The concentration 
of Reformatsky reagent was calculated with the following equation: Reformatsky reagent (M) = (20 
− X) × 0.1 (where X is a amount of 0.10 N NaOH consumed). 
 
6.3.32. General procedure for asymmetric Reformatsky reaction 
 
Synthesis of tert-Butyl 2-{6-[(diisopropylamino)carbonyl]-2-naphthyl}-2(S)-hydroxy-2- 
(1-trityl-1H-imidazol-4-yl)acetate (103b, entry 2 in Table 14). 
Cinchonine (142 mg, 0.42 mmol) was added to a cooled (0°C) solution of 102b (1.47 mmol), and 
the solution was stirred for 20 min at 0°C. After cooling to the appropriate temperature, a solution of 
98 (250 mg, 0.42 mmol) in anhydrous THF (2.5 mL) was added dropwise over a 5 min period, and 
the mixture was stirred until completion of the reaction (checked by HPLC). The optical purity of 
103b was determined by HPLC using a chiral column (Chiralpak AD, 4.6 mmID × 250 mmL). The 
analytical conditions were as follows: mobile phase; hexane/EtOH = 85/15, flow rate; 0.8 mL/min, 
temperature; 25 to 35°C, detection; UV (254 nm), retention time (t/min); (R)-103b (13.0 min), 
(S)-103b (18.4 min), 98 (21.2 min). The yield of 103b was determined by the rate of the peak 
intensity of 103b (ε at 254 nm in EtOH = 12,700) and 98 (ε at 254 nm in EtOH = 32,000). 
The reaction of 98 with 102a to produce 103a was conducted in a similar manner as described 
above. 
 
6.3.33. Large scale preparation of 103b (entry 6 in Table 14) 
 
A solution of 102b (0.35 M; 48.2 mL, 16.9 mmol) and pyridine (1.37 mL, 17.0 mmol) was added 
dropwise to a cooled (0°C) solution of cinchonine (1.55 g, 5.28 mmol) in anhydrous THF (10 mL), 
and the solution was stirred for 20 min at 0°C. After cooling to −42°C, a solution of 98 (2.50 g, 4.22 
mmol) in anhydrous THF (20 mL) was added dropwise over 10 min, and the mixture was stirred for 
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4 h at −42°C. The mixture was diluted with 1 N HCl, and then diluted with AcOEt. The resulting 
solution was successively washed with 1 N HCl (×2), water, saturated NaHCO3 solution, and brine 
followed by drying over MgSO4. After removal of the solvent in vacuo, the residue was purified by 
flash column chromatography on silica gel (hexane/AcOEt = 3:1 to 2:1) to give 103b (2.9 g, 97%, 
92% ee) as a colorless amorphous solid: 
1
H NMR (CDCl3) δ: 1.31 (9H, s), 1.0–1.6 (12H, br d), 3.12 
(1H, d, J = 16.0 Hz), 3.40 (1H, d, J = 16.0 Hz), 3.69 (2H, br s), 5.26 (1H, s), 6.86 (1H, d, J = 1.8 Hz), 
7.07–7.12 (6H, m), 7.25–7.32 (9H, m), 7.36–7.39 (2H, m), 7.70 (1H, dd, J = 1.8, 8.7 Hz), 7.73–7.78 
(2H, m), 7.82 (1H, d, J = 8.4 Hz), 8.03 (1H, s); IR (KBr) 3462, 2972, 1732, 1705, 1634, 1445, 1369, 
1337, 1159 cm
−1
. 
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6.4.1. Alignment of amino acid sequences 
 
The amino acid sequences of CYP3A4 and 17,20-lyase (CYP17) were taken from the ExPASy 
web site (http://tw.expasy.org/). The amino acid sequences for which three-dimensional (3D) 
structures were available at the time (Pseudomonas putida P450CAM, Pseudomonas sp. P450TERP, 
Saccharopolyspora erythraea P450eryF, Fusarium oxysporum P450NOR, Bacillus megaterium 
P450BM3, and mammalian CYP2C5) were aligned according to their 3D structures using the 
homology module of Insight II (ver. 2000, Accelrys Inc.). Subsequently, amino acid sequences of 
human CYPs were aligned by sequence homology using ClustalW. The combined alignments were 
manually modified so there were no insertions or deletions in the portions corresponding to probable 
secondary structures. The following four characteristic motifs of CYPs were aligned: WXXXR 
(where W is tryptophan, R is arginine, and X is any amino acid) in the alpha-helix C; EXXR (where 
E is glutamate, R is arginine, and X is any amino acid) in the alpha-helix K; ZXXPXXZXPXXZ 
(where P is proline, Z is an aromatic amino acid, and X is any amino acid) after the alpha-helix K; 
and FXXGXXXCXG (where F is phenylalanine, G is glycine, C is cysteine, and X is any amino 
acid) before the alpha-helix L. 
 
6.4.2. Homology modeling 
 
According to the alignment, homology models of CYP3A4 and 17,20-lyase (CYP17) were 
constructed based on the crystal structure of mammalian CYP2C5 (PDB code: 1DT6) using the 
homology module of Insight II. Using the search/generate loops function of Insight II, conformations 
of the insertion and deletion sections in the alignment were obtained according to the known 3D 
structures. After making some manual adjustments to remove large steric hindrances, the whole 
structure was subjected to energy minimization for 1000 steps with the steepest descent minimizer, 
and subsequently 5000 steps with the conjugate gradient minimizer, to a maximum gradient of 0.1 
kcal/mol
−1
 Å
−1
, using the Discover-ESFF force field (ver 980, Accelrys Inc.). During the 
minimization procedure, the dielectric constant was set to 4 * r, where r is the distance between two 
interacting atoms. The force constant of tethering constraints for the backbone of structurally 
conserved regions and heme was set to 40 kcal/Å
2
 to prevent large movement from the initial 
positions. 
 
6.4.3. Docking of Inhibitors 
 
Covalent bonding models of imidazole were constructed by full energy minimization using the 
Discover-ESFF force field (v980, Accelrys Inc.). The residual parts of compounds were then 
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connected to the imidazole. After connecting the compounds to the heme Fe in the 17,20-lyase 
model, its binding modes were explored by systematic analysis around the rotatable bonds within the 
ligands and protein side chains within 4 Å of the ligand (torsion driving). During this procedure, 
energy values were estimated based on the Discover-ESFF force field. The most stable binding mode 
of compounds was energy minimized with the 17,20-lyase model using the Discover-ESFF force 
field. In the minimization procedure, heme and the backbone of the protein was fixed. All 
computational procedures were carried out on O2/R10000 workstations of Silicon Graphics Inc. 
 
6.4.4. Determination of the absolute configuration of 48 
 
A single crystal (0.50 × 0.20 × 0.16 mm) of 48 was obtained by recrystallization from AcOEt. 
The reflection data were collected using a Rigaku AFC5R diffractometer with graphite 
monochromated Cu Kα radiation. The structure was determined by direct methods (SIR92), and 
refined by the full-matrix least-squares techniques (shelxl-97) with anisotropic temperature factors for 
the non-hydrogen atoms. Hydrogen atoms were included using a riding model. The absolute 
configuration was determined by the Flack parameter of 0.00 (2). Crystal data: C32H29BrN2O; M = 
537.50; orthorhombic; space group P212121 (#19); cell constants a = 11.040 (2) Å, b = 46.207 (3) Å, 
c = 10.827 (4) Å, V = 5523 (2) Å
3
; Z = 4; Dc = 1.293 g/cm
3
; unique reflections, 9,330; observed 
reflections [I > 2σ(I)], 6,988; R1 = 0.048, wR2 = 0.124. Further details of the X-ray structure data are 
available on request from the Cambridge Crystallographic Data Centre (deposition number CCDC 
781830). 
 
6.4.5. Determination of the absolute configuration of 78 
 
A single crystal (0.40 × 0.40 × 0.16 mm) of 78 was obtained by recrystallization from 
THF/MeOH. Reflection data were collected using a Rigaku AFC5R diffractometer with graphite 
monochromated Cu Kα radiation. The structure was determined by direct methods (SIR92), and 
refined using the full-matrix least-squares techniques (SHELXL-97) with anisotropic temperature 
factors for the non-hydrogen atoms. Hydrogen atoms were included using a riding model. The 
crystal contained two host (78) molecules and two methanol molecules in the asymmetric unit. The 
absolute configuration was determined by the Flack parameter of −0.03 (3). Crystal data: 
C26H24BrN3O4S·CH3OH; M = 586.50; monoclinic; space group P21 (#4); cell constants a = 
14.684(2) Å, b = 10.318(1) Å, c = 18.927(2) Å, β = 112.256(7)°, V = 2653.9(5) Å
3
; Z = 4; Dc = 
1.468 g/cm
3
; unique reflections, 9180; observed reflections [I > 2σ(I)], 5158; R1 = 0.072, wR2 = 
0.241. Further details of the X-ray structure data are available on request from the Cambridge 
Crystallographic Data Centre (deposition number CCDC 781827). 
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6.4.6. Determination of the Absolute Configuration of 88 
 
A colorless platelet (0.15 × 0.15 × 0.05 mm
3
) of 88 was obtained by re-crystallization from 
AcOEt and THF. A diffractometer Rigaku RAXIS RAPID was used with graphite monochromated 
Cu-Kα radiation to obtain the following crystal data: C25H24BrN3O4S, 0.5C4H8O, crystal system 
monoclinic, space group P21 (#4), lattice parameters a = 14.3835(3) Å, b = 10.6353(2) Å, c = 
17.6165(3) Å, α = 90°, β = 110.3646(7)°, γ = 90°, V = 2526.41(8) Å
3
, Z = 4, T = 100 K. Of the 
25,453 reflections collected, 8673 were unique (Rint = 0.054). The refinement converged with R1 = 
0.059 and wR2 = 0.138 for 7131 reflections with I > 2σ(I). The absolute configuration of 88 was 
established as S based on the Flack parameter,
81
 0.03(2), refined using 3806 Friedel pairs. The 
crystal contained two molecules of 88 and a molecule of THF in the asymmetric unit. Further details 
of the X-ray structure data are available on request from the Cambridge Crystallographic Data 
Centre (CCDC deposition number: 794848). 
 
6.4.7. Determination of the absolute configuration of (+)-89c (orteronel) 
 
A colorless platelet of (+)-89c with (2S,3S)-(-)-tartranilic acid (0.35 × 0.10 × 0.01 mm
3
) was 
obtained by re-crystallization of MeOH/i-Pr2O/THF. A diffractometer Rigaku RAXIS RAPID was 
used with graphite monochromated Cu-Kα radiation to obtain the following crystal data: 
C18H17N3O2, 2C10H11NO5, crystal system monoclinic, space group C2 (#5), lattice parameters a = 
28.9799(6) Å, b = 5.4377(1) Å, c = 26.0080(6) Å, α = 90°, β = 103.338(1)°, γ = 90°, V = 3987.9(2) 
Å
3
, Z = 4, T = 173 K. Of the 22,522 reflections collected, 7029 were unique (Rint = 0.065). The 
refinement converged with R1=0.127 and wR2 = 0.388 for 2903 reflections with I > 2σ(I). The 
absolute configuration of (+)-89c was established as S using the absolute stereochemistry of 
(2S,3S)-(-)-tartranilic acid as an internal reference. The crystal contained one molecule of (+)-89c 
and two molecules of tartranilic acid in the asymmetric unit. There were two tunnel-shaped solvent 
domains along the b-axis in a unit cell. Although several peaks originating from the crystallization 
solvent were observed in these solvent domains, they were disordered. Therefore, the solvent peaks 
were excluded from the structure refinement process. Further details of the X-ray structure data are 
available on request from the Cambridge Crystallographic Data Centre (CCDC deposition number: 
781831). 
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6.4.8. Inhibitory activity on rat steroid 17,20-lyase in vitro 
 
Inhibitory activity against rat enzymes was determined according to a method described 
previously
82
 with some modifications. Testes excised from 13-week-old male SD rats were 
homogenized, and testicular microsomes were prepared by centrifugation. The reaction mixture 
contained 75 mM phosphate buffer (pH 7.4), 7 μg of the microsome protein, 10 nM 
[1,2-
3
H]-17α-hydroxyprogesterone (NEN), 5 mM NADPH (Oriental Yeast), and 1–1000 nM test 
compounds in a total volume of 20 μL at room temperature. The concentration of reagents was 
expressed as the final concentration in the reaction mixture. The test compounds were serially 
diluted with dimethylformamide, and then diluted fivefold with distilled water before 5 μL of the 
diluted solution was added to the reaction mixture. After incubating for 15 min at 37°C the reaction 
was terminated by the addition of 40 μL of ethyl acetate, then vortexed for 30 s and briefly 
centrifuged. Thirty microliters of the organic phases were applied to silica gel TLC plates (Whatman, 
LHPK). The substrate and the products, androstenedione and testosterone, were separated using the 
toluene–acetone (7:2) solvent system. Detection of the spots and measurement of the radioactivity as 
PSL were performed with a BAS2000 Bio-image analyzer (FUJIX). The concentration of the test 
compounds needed to reduce the concentration of the products by 50% (the concentration of the 
control group in which no test compound is added is taken as 100%) was calculated. 
 
6.4.9. Inhibitory activity on human steroid 17,20-lyase in vitro 
 
Inhibitory activity on human enzymes was determined as described above. The reaction mixture 
contained 75 mM phosphate buffer (pH 7.4), 1 mM magnesium chloride, 0.5 pmol of recombinant 
P450c17 (Biotechnology Laboratories, Takeda), 0.5 pmol of recombinant cytochrome b5 (Pan Vera), 
20.8 ng of recombinant NADPH-cytochrome P450 reductase (Pan Vera), 10 nM 
[1,2-
3
H]-17α-hydroxypregnenolone (Amersham), 5 mM NADPH (Oriental Yeast), and 1–1000 nM 
test compound in a total volume of 20 μL. The concentration of reagents was expressed as the final 
concentration in the reaction mixture. The test compounds were serially diluted with 
dimethylformamide, and then diluted fivefold with distilled water before 5 μL of the diluted solution 
was added to the reaction mixture. After incubating for 15 min incubation at 37°C the reaction was 
terminated by the addition of 40 μL of ethyl acetate, then vortexed for 30 s and briefly centrifuged. 
Thirty microliters of the organic phases were applied to silica gel TLC plates (Whatman, LHPK). 
The substrate and the product DHEA were separated using the cyclohexane–ethyl acetate (3:2) 
solvent system. 
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6.4.10. Inhibitory activity on rat 11-hydroxylase in vitro 
 
Adrenal glands excised from SD rats were homogenized, and the mitochondrial fraction was 
prepared at room temperature by serial centrifugation. Rat 11-hydroxylase activity was measured 
according to a method described for side-chain cleavage activity previously
83
 with some 
modifications. The reaction mixture contained 200 mM mannitol, 4.5 mM HEPES, 2.3 mM 
potassium phosphate (pH 7.4), 0.1 mM EDTA·2 K, 0.03% BSA (crystallized, Miles), 4.5 mM 
NADPH (Oriental Yeast), 11 mM calcium chloride, 4 μg of mitochondria protein, 10 nM 
[1,2-
3
H]-hydroxy-11-deoxycorticosterone (11-deoxycortisol) (NEN, dissolved in 0.02% Tween-80), 
and 1–1000 nM test compounds in a total volume of 150 μL. The concentrations of reagents were 
expressed as the final concentration in the reaction mixture. The test compounds were serially 
diluted with dimethylformamide, and 1.5 μL was added directly to the reaction mixture. After 30 min 
incubation at 37°C the reaction was terminated by addition of 400 μL of ethyl acetate and 100 μL of 
distilled water, then vortexed for 30 s and briefly centrifuged. Three hundred microliters of the 
organic phase was transferred to a new tube and evaporated until dry using nitrogen gas. The steroids 
were dissolved with 30 μL of ethyl acetate and the whole volume was applied to silica gel TLC 
plates (Whatman, LHPK). The substrate and the products (11-deoxycortisol and cortisol) were 
separated in the toluene–acetone (7:2) solvent system. 
 
6.4.11. Inhibitory activity on CYP3A4 in vitro for screening (Table 1-5, 7-10 and 15-17) 
 
The reaction mixture contained 50 mM phosphate buffer (pH 7.4), 10 pmol/mL recombinant 
CYP3A4 (Gentest), 100 μM testosterone, NADPH regenerating system (0.5 mM NADP (Oriental 
Yeast)), 5 mM glucose-6-phosphate (Oriental Yeast), 1 mM MgCl2, 1.5 unit/mL G-6-P 
dehydrogenase (Oriental Yeast), and 1 or 10 μM test compounds in a total volume of 200 μL. The 
total microsome protein content was adjusted by control microsome protein (Gentest). The 
concentration of reagents was expressed as the final concentration in the reaction mixture. The 
reaction mixture was incubated for 30 min at 37°C and terminated by the addition of 200 μL of 
acetonitrile. After addition of 400 μL of water, the reaction mixture was centrifuged at 14,000 rpm 
for 10 min. The 6-hydroxytestosterone contents in the supernatants were determined using a HPLC 
system (Shimadzu LC-10, column: Inertsil ODS-3 (4.6 × 150 mm), GL Sciences). 
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6.4.12. Effect of (−)-74b and (+)-89c on metabolic activities of CYP-expressing microsomes 
(Table 11 and 20) 
 
The effect of (−)-74b and (+)-89c on CYP isoforms was assessed by incubating a marker 
substrate with the microsomes expressing each human CYP isoform in the presence of 3, 10, 30 and 
100 μmol/L of each test compound. The incubation mixture contained 10 mmol/L MgCl2, 3.2 mg/mL 
glucose-6-phosphate, 0.8 mg/mL β-NADP+ and 4 units/mL glucose-6-phosphate dehydrogenase in 
80 mmol/L phosphate buffer (pH 7.4). In the case of CYP2A6, 2B6 and 2C9, 80 mmol/L Tris–HCl 
buffer (pH 7.4) was used instead of the phosphate buffer. After preincubation of each test compound 
and CYP isoform-specific substrate mixture at 37°C for 5 min, the reaction was initiated by adding 
microsomes derived from specific CYP-expressing human B-lymphoblastoid cells. The 
concentration of the substrate was referenced from the data sheet from GENTEST Corp. 
(7-ethoxyresorufin O-deethylation for CYP1A2, coumarin 7-hydroxylation for CYP2A6, 
S-(+)-mephenytoin 4'-hydroxylation for CYP2C19, (±)-bufuralol 1'-hydroxylation for CYP2D6, 
4-nitrophenol hydroxylation for CYP2E1 and testosterone 6β-hydroxylation activity for CYP3A4) or 
the published reports (ethoxycoumarin O-deethylation for CYP2B6 and tolbutamide hydroxylation 
for CYP2C8 and 2C9) 
84, 85
 with slight modifications. 
The marker reactions specific for CYP isoforms other than CYP3A4 were measured according to 
published analytical methods
84, 86-90
 with slight modifications. Testosterone 6β-hydroxylation activity 
for CYP3A4 was analyzed using the following HPLC conditions: column, Inertsil ODS-2 (150 × 4.6 
mm I.D.; GL Science, Tokyo, Japan); detection wavelength, 254 nm; flow rate, 1.0 mL/min; column 
temperature, 50°C; mobile phase, 10 mmol/L acetate buffer (pH 4.3)/acetonitrile = 7/3. Control 
marker enzymatic activities were measured for the preincubation samples in the presence of 
methanol alone without each test compound. 
 
6.4.13. Effect of (−)-19, (−)-74b, (+)-89c and (−)-89c in male cynomolgus monkeys (Table 6, 12, 
18 and 19) 
 
Adult male cynomolgus monkeys (Keari, Wakayama, Japan) housed in a temperature-controlled 
room (23 ± 2°C) with a 12:12 h light/dark cycle (illumination from 7:00 am to 7:00 pm) were used 
for the single dosing experiments. The care and use of animals and the experimental protocol used in 
this study were approved by the Experimental Animal Care and Use Committee of Takeda 
Pharmaceutical Company Ltd. The test compounds (−)-19, (−)-74b, (+)-89c and (−)-89c were 
suspended in 0.5% methylcellulose and administered orally at a dose of 3 mg/kg for (−)-19 and 1 
mg/kg for (−)-74b, (+)-89c and (−)-89c. Blood samples were collected just before dosing, and 2 h 
and 8h for (−)-19, 4 h and 8 h for (−)-74b, 8 h for a preliminary study of (+)-89c and (−)-89c or 2, 5 
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and 10 h for (+)-89c after dosing. Serum was stored at −30°C until assayed by radioimmunoassay 
(RIA). Concentrations of testosterone and DHEA were determined using a Testosterone I-125 kit 
(Dia Sorin s.r.l., Italy) and a DHEA RIA kit (Diagnostics System Laboratories, USA), respectively, 
according to the manufacturer’s instructions. 
Serum steroid concentrations are highly variable among individuals, show circadian variation, 
and are affected by stress. Thus, serum steroid concentrations were expressed as percentages of the 
mean pretreatment values (the mean concentrations in sera collected 48 and 24 h and just before 
treatment) in the single administration experiments. 
 
6.4.14. Pharmacokinetic studies (Table 13) 
  
Compound (−)-74b was administered to non-fasted Crl:CD(SD)IGS rats (male, 8 weeks old, n = 
3) intravenously at a dose of 1 mg/kg and orally at a dose of 10 mg/kg. Blood samples were 
collected at 5, 10, 15, and 30 min and 1, 2, 4, 8, 24 h after intravenous administration, or at 15 and 
30 min and 1, 2, 4, 8, 24 h after oral administration. The blood samples were centrifuged to obtain 
the plasma fraction. The plasma samples were deproteinized with acetonitrile. After centrifugation, 
the supernatant was dried under N2. The residue was reused with HPLC mobile phase (A:B = 90:10) 
and analyzed by HPLC. The analytical conditions using HPLC were: column, L-column ODS (4.6 
mm × 250 mm); mobile phase, (A) 0.01 mol/L ammonium acetate:(B) acetonitrile = 78:22; flow rate, 
1.0 mL/min; column temperature, 40°C. 
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